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1. Cervical cancer 
Cervical cancer is an important public health problem. With 530,0000 new cases 
and 275,000 deaths per year, cervical cancer is the third most common malignancy 
in women worldwide.1;2 Cervical cancer affects relatively young women, mostly 
under the age of 45.2 Furthermore, a disproportionally high incidence is observed in 
developing countries, especially in Africa, South Asia, and parts of Latin America, 
with incidence rates >20 per 100,000 women.1 The lowest rates are found in Western 
Asia, Australia, New Zealand, North America, and Western Europe (Figure 1). In the 
Netherlands in 2010, cervical cancer was newly diagnosed in 718 women (age-
standardised incidence rate of 6.0/100,000) and 205 cervical cancer deaths were 
observed (age-standardised mortality rate of 1.3/100,000).3 
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Figure 1 World Standard cervical cancer incidence and mortality rates per country (rate per 100,000).1
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1.1 Precursor lesions of cervical cancer
According to the classic concept cervical cancer usually arises in the cervical 
transformation zone. The transformation zone consists of metaplastic squamous 
epithelium that is located at the site where the squamous epithelial cells of the 
ectocervix (outer part of the cervix) meet the glandular columnar epithelial cells of 
the endocervix (inner part of the cervix). The position of the transformation zone is 
dynamic, shifting outwards during puberty, and, over the following years, gradually 
shifting towards, and into, the endocervical canal as squamous epithelium replaces 
the glandular epithelium. However, recent collected data supports the concept that 
cervical cancer and its high-grade precursor lesion develops from a discrete population 
of ectoendocervical squamocolumnar junctional cells, rather than cells from the 
transformation zone.4 Apparently, these cells are more susceptible to the human 
papillomarvirus (HPV) mediated transformation and therefore prone to cervical 
cancer development.
 Cervical cancer can be classified into different histological subtypes, of which 
squamous cell carcinoma is the most common one (accounting for about 80% of all 
cervical cancers). The second most common type is adenocarcinoma, accounting 
for approximately 15% of cervical cancers. Very rarely, other types, such as 
neuro-endocrine carcinomas and clear-cell carcinomas, are diagnosed. 
 Cervical squamous cell carcinomas develop through premalignant precursor 
lesions called cervical intraepithelial neoplasia (CIN). CIN lesions are classified into three 
groups: mild (CIN1), moderate (CIN2), or severe (CIN3, including carcinoma in situ) 
lesions, depending on the extent of replacement of the epithelial lining by atypical 
cells. In CIN1, which represents productive infections (see 2.2), up to one-third of 
the cells of the lower epithelial layer is replaced by atypical cells. In CIN3, the most 
advanced precursor stage representing a transforming HPV infection (see 2.2), 
from two-thirds up to the whole epithelial layer consists of atypical cells (Figure 2). 
Moreover, from CIN1 to CIN3, the cells become more atypical. Lesions are graded 
as carcinoma when atypical cells pass the basal layer (invasion). Whether cervical 
cancer develops through consecutive CIN1, 2 and 3 is under debate, since CIN2/3 
lesions may develop rapidly following a high-risk HPV (hrHPV) infection, leaving only 
a very limited time frame for a preceding CIN1 lesion.5;6 The premalignant lesions can 
regress, persist, or progress. Lesions graded as CIN1 display a high regression rate, 
whereas CIN3 has the lowest regression rate. CIN2 lesions, a subset of which represents 
productive infections, have an estimated risk of cervical cancer of about 40%.7;8 CIN3 
lesions have the highest risk of about 50% to progress to invasive cervical cancer.8-10 
Regression of CIN lesions is always associated with hrHPV clearance.11
 Together, CIN2 and CIN3 lesions are referred to as high-grade CIN. As mentioned 
before, the majority of the high-grade lesions would never progress to cancer in 
absence of treatment.8 However, at present it is not possible to distinguish morphological 
non-progressive lesions from progressive lesions. Therefore, women with high-grade 
lesions (CIN2+) are usually treated, resulting in a certain amount of overtreatment. 
These women are mainly treated through a loop electrosurgical excision procedure 
(LEEP).12 CIN1 lesions are called low-grade CIN.5;8 Women with these lesions are not 
treated but are recalled for a repeat cytology smear.13  
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2. Human papillomavirus (HPV)
Persistent infection of the cervical epithelium with hrHPV is necessary for the 
development of cervical cancer.14-17 HrHPV can be detected in almost all 
cervical squamous cell carcinomas14 and in 94% to 100% of all adenocarcinomas.18-20 
 Papillomaviruses are small, double-stranded DNA viruses. So far, more than 100 
different HPV types have been identified. HPV types that are associated with cervical 
cancer are classified as ‘high-risk’ (hr) or carcinogenic. Based on epidemiologic criteria 
at least a dozen high-risk HPV types have been identified (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, and 59).16;18;21 In addition, HPV types 26, 53, 66, 68, 73, and 82 are considered 
probably high-risk.22 Low-risk (lr) HPV types such as HPV6 and HPV11 are associat-
ed with benign wart-like lesions. The risk for cervical cancer differs between hrHPV 
types. Women with an HPV16 infection have a significantly greater risk for developing 
CIN3 or cervical cancer (CIN3+) compared to those infected with other oncogenic 
types.23-25 For example, in the POBASCAM trial, 18-month risk of CIN2+ in hrHPV-positive 
women was 13% after normal cytology and 34% after borderline or mild cytological 
abnormalities. If positive for HPV16, CIN2+ risks were 27% and 48%, respectively.25 
Likewise, HPV18-positive women have an increased risk for CIN3+, although to a lesser 
extent as HPV16.24;25 Longitudinal studies with extensive genotyping have furthermore 
revealed that HPV31 and 33 conveyed increased risks of CIN2+ or CIN3+.24-26 In fact, 
in a study reported by Naucler et al.26 infection with HPV16, 31 and 33 conferred the 
highest risks of CIN2+ within 4 years of follow-up and were responsible for 33.1%, 18.3% 
and 7.7% of CIN2+ cases. Given these figures, it is not surprising that HPV16 causes more 
than half of the cervical cancers worldwide, followed by HPV18 (~16%), and HPV33 
(~4%).27 In addition, hrHPV infections can also cause cancer in other parts of the ano-
genital tract, such as anal, vulvar, and penile cancer, as well as in the head and neck, 
particularly of oral and oropharyngeal origin.22;28-31
2.1 Prevalence of HPV infections
Genital HPV infections are relatively common among sexually active women.32;33 
It is estimated that about 80% of women are infected with a genital HPV infection 
during their lifetime.33 Since hrHPV is transmitted through sexual contact,34 the 
prevalence of hrHPV infection is highest in young women (ages 20-24) after starting 
sexual contact. 32;35;36 
 In the Netherlands, the highest prevalence of about 24% is detected in 22-year-old 
women. The prevalence gradually declines by increasing age to under 3% in women 
older than 45 years.37 Estimates of single-point prevalence of hrHPV infection among 
women participating in the screening programme in the Netherlands are between 
4% and 5%.38;39 Risk factors that are associated with acquiring an hrHPV infection are 
the number of sexual partners, the age at which sexual intercourse was initiated, and 
smoking.17;40;41 In addition, contact with men who have promiscuous sexual behaviour 
is associated with increased risk for acquiring an hrHPV infection.33;34 
 Fortunately, most women clear the hrHPV infection within 1-2 years.17;42 Persistent 
infection with hrHPV is a necessary but insufficient cause of cervical cancer.14;18 Decreased 
efficiency of the immune system to clear an hrHPV infection and additional (epi) 
genetic transforming events are necessary for malignant progression. 
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2.2 The viral life cycle and transforming infections
The viral life cycle is dependent on the differentiation of infected epithelium, and 
the virus uses the host replication machinery to generate progeny. The process 
is as follows: HPV infects the basal cells in the cervical epithelium and replicates in 
differentiating epithelial cells. Encapsidation takes place in the upper layers of the 
host epithelium and, finally, viruses are shed when the superficial epithelial cells die. 
HPV is thought to access the basal cells of squamous epithelium through small tears, 
known as microtraumas, in the mucosal surface (Figure 2). Besides the viral proteins 
E1 and E2, which are essential for viral replication, the virus relies entirely on the host 
cell DNA replication machinery for viral DNA synthesis. Viral E6 and E7 proteins are 
needed to create conditions that allow viral replication in differentiated, non-dividing 
epithelial host cells, in which the DNA replication machinery is normally not activated. 
The location of expression of the latter viral proteins is tightly regulated to the mid-zone 
of the epithelium. E6 binds to the human tumor-suppressor protein p53 and degrades 
it; p53 plays an important role in cell cycle control and apoptosis. E7 binds to the 
retinoblastoma protein (pRb) tumor suppressor protein and thereby disrupts the binding 
of pRB to E2F, which leads to S-phase entry through released E2F.43;44 Thus, E6 and E7 
stimulate a condition of DNA synthesis in the infected host cell, thereby supporting 
viral replication. Many HPV infections are productive infections, in which new viral 
particles are formed and released. Productive infections of the cervix may give rise to 
mild to moderate cellular abnormalities, histologically comparable with CIN1/CIN2, 
but not often to true pre-cancerous stages of cervical cancer. 
 Under conditions that the viral E6/E7 proteins are improperly expressed in the 
proliferating basal cells, they may stimulate viral transformation.45;46 These so-called 
transforming infections are associated with histologically CIN2, CIN3 and cervical 
cancer (CIN2+). The mechanism underlying the deregulation of E6 and E7 expres-
sion is not completely understood. A possible explanation is integration of viral DNA 
in the host cell genome,47;48 but methylation of E2 binding sites within the viral long 
control region (LCR) has also been suggested.49 Deregulated expression of E6 and E7 
in the basal cells will result in chromosomal instability and provides the driving force for 
further progression towards cancer. Free E2F resulting from interaction of E7 with 
pRb stimulates uncontrolled cell growth in proliferating cells.50 With less p53 due to 
degradation by E6, the cell cannot cope with uncontrolled cell growth,51 which triggers 
the development of genetic instability. As a consequence of deregulated E7 expression, 
the tumour suppressor p16INK4a is up-regulated. P16INK4a is a cyclin dependent 
kinase inhibitor that normally prevents inactivation of pRb by cyclin D1 and therefore 
induces cell cycle arrest at G1. However, in the presence of hrHPV E7 protein, upregulated 
p16INK4a has no effect since pRB is already inactivated by E7. The overexpression 
of the tumour suppressor p16INK4a throughout the cervical epithelium (i.e. diffuse 
immunostaining for p16INK4a) can be considered as a marker for lesions that harbour 
a transforming hrHPV infection.52-54
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3. High-risk HPV and cervical carcinogenesis
Cervical cancer develops through the following steps: hrHPV infection, hrHPV 
persistence, hrHPV transformation and development of precancerous lesions, and 
finally progression to invasive cervical cancer (Figure 2).17 Backward steps do also 
occur, with hrHPV clearance and regression of cervical lesions to normality.
 About 80% of all hrHPV infections are cleared and will not result in premalignant 
lesions.5;40;55;56 The majority of the remaining 20% will develop into non-progressive 
low-grade CIN lesions characterized by a productive hrHPV infection. Only a small 
group of CIN lesions containing a transforming hrHPV infection are at risk of progression 
to cervical cancer. Next to viral persistence and a molecular switch into a transforming 
infection accumulation of additive (epi)genetic alterations is necessary for further 
progression towards invasive cancer. 
Figure 2 Schematic representation of cervical cancer development [adapted from 57]. * Activation of oncogenes, loss of 
tumour suppressor gene function, p16INK4a overexpression, and chromosomal instability.
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4. Cervical cancer prevention
Two ways of cervical cancer prevention can be recognised: primary prevention and 
secondary prevention. Primary prevention is defined as an intervention aimed at 
taking the risk factor of cervical cancer, i.e. hrHPV infection, away in healthy women. 
Prophylactic vaccination with HPV16/18 L1 virus-like particles (VLPs), which was 
introduced in the Netherlands in 2009, is an example of primary prevention. Secondary 
prevention is an intervention to prevent cervical cancer by treatment of women who 
have subclinical (non-symptomatic) disease. Cervical cancer screening by detection 
of abnormal cells in cervical smears (also called a Pap smear) is an example of 
secondary cancer prevention.
4.1 Primary prevention by vaccination
Two prophylactic vaccines are available, a bivalent vaccine that protects against 
HPV16 and HPV18 (Cervarix®, GSK) and a quadrivalent vaccine that includes the 
low-risk types HPV6 and HPV11 as well (Gardasil®, Merck).58-64 At present, vaccination 
does not eliminate the need for cervical cancer screening. Since the HPV vaccine 
protects against infection of HPV16 and HPV18, which together cause about 70% of 
cervical cancer cases,58-60;65 screening will still be needed as a supplementary tool 
for the remaining 30%. Even with cross protection against non-vaccine HPV types, 
not more than 77% of cervical cancers will be prevented (HPV31 and 45 contribute 
to 7% of cervical cancer cases).20 Moreover, by no means will all individuals of the 
target group come forward for vaccination. In the Netherlands, the HPV vaccine is 
given to HPV-negative (naïve) 12-year-old girls with an initial catch-up vaccination for 
13- to 16-year-old girls, and an average of 56% coverage is observed.66 As a result, 
for the majority of women, screening will remain the most important preventative 
strategy at least for the next 20 years. 
4.2 Secondary prevention 
Screening is an important cancer prevention tool. It is believed that nearly all cervical 
cancer-deaths could be prevented if women and their healthcare providers would 
fully adhere to screening recommendations and follow-up regimens. 
 Success of cervical cancer screening is due to three factors: first, cervical cancer 
has a long-lasting pre-invasive phase, allowing time for detection. The median time 
between precursor lesions and cervical cancer is estimated to be more than 10 
years.67;68 Second, cellular morphological changes on the cervix can be seen in the 
Pap smear and used for early diagnosis. Third, disease can be simply and effectively 
treated in the pre-invasive phase.
 Tests used in primary cervical screening should fulfil certain requirements. Clinical 
sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive 
value (NPV) are statistical measurements to express performance of a test. Clinical 
sensitivity is the probability that a test correctly classifies people with clinically meaningful 
disease at a preclinical stage as positive (e.g. the percentage of people with 
disease who are correctly identified as having the condition). Clinical specificity is the 
probability that a test classifies people without disease as negative (e.g. the percentage 
of healthy people who are correctly identified as not having the condition). Predictive 
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values of test results depend on the prevalence of disease in the population. The positive 
predictive value (PPV) is the proportion of people with a positive test result who have 
the disease. The negative predictive value (NPV) is the proportion of people with a 
negative test result who do not have the disease. 
 Cervical screening should be performed in organized programmes with quality 
assurance at all levels and good information should be provided about the benefits 
and risks. Opportunistic screening activities are usually not acceptable as they may 
not achieve the potential benefits and may cause unnecessary negative side effects. 
The benefit of screening on the reduction of cervical cancer cases depends on the 
clinical sensitivity of the screening test, participation of invited women, and availability 
of adequate treatment and follow-up algorithms for women with abnormal test 
results.17 The test used in screening needs to be robust and highly reliable and should 
therefore display high intra-laboratory reproducibility in time and inter-laboratory 
agreement. However, screening also has negative side effects. The negative effects 
of screening depend on the sensitivity (false negative tests) and specificity of the test 
(false positive tests, resulting in unnecessary treatment and distress about a positive 
test) and on the possible side effects of early treatment. 
4.2.1 Cytology screening
The development of the Pap smear 69 has resulted in the implementation of cytology-
based cervical cancer screening programmes.
 For a cytological diagnosis, cells are scraped from the transformation zone of the 
cervix. These cells are placed on a glass slide, fixed, and coloured. The morphological 
changes of the cells are graded based on the subjective interpretation of the degree 
of abnormality. There are several commonly used classifications. In the Netherlands, 
the CISOE-A coding system is used (in Dutch KOPAC-B).70;71 The American Bethesda 
Table 1. Cytomorphological classification: the CISOE-A and Pap classification compared to Bethesda 2001 clas-
sification.  
 CISOE-A S0, O0, S1, O1 S1, O1 S2-3,  S4, O4,  S5, O5,  S6, O6, S7, E7 S8-9, 
   E0 E1-2 E1-2 O3, E3 E4 E5 E6  O7-8, E9
 Pap Pap0 Pap1 Pap1 Pap2 Pap3a1 Pap3a2 Pap3b Pap4 Pap5
Description Inadequate Normal Border- Mild Moderate Severe Carcinoma Carcinoma
    line    in Situ 
 Dyskaryosis 
 Bethesda Un- NILM Atrophy, ASC-US/ ASC-H/ HSIL SSC
 2001 satis-factory  NILM ASC-H LSIL    
 for   
  evaluation     AGC AGC favor neoplastic AIS AC
CISOE-A, C composition, I inflammation, S squamous epithelium, O Other abnormalities and endometrium, and 
E endo-cervical columnar epithelium; the acronym CISOE-A is KOPAC-B in Dutch. NHIL, negative for intra- 
epithelial lesions or malignancy; ASC-H, atypical squamous cells cannot exclude HSIL; ASC-US, atypical squamous 
cells of undetermined significance; AGC, atypical glandular cells; LSIL, low grade squamous intraepithelial lesion; HSIL, 
high grade squamous intraepithelial lesion; AIS, endocervical adenocarcinoma in situ; SCC, squamous cell 
carcinoma; AC, adenocarcinoma. 
C
H
A
PTER 1
Introduction: Impact of HPV DNA testing on cervical screening 
CHAPTER 1
16
classification is most commonly used in internationally published studies on cervical 
cancer screening.72;73 The CISOE-A classification can be converted into the Bethesda 
system (Table 1).74;75   
 Until now, primary cervical cancer screening has been based on cytology. 
Several epidemiologic studies have shown that cytological screening has been 
successful in reducing the incidence and mortality of cervical cancer.7;76-78 However, 
the cytology test has some limitations. The sensitivity of cytology for high-grade lesions 
is quite low (50-70%) and the performance is heterogeneous across populations 79. 
Cervical high-grade lesions are missed by cytology due to sampling and detection 
failures.80 To compensate for the low sensitivity of a single cytology test, frequent testing 
is necessary. Since the specificity of cytology is about 95%,79;81 a substantial number of 
women with minor abnormalities, and who do not harbour any underlying high-grade 
disease, have unnecessary follow-up procedures. Moreover, adenocarcinoma and its 
precursors are frequently missed by cytology. In addition, cytology is a subjective 
test and labour intensive.82  
 Liquid-based cytology is a technique that has been developed to reduce variation 
in quality of cytology. With this technique, the cell sample is collected as in the 
conventional cytology test, but cells are immersed in a vial with preservation solution 
instead of spread onto a slide. In the laboratory, a concentrated monolayer of cells is 
prepared. The advantage of liquid-based cytology is that the slides are easier to 
interpret because the process reduces the amount of obscuring material, such as 
blood and leucocytes. The number of cytological preparations read by 
cytotechnicians per hour can be increased substantially using liquid-based 
cytology. Moreover, liquid-based specimens can be used for other ancillary 
tests, such as hrHPV tests and tests for other biomarkers. However, in contrast to 
what has been claimed in earlier publications, liquid-based cytology is not more 
sensitive for detecting high-grade cervical lesions than a conventional smear.83-86 
Disadvantages of liquid-based cytology include a lower number of cells and loss 
of structural integrity of cell groups, by which cohesion of neoplastic cells disappears. 
As a result, high-grade lesions and carcinomas might be missed.
4.2.2 Current screening in the Netherlands 
In the Netherlands, cytological screening programmes were introduced in the 1970’s. 
In three regions, Nijmegen, Utrecht, and Rotterdam, a pilot-screening programme 
was introduced. Nationwide screening was introduced in 1988 for women aged 35-54 
with a 3-year interval. In 1996, the cytological screening programme was restructured; 
screening ages were extended to women aged 30-60 years, and the screening 
interval was widened to 5 years.70 In addition, a cytological smear with cytomorphologic 
signs of inflammation and/or presence of specific microorganisms was no longer 
classified as Pap 2 (i.e. borderline dyskaryosis), but classified as within normal 
limits.71;87 Moreover, a compact disc with microscopic examples of abnormal cytology 
was provided to the all the pathologists. This resulted in a decrease in the number of 
equivocal diagnoses from 11.3% to 2.6%.74 Normal smears without endocervical cells 
were no longer repeated until a smear with endocervical cells was obtained, as there 
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was doubt about the importance of these cells in cervical smears.88 Furthermore, for 
quality control, the evaluation of the screening programme was improved. In 2006, 
negative triage with hrHPV testing on repeat smears after a borderline smear was 
incorporated.89 Since 2008, both the conventional and the new liquid-based cytology 
technique have been accepted for the national screening programme. 
 In the present day, approximately 800,000 women are annually invited for cervical 
screening in the Netherlands.90 In 2008, 550,000 women participated in the screening 
programme (67% of the invited population).91 About 95% of the participating women 
had a normal smear. These women were invited for the next screening round after five 
years. In 1.9% of the women, the smear was inadequate, and these women needed to 
repeat the smear after six weeks. A smear with borderline or mild dyskaryosis (BMD) was 
observed in 2.5% of the women. Women with BMD were recalled for repeat cytology 
after 6 and 18 months and were referred for colposcopy if the repeat test result was 
positive (BMD or worse). This policy is used because only 5%-15% of women with BMD 
have or will develop high-grade cervical lesions.92-94 Since 2006, an hrHPV test can be 
added to cytology for the first follow-up smear at 6 months after the baseline BMD 
smear.89 This leads to a reduction in the number of repeat smears, as it is considered 
safe to refer women with normal cytology and a negative hrHPV test back to routine 
screening. In 0.7% of the women, a smear with moderate dyskaryosis or worse 
(>BMD) was present. These women were directly referred to the gynaecologist for 
colposcopy examination.95;96
 The detection of cervical lesions classified as CIN1 or worse was 5.3 per 
1,000-screened women. Of the women who were directly referred, 60% had CIN3+ 
and 17% had a CIN2 lesion.96 
4.2.3. Screening in other European countries
Almost all European countries have cervical cancer screening. However, only 
seven have a national organized screening programme (Denmark, Finland, Hungary, 
the Netherlands, Slovenia, Sweden, and the United Kingdom).97 Although all policies 
are mainly in line with the European recommendations (screening women every 3-5 
years), there is a large variation in screening intensity. The number of smears taken in a 
lifetime varies between 7-16 per women, with the exception of Germany with a 1-year 
interval and over 50 smears taken in a lifetime. 
 The number of opportunistic smears taken in addition to screening varies strongly 
between countries. In the Netherlands, 77% of women aged 30-64 years had at least 
one smear in the past 5 years, whereas the response to the screening invitations was 
65%.91;98 Unlike in the Netherlands, in Finland there are many opportunistic smears 
taken in addition to screening. Annually, 460,000 smears are made while only 270,000 
women per year are eligible for a smear.99 An explanation for this might be that in the 
Netherlands the smears taken outside the screening programme are not reimbursed. 
In addition, in the Netherlands the general practitioner and assistant sample for 
cytology-screening tests, and they are well informed about the guidelines. Furthermore, 
many women in Finland have had a smear taken before the first invitation for cervical 
screening. Opportunistic smears add little to the effectiveness of the regular 
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programme, and therefore decrease the cost-effectiveness of the screening activities. 
 Also age at which women are screened for the first time varies between countries. 
In Luxembourg, women are screened starting at the age of fifteen, in Belgium at the 
age of eighteen and in Germany at the age of twenty. Finland and the Netherlands 
have the highest age, i.e. thirty years, at which women are screened for the first time. 
With the upper age limit of 60 years, as also used in Denmark and Sweden. 
 Cervical cancer incidence rates vary widely across Europe. The highest incidence 
rates are seen in Eastern European countries. The lowest rates are seen in countries 
such as Italy, Switzerland, Spain, Finland, and the Netherlands.1
 Despite the presence of a relatively effective screening programme in the 
Netherlands, cervical cancer continues to be a considerable public health 
problem.100;101 The main reasons for missing cervical cancer cases despite a screening 
programme are a relatively low adherence to the screening programme  (65% per round 
attendance rate of invited women) and a relatively high number of false-negative 
cytology tests (low sensitivity).102;103 In addition, the follow-up of screen-positive women is 
not optimal. Therefore, over the last decades, efforts to improve screening have 
focused on increasing attendance and on development of alternative screening 
tests that are more sensitive than cytology.
5. Improvement of cervical cancer screening
Several trials have studied the value of hrHPV testing in cervical cancer screening 
programmes (Table 2). These studies have shown that hrHPV testing has a higher 
sensitivity for high-grade CIN than cytology testing.79;104-108 However, the hrHPV test has 
a lower specificity because the hrHPV test detects a substantial number of women 
with transient hrHPV infections that will not lead to clinically meaningful lesions.79;109 
This may lead to over-referral for colposcopy and thus over-treatment.107 As a result, 
women with a positive hrHPV test result should not be offered colposcopy immediately 
but should be further stratified by means of triage and repeat testing. 
 Testing for hrHPV can be used for various purposes: as a primary screening test, 
as triage for women with minor cytological abnormalities (BMD), and as follow-up test 
after treatment of pre-invasive lesions.110
 A seemingly effective method of improving screening coverage is by sending 
self-sampling devices to women who do not respond to invitation for the screening 
programme.111-113 About 30% of the non-attendees respond by returning 
their self-sampler.112;114 Moreover, the detection of high-grade lesions in the self-
sampling group was higher than in the regular screening programme.112;114;115 
Studies using interview surveys have shown that women prefer self-collection over 
physician-collection.116-118 Time and place of sampling, privacy, and ease of sampling 
have been mentioned as advantages of self-sampling. 
C
H
A
PT
ER
 1
Introduction: Impact of HPV DNA testing on cervical screening 
CHAPTER 1
19
5.1 HPV detection methods
A variety of hrHPV tests are currently available. HrHPV nucleic acids can be detected 
by target or signal amplification assays. Target amplification assays mainly comprise 
polymerase chain reaction (PCR)-based methods 119 and isothermal RNA amplification 
methods. PCR assays that are used include GP5+/6+,120;121 PGMY09/11,122 SPF10 123 and 
the Roche Amplicor HPV test.124 Examples of signal amplification assays are the Hybrid 
Capture 2 (HC2) test (Qiagen), Invader technology (Cervista HPV-HR Hologic), and 
in situ hybridisation (ISH) assays. In HC2, hybridisation of one of the RNA probes to 
hrHPV DNA is detected by biotin-labelled antibodies that recognize RNA/DNA hybrids 
following capture in streptavidin-coated microwell plates. The outcome of this test is 
expressed in relative light units per calibrator cut-off (RLU/CO). 
 When considering hrHPV tests, it is important to recognize the difference between 
analytical sensitivity and specificity versus clinical sensitivity and specificity. Analytical 
sensitivity and specificity refer to the detection of all hrHPV infections, including transient 
infections and those associated with high-grade lesions. Instead, clinical sensitivity and 
specificity point to the detection of only those hrHPV infections that are associated 
with clinically meaningful lesions. Ideally, the hrHPV test used in clinical settings should 
detect only women at risk for cervical cancer but not those with transient hrHPV infections. 
 The hrHPV tests GP5+/6+ PCR and HC2 have been used in large randomised 
controlled trials (Table 2) and have proven to perform well in cervical screening 
programmes. As such these assays are considered clinically validated. Both 
assays detect the hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, and, 
additionally, HPV66 is targeted by GP5+/6+ PCR and detected by HC2 as a result of 
cross-hybridisation.
 However, many new hrHPV tests have been developed, and the clinical performance 
of these tests is mostly unknown. Therefore, standards for hrHPV test performance 
and characteristics in clinical practice have been formulated.125 Using these 
guidelines, three hrHPV DNA tests (cobas®  4800, [Roche Molecular Systems Inc., 
Alameda, CA, USA], RealTime PCR [Abbott Molecular, Des Plaines, Il, USA] and 
Papillocheck® [Greiner Bio-One, Frickenhausen, Germany]) have proven to ful-
fil the sensitivity and specificity criteria for cervical screening purposes and can be 
considered clinically validated following demonstration of a sufficient reproducibility.126-129
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Table 2: Studies with hrHPV testing and cytology in cervical cancer screening
Study Study Age Population Primary Primary
 type   screening  screening
    test in  test in
    intervention control arm
    arm 
Hart study Multicentre 30-60 10,358 Conventional Conventional
(Cuzick, 2003) screening   women, cytology + cytology + HC2
 study  United  HC2
   Kingdom  
    Borderline Borderline cyto
    cyto and    and   hrHPV+
    hrHPV+ &  & normal cyto
    normal cyto ->Follow-up
    ->Referred for with repeat
    immediate  hrHPV and
    colposcopy cyto and
     colposcopy at   
     12 months
NTCC, Phase I RCT 25-60 45,174 LBC + HC2 Conventional
(Ronco 2006,    women,  cytology
2010)   Italy
NTCC, Phase II RCT 25-60 49,196 HC2 Conventional
(Ronco 2008,    women,  cytology
2010)    Italy  
POBASCAM RCT 29-56 40,105 Conventional Conventional
(Bulkmans 2007,   women, cytology + cytology
Rijkaart 2012)   the  GP5+/6+
   Netherlands
Swedescreen RCT 32-38 12,527 Conventional Conventional
(Naucler 2007)   women,  cytology + cytology
   Sweden  GP5+/6+  
CCCaST, RCT 30-69 10,154 HC2 Conventional
(Mayrand 2007)   women,   cytology
   Canada  
ARTISTIC RCT 20-64 24,510 LBC + HC2 LBC
(Kitchener 2009)   women, 
   United Kingdom  
India screening trial RCT 30-59 131,746 HC2 vs.  No screening
(Sankaranarayanan 2009)  women, Conventional
   India cytoloygyvs VIA 
Finnish screening trial RCT 30-60 38,670 HC2 +  Conventional
(Anttila 2011)   women, Conventional cytology
   Finland cytology triage 
VUSA-Screen Cohort study 30-60 48,088 Conventional Conventional
(Rijkaart 2010)   women, cytology+ HC2 cytology
   the Netherlands  
LBC: liquid-based cytology, RCT: randomised controlled trial, VIA: visual inspection with acetic acid 
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6. Outline of this thesis
Infection with hrHPV plays a causal role in the development of cervical cancer.14;16 
This has resulted in the development of hrHPV testing suitable for population-based 
screening. The goal of this thesis is to examine whether cervical screening can be 
improved by 1) hrHPV testing in triage of borderline or mild dyskaryotic cytology, and 
2) hrHPV testing as a primary screening test. Other goals were to evaluate the potential 
clinical impact of hrHPV screening compared to cytology. In addition, we studied the 
optimal follow-up algorithm for hrHPV-positive women. 
 In most countries that screen for cervical cancer, including the Netherlands, women 
with borderline or mild dyskaryosis (BMD, similar to Pap2 and Pap3a1, in CISOE-A: S2-4, 
O3 E3-5) are recalled for repeat testing, and they are only referred for colposcopy if 
the cytological abnormality persists. This algorithm was developed since only 5%-15% 
of these women develop high-grade lesions (CIN2+). The disadvantage of this repeat 
testing algorithm is the loss of follow-up and distress for the women because of the 
uncertain diagnosis. In Chapter 2, we answer the question: is it feasible to use hrHPV 
triage for women with BMD? The VUSA-Screen study (Vrije Universiteit Medical Center 
Saltro laboratory population-based cervical screening) was designed to investigate 
the efficacy of additional testing for hrHPV in the cervical screening programme. 
In this study, women aged 30-60 years were offered hrHPV testing and cytology 
(intervention group) or cytology only (control group). In the intervention group, women 
with BMD and an hrHPV-positive test were immediately referred for colposcopy, 
whereas hrHPV-negative BMD women were advised to repeat cytology at 6 and 18 
months and were referred for colposcopy when the repeat test result was positive. We 
compared hrHPV and cytology triage algorithms for women with BMD using the end 
point of histologically confirmed CIN3+, the number of repeat smears, the number of 
colposcopy referrals, and the medical costs.
 Data from randomised controlled trials indicate that hrHPV screening has a higher 
sensitivity than cytology screening for detecting high-grade cervical lesions.79;104-108;130 
However, implementation of hrHPV testing as a primary screening instrument in cervical 
screening is still under debate. In Chapter 3, we present results from the VUSA-Screen 
study focusing on the following three implementation issues: 1) whether hrHPV testing 
in primary screening should be offered alone or as an adjunct to cytology, 2) how 
to manage hrHPV-positive women, and 3) the age of application of hrHPV-based 
screening.
 In Chapter 4, we present the definitive 5-year results of the POBASCAM trial 
(Population Based Screening Study Amsterdam), a population-based, randomised 
controlled trial in which women were screened at baseline with either combined 
hrHPV testing and cytology or conventional cytology alone, from January 1999 to 
September 2002. At the subsequent screening round after 5 years, all women were 
screened with both hrHPV testing and cytology. Our main goal was to assess whether 
hrHPV testing decreases detection of CIN3+, CIN2+, and of cervical cancer in the 
second screening round. An additional goal was to assess the most appropriate age 
at which hrHPV testing should start. We also evaluated how detection of high-grade 
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lesions in two screening rounds was associated with particular HPV genotypes. 
 Several studies have shown that hrHPV testing has a lower specificity than cytology 
screening for detecting high-grade cervical lesions.79;104-108 The lower specificity has 
raised concerns that primary screening with hrHPV leads to increased referral rates for 
colposcopy and to overtreatment. Therefore, hrHPV-positive women should not be 
referred for colposcopy immediately. In Chapter 5, we used data from the intervention 
arm of the VUSA-Screen study to evaluate fourteen triage and repeat testing strategies 
for hrHPV-positive women. Another potentially cost-saving and simple option is to 
adapt the threshold for considering an hrHPV test as positive, i.e. increase the relative 
light unit/cut-off (RLU/CO) threshold of the Hybrid capture 2 (HC2) test. In Chapter 6, 
we studied the effect of hrHPV testing with higher HC2 thresholds on sensitivity, 
the colposcopy referral rate, and the false positive rate. 
 The results of the preceding chapters are discussed in Chapter 7 and summarized 
in Chapter 8. 
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ABSTRACT
Aim 
We studied the effectiveness of high-risk human papillomavirus (hrHPV) triage for 
immediate colposcopy in women with borderline or mild dyskaryosis (BMD). 
Methods
In the Utrecht province of the Netherlands, women aged 30–60 years who 
participated in the regular cervical screening programme were offered hrHPV 
testing and cytology (intervention group) or cytology only (control group). 
In the intervention group (n = 337), women with BMD were immediately 
referred for colposcopy only if the sample was hrHPV positive. Women with a hrHPV 
negative test were advised to repeat cytology at 6 and 18 months and were 
referred for colposcopy if and when the repeat test result was positive (BMD or worse). 
In the control group (n = 329), referral of women with BMD was delayed until cytology 
was repeatedly positive at 6 or 18 months. 
Results 
The CIN3 detection rates were 10.7% (36/337) in the intervention group and 6.4% 
(21/329) in the control group (p = 0.047). Moreover, hrHPV triaging resulted in 
shorter time to diagnosis (154 vs. 381 days). Although the number of colposcopy 
referrals was 51.5% higher in the intervention group than in the control group, the 
medical costs per detected CIN3 were slightly lower ([euro] 4781 vs. [euro] 6235). 
If, in addition, hrHPV negative women had been referred back to routine screening at 
baseline, the CIN3 rate would have been 10.1% (34/337) and colposcopy rate would 
only have been 30.4% higher than in the control group. 
Conclusion 
This study show s that hrHPV triaging of women with BMD is at least as effective for 
detecting CIN3 as repeat cytology, also when hrHPV negative women are referred 
back to routine screening.
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Introduction
In many European population-based screening programmes, women with 
borderline or mild dyskaryosis (BMD) are recalled for repeat cytology before being 
referred for colposcopy only if the cytological abnormality persists. This policy is used 
because only 5–15% of these women have or will develop high-grade cervical 
lesions.1–3 A disadvantage of repeat testing is that women may become lost 
during follow-up.4 Repeat cytology also induces a considerable amount of side 
effects in terms of psychological distress.5,6 Several groups have studied the pos-
sible value of hrHPV testing and cytology for the detection of cervical lesions.7,8 
Most studies show that hrHPV testing is a sensitive instrument to triage women with 
BMD, but the optimal triaging strategy remains controversial.9,10 
 In the Netherlands, women with BMD are followed with cytology testing at 6 and 
18 months. Since 2006, screening laboratories may choose to include a hrHPV test in 
the repeat cytology at 6 months.11 This leads to a reduction in the number of repeat 
smears as it is considered safe to refer women with normal cytology and a negative 
hrHPV test back to the routine screening. A more substantial reduction in the number 
of repeat smears is expected when women with BMD are tested for hrHPV at baseline. 
However, population-based prospective evidence, in terms of the end-points CIN3 
or cancer (CIN3+), colposcopy referrals and medical costs needed to support 
implementation of this strategy, is lacking. 
 To study the feasibility of hrHPV triage at baseline, we compared repeat cytology 
to direct referral of hrHPV-positive BMD women in a sub-study of the VUSA-Screen 
study (Vrije Universiteit Medical Centre SAltro laboratory population-based cervical 
SCREENing study). Outcome measures were CIN3+ and CIN2+ detection rates, number 
of colposcopy referrals, and medical costs.
Material and Methods
The present cohort study is part of the VUSA-Screen study. VUSA-Screen is an 
intervention study designed to evaluate the effectiveness of combined cervical 
cytology screening with hrHPV testing by Hybrid Capture 2 hybridization assay (HC2, 
Digene Corporation). The VUSA-Screen study has 2 aims. First, we evaluated the 
effectiveness of hrHPV triage in women with BMD by comparing current screening 
protocols using conventional cytology with a strategy where women with BMD were 
advised on the basis of hrHPV test result. 
 The second aim of the VUSA-Screen study was to evaluate the 
risk of developing high-grade CIN lesions in cytologically normal 
women with a hrHPV positive versus a hrHPV negative test result. Therefore, 
women with normal cytology and a positive hrHPV test were retested for cytology 
and hrHPV at 12 and 24 months. Women were referred if cytology was abnormal at 
12 months and if cytology was abnormal and/or hrHPV positive at 24 months. Each 
hrHPV positive, cytologically normal woman was matched to 3 randomly chosen hrHPV 
negative, cytologically normal women of the same age, who were also rescreened 
at 24 months. In this article, we present the results of the BMD women only. 
 The study was carried out in the Utrecht province of the Netherlands in the setting 
of the regular Dutch screening programme. Women aged 30–60 years were advised 
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to visit their general practitioner (GP) for cytology screening every 5 years by means 
of a call and recall method. Between October 2003 and August 2005, GPs affiliated 
to the Saltro laboratory in Utrecht were asked to participate in the VUSA-Screen study. 
After education of 500 GPs, 254 agreed to participate and recruited women for both 
cytology and hrHPV testing. Women who agreed to receive cytology and hrHPV 
testing gave written consent and these women formed the intervention group. This 
group was compared with women visiting the GP for regular cytological screening 
who did not participate in the VUSA-Screen study, but were affiliated to the Saltro 
laboratory (control group). Women in the control group were screened according to 
the national guidelines12,13 and data were analyzed anonymously. 
 Women were excluded from the analysis if they had a history of cervical intrae-
pithelial neoplasia grade 2 or worse (CIN2+) or abnormal cytology in the preceding 
2 years. All cytology and HC2 tests were performed in the Saltro laboratory in Utrecht 
under the supervision of a pathologist from the department of Pathology of the Vrije 
Universiteit Medical Center in Amsterdam. All study participants of the intervention 
group were given written information before screening regarding hrHPV infection 
and its role in carcinogenesis. A physician staffed telephone help desk was available 
throughout the study and follow-up period. The Ministry of Public Health obtained 
approval before the study started (advice nr 2002/02-WBO; ISBN-10: 90-5549-452-6), 
according to Dutch law. The study was registered in the trial register as NTR215, 
ISRCTN64621295. 
Figure 1 Flowchart study design. The baseline cytology results of the VUSA-Screen study and study design of women with 
BMD
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n = 22 217 
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 The triage design of the study and the baseline characteristics of women with 
minor cytological abnormalities are presented in Figure 1. Women in the intervention 
group were triaged according to both cytological testing and hrHPV DNA results. 
Women with BMD and a positive hrHPV test were directly referred to colposcopy. 
Women with BMD at baseline and a negative hrHPV test were tested for cytology 
at 6 and 18 months and referred if cytology was abnormal at one of these occa-
sions. Women in the control group were tested with cytology according to the current 
guidelines for cervical screening in the Netherlands.12 Women with BMD were advised 
to repeat the tests after 6 and 18 months. If one of the repeat tests was abnormal, 
women were referred to colposcopy. 
 A scrape was taken using a cytobrush (Rovers, Oss). After preparation of a 
conventional smear on a glass slide, the brush was placed in a vial containing 1 ml 
UCM (Universal Collection Medium, Dgene) for hrHPV testing. Cervical cytology results 
were reported, blinded to the hrHPV DNA testing results, according to the CISOE-A 
classification, which is routinely used in the Netherlands and can be easily converted 
into the BSCC classification.14 Cytological results were grouped as normal, BMD and 
moderate dyskaryosis or worse (>BMD). 
 HrHPV testing was performed by the Hybrid Capture 2 (HC2) high-risk HPV DNA 
test in an automated format on a rapid capture system (RCS) according to the 
manufacturer’s instructions (Qiagen, Gaithersburg, MD). This test uses a cocktail probe 
to detect 13 high-risk HPV types: 16, 18, 31,33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. 
Positive controls containing 1 pg/ml of cloned HPV-16 DNA and negative 
controls (provided by the manufacturer) were included in each assay.15 The results 
of the HC2 assay were expressed as relatively light units per cut-off value (RLU), 
representing the ratio between the emission from a sample to the average of 3 positive 
controls. Samples were considered positive if they attained or exceeded threshold of 
1.0 RLU/CO (corresponding with 1 pg/ml HPV16 DNA). 
 Of the women that were referred to a gynaecologist for colposcopy, colposcopy- 
directed biopsies were taken from suspicious areas of the cervix, according to 
standard procedures in the Netherlands.16 Histological examination of biopsies 
was done at local pathology laboratories and classified as normal, cervical 
intra-epithelial neoplasia grade 1, 2 or 3 or as invasive cancer, according to international 
criteria.17,18 High-grade lesions were reviewed by 2 independent pathologists. 
Cytology and histology results of both the intervention and control group were 
retrieved from the nationwide network and registry of histopathology and 
cytopathology (PALGA; Bunnik, the Netherlands). 
 The primary outcome measure of the study was histologically confirmed CIN3+. 
Secondary outcome measures were histologically confirmed CIN2+, number of 
colposcopy referrals, and medical costs. The follow-up time was set at 3 years. 
 Baseline differences between the intervention and control group were examined 
for age (Mann-Whitney test), the prevalence of BMD in the screened population 
(Pearson Chisquare test), the percentage of women that attended the previous 
screening round (Chi-square test), and the socioeconomic status rank score 
(Mann-Whitney test). A woman was considered as a participant at the previous 
screening round if she had her last smear within 7 years. The socioeconomic status 
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score was postcode based and retrieved from the governemental ‘‘Sociaal en 
Cultureel Planbureau’’ (http://www.scp.nl/onderzoek/statusscores). The outcome 
measures, number of CIN3+, CIN2+ cases and colposcopy referrals were compared 
by Pearson’s Chi-square test. Loss to follow-up was defined as no cytological or 
histological information obtained from women who were eligible for follow-up. 
The time to reach diagnosis was the time between baseline smear and histological 
diagnosis. 
 Women were referred to colposcopy on the basis of the study protocol. A woman 
could only be counted once for a referral to colposcopy. The colposcopy referral 
advices given by the gynaecologist after abnormal histology were not taken into 
account. Some women were referred for colposcopy despite the fact that the 
advice was repeat testing or return to routine screening programme. These cases 
were included in the calculation of the total number of colposcopy referrals. 
All calculations were repeated after omitting the follow-up of hrHPV-negative women 
in the intervention group. Clopper-Pearson confidence intervals were used for the 
detection rates, and normal intervals were used for the detection ratios and for the 
times to referral and diagnosis. The calculations were performed in STATA 10.0. Tests 
were two-sided and a test was significant if p < 0.05. 
 The number of screened women was targeted at 25,000 in both groups. 
Assuming a BMD prevalence of 2.5%, the sample size is sufficient to achieve 80% power 
to detect a 5% difference in CIN3+ yield. 
 The direct medical costs in euros per unit of health care resource utilization are 
included in the analysis and presented in Table 3. A health care perspective was 
taken and indirect costs and time and travel costs were not included. All costs 
were indexed at year 2006. The costs of screening and treatment were published 
previously and were updated to 2006 using the consumer price index.9,19,20 
The utilities for different health states (Table 3) were based on international 
publi-cations.21,22 Following the Dutch guidelines, the discounting rate per year for 
costs and health effects were set at 4% and 1.5%, respectively.
Results
The patient characteristics of women with BMD are presented in Table 1. The intervention 
group and control group were comparable on all baseline characteristics. 
Table 1 Characteristics of the women with BMD in the intervention and control group
Characteristics Intervention group Control group p
Year of intake 2003-2005 2003-2005 
Region  Utrecht Utrecht 
Median age 40.0 39.0 0.099
Prevalence of BMD in screening population 1.3% 1.5% 0.095
Borderline dyskaryosis 73.9% 72.0% 0.591
Mild dyskaryosis 26.1% 28.0% 0.591
Attendance at previous screening round1 82.5% 80.9% 0.637
Median socioeconomic status rank score2 0.43 0.47 0.677
1 Computed for women who had received an invitation at a previous screening round (i.e. women ≥ 34 years of age). 
Attendance was defined as having a screening result within the last 7 years. 2 Ranks ranged from 0 to 1.
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 Table 2 shows the histological results and the total number of gynaecological 
referrals for all women with BMD. The cumulative 3-year CIN3 detection rate was 
higher in the intervention group than in the control group (10.7% vs. 6.4%, p = 0.047). 
No cancers or adenocarcinoma in situ were detected. The CIN2+ rate was not 
statistically different between both groups (22.3% vs. 18.5%, p = 0.235), whereas the 
≤CIN1 rate was higher in the intervention than in the control group (23.4% vs. 12.2%, 
p < 0.001). Of the 337 women with BMD in the intervention group, 167 (49.6%) were 
hrHPV positive. Of these, 34 (20.4%, 95%CI 14.5-27.3) had a CIN3 diagnosis. 
Of 170 hrHPV negative women with BMD, 2 (1.2%, 95%CI 0.1–4.2) had CIN3. Of the 329 
women in the control group, 21 were diagnosed with CIN3 (6.4%, 95%CI 4.0–9.6). The 
colposcopy referral rate was higher in the intervention group than in the control group 
(57.6% vs. 38.0%, p < 0.001). However, the number of referrals per detected CIN3 was 
equal in both groups (5.4 vs. 6.0, p = 0.689). There was a marginal difference in the 
number of referrals per detected CIN2+ (2.6 vs. 2.0, p  = 0.074). 
 Women with hrHPV negative test and women in the control group showed the 
same cytology follow-up at 6 and 18 months (75.3% vs. 76.9% p = 0.690 and 41.1% vs. 
39.4% p = 0.779, respectively). The overall loss to follow-up was not statistically different 
between both groups (13.5% vs. 13.7%, p = 0.935). 
 Among women with a colposcopy referral, the mean time to referral was 39 
(95%CI 22-55) days in the intervention group and 298 (95%CI 259-336) days in the 
control group. Among women with a histological diagnosis, the mean time to 
Table 2. Follow-up results of women with BMD: 3-year cumulative colposcopy referrals and histology 
 Number (% of total; 95 CI%) Ratio, % (95% CI)
       Intervention  
        (follow-up of
  Control  Intervention Intervention  Intervention Intervention hrHPV-negative    
  group group  group, hrHPV+  group, hrHPV- vs control women omitted) 
   Total n = 329 n = 337 n = 167 n = 170 hr group vs control group 
 No colposcopy 204 143 0 143 0.68 0
 referrals (62.0; 56.5–67.2) (42.4; 37.1-47.9)  (84.1; 77.7-89.3) (0.59-0.80) 
 Colposcopy 125  194 167 27 1.52 1.30
 referrals1 (38.0; 32.7-43.5) (57.6; 52.1-62.9) (100) (15.9; 10.7-22.3) (1.28-1.79) (1.10-1.55)
 No biopsy              24 40 33 7 1.63 1.34
  (7.3; 4.7-10.7) (11.9; 8.6-15.8) (19.8; 14.0-26.6) (4.1; 1.7-8.3) (1.00-2.64) (0.81-2.22)
 CIN0/1 40 79 64 15 1.93  1.56
  (12.2; 8.8-16.2) (23.4; 19.0-28.3) (38.3; 30.9-46.2) (8.8; 5.0-14.1) (1.36-2.73)  (1.09-2.25)
   CIN2+ 61  75 70 5 1.20  1.12
  (18.5; 14.5-23.2) (22.3; 17.9-27.1) (41.9; 34.3-49.8) (2.9; 1.0-6.7) (0.9-1.62) (0.8-1.52)
     CIN2 40 39 36 3 0.95 0.88
  (12.2; 8.8-16.2) (11.6; 8.4-15.5) (21.6; 15.6-28.6) (1.8; 0.4-5.1) (0.63-1.44)  (0.58-1.34)
    CIN3 21 36 34 2 1.67 1.58
  (6.4; 4.0-9.6) (10.7; 7.6-14.5) (20.4; 14.5-27.3) (1.2; 0.1-4.2) (1.00-2.81) (0.90-2.67)
hrHPV+= hrHPV positive; hrHPV-= hrHPV negative; CI= confidence interval; ≤CIN1= normal or CIN 1; CIN2+= CIN 2 or 
worse.1Criteria for referral to colposcopy: abnormal cytology or positive hrHPV test. Referrals include colposcopies that 
were performed despite the fact that the advise was repeat testing or return to routine screening programme.
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diagnosis was 154 days (95%CI 124-184) in the intervention group and 381 days (95%CI 
323-440) in the control group. 
 The medical costs of screening, diagnosis and treatment were €512 per woman 
in the intervention group and €398 per woman in the control group as shown in 
Table 3. Per detected CIN3, the medical costs were €4,781 in the intervention group 
and €6,235 in the control group. To study the impact of negative hrHPV triaging, 
we repeated the analyses while omitting follow-up after a hrHPV-negative test. In 
that case, the CIN3 detection ratio was 1.58 (95%CI 0.90–2.67%) compared with the 
control group and the colposcopy referral ratio was 1.30 (95% CI 1.10–1.55) 
compared with the control group. The medical costs per woman became €447 and 
the medical costs per detected CIN3 became €4,429 (Table 3).
Discussion
HrHPV testing to triage women with borderline or mild dyskaryosis resulted in a 
much earlier diagnosis and was at least as effective for detection of CIN3 as repeat 
cytological testing. Although hrHPV triaging led to an increase in the number of 
colposcopies, this did not lead to an increase in the referral rate per CIN3. 
The medical costs per woman were similar for hrHPV triaging and repeat cytological 
testing and the costs per detected CIN3 were even slightly lower for hrHPV triaging. 
 The high CIN3/CIN2+ detection rate of the hrHPV triaging strategy is in line with 
a recent meta-analysis,7 where it has been shown that hrHPV triaging has a higher 
sensitivity than repeat cytology (at the ASCUS threshold) for detection of CIN2+, 
without a marked specificity loss. We, therefore, evaluated the impact of ‘‘negative 
triaging’’ in which women with BMD and a negative hrHPV test are considered 
Table 3 Medical procedure costs (screening, diagnosis, treatment): unit costs, costs per woman, costs per detected 
CIN2+ and CIN3 
 Costs per woman with BMD (€)2  
 Intervention group  
	 	 	 	 Follow-up	of	   
	 	 Unit	 	 hrHPV-negative		 Control
	 	 costs	(€)1	 	 women	omitted group
 First cytology3 57.0 57.0 57.0 57.0
 Repeat cytology(s)4 55.0 43.2 11.6 57.8
   133.6 102.0 114.8
 Colposcopy 158.4 91.2 79.2 60.2
 Biopsy 68.1 31.1 27.1 20.9
Treatment and follow-up of:     
 CIN 25 946.8 109.8 101.1 115.1
 CIN 35 1362.4 145.8 137.5 87.0
 Total costs per women  511.5 446.9 398.0
Costs per detected CIN2+  2298.3 2151.5 2146.6
Costs per detected CIN3  4781.3 4428.8 6235.4
1Unit cost of medical procedures, screening, diagnosis and treatment, based on recent Dutch data. 2The costs of the 
average number of diagnostic. 3Includes invitation organization, the visit at the GP and the collection of sample 
material and laboratory costs. 4Includes the visit at the GP and the collection of sample material and laboratory costs. 
5Treatment costs include the charge per type of treatment, preoperative diagnostics and cost of hospital days.
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not to be at increased risk and thus able to return to the regular screening 
programme. This strategy has been suggested by several authors.23–25 Therefore, we 
recal-culated the CIN3 yield after omitting the follow-up of hrHPV-negative women. 
This yield would still be at least as high as in the repeat cytology arm, indicating 
that hrHPV testing after BMD has a high-negative predictive value. This ensures that 
implementation of a protocol in which hrHPV-negative BMD women return to the regular 
screening programme does not lead to an increase in undetected lesions that are 
clinically meaningful. 
 We found higher colposcopy referral rates in the hrHPV triage arm than in the 
repeat cytology arm (57.6% vs. 38.0%). The ≤CIN1 rate was also higher in the hrHPV 
triage arm (23.4%) than in the repeat cytology arm (12.2%). This carries the potential 
risk of over-treatment in an additional 10% of cases. Our data did not allow us to 
analyze whether such was indeed the case. If women had been referred to the 
regular screening programme after a negative hrHPV test at baseline, the increase 
in colposcopy rate would have dropped from 51.5% to 30.4%. This increase in 
colposcopy rate, regardless whether it is implemented with or without negative 
hrHPV triaging, is not expected to lead to capacity problems in a country such as 
the Netherlands where the annual number of primary smears read as BMD is about 
8,700.26 On the basis of our study, introducing hrHPV triaging is expected to increase 
the number of colposcopies by about 1,700 without and 1,000 with a negative hrHPV 
triage scenario. The latter increase translates into an increase in the annual medical 
costs of 226,500 euros. In the Netherlands, the BMD prevalence is low and hrHPV 
positivity in BMD was 50% in our study. In countries where BMD rates are higher, 
hrHPV positivity in BMD may be lower in which case hrHPV triaging will be more 
efficient than in the Netherlands. This argument does not need to hold for a relatively 
young screening population in which hrHPV positivity and BMD rates are both high. 
A study by Moss et al.10 in which most women were between 20–34 years old, 
showed higher colposcopy referral rates in the hrHPV triaging arm and lower 
colposcopy referral rates in the repeat cytology arm than our study. 
 Our study was a cohort study and not a randomized controlled trial. The study 
was performed in the setting of a private laboratory, a real life situation, and this 
made it difficult to organize randomization. Therefore, women may have different 
baseline characteristics, specifically as both groups were not recruited from the same 
GPs. To assess the possible effects of baseline differences, we compared the interven-
tion and control group on the available characteristics; age, prevalence of BMD, 
screening history, and postcode-based socioeconomic status. We did not find any 
significant differences between the 2 groups, which strengthen the results in our study. 
In addition, the loss to follow-up was not statistically different between hrHPV negative 
women in the intervention group and the women in the control group.
 The development of screening programme guidelines requires careful consideration 
of the benefits, burdens, and costs that are associated with the adaptation of 
new technologies. Our study clearly supports the evaluation of new guidelines for 
management of BMD, as early hrHPV triaging leads to equal or better CIN3 
detection and can be implemented against low costs. The use of hrHPV triaging will 
lead to a faster diagnosis and less distress and is therefore an important step in improving 
the woman-friendliness of screening. 
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ABSTRACT
Background 
Human papillomavirus (HPV) testing is more sensitive than cytology for detecting 
high-grade cervical intraepithelial neoplasia (CIN). We evaluated the performance 
of high-risk HPV (hrHPV) testing in routine screening.
Methods 
In all, 25 871 women (29–61) enrolled in our population-based cohort study were 
offered both cytology and hrHPV testing. High-risk HPV-positive women with normal 
cytology and an age-matched subcohort of hrHPV-negative women with normal 
cytology were invited for repeat testing after 1 and/or 2 years and were referred for 
colposcopy if they presented with abnormal cytology and/or a positive hrHPV test. 
The hrHPV-positive women with borderline or mild dyskaryosis (BMD) and all women 
with moderate dyskaryosis or worse (>BMD) were directly referred for colposcopy. 
Women with BMD and an hrHPV-negative test were advised to repeat cytology at 
6 and 18 months and were referred for colposcopy if the repeat cytology test was 
abnormal. The main outcome measure was CIN grade 3 or worse (CIN3+). 
Results were adjusted for non-attendance at repeat testing.
Results
The hrHPV-positive women with abnormal cytology had a CIN3+ risk of 42.2% (95% 
confidence interval (CI): 36.4-48.2), whereas the hrHPV-positive women with normal 
cytology had a much lower risk of 5.22% (95% CI: 3.72-7.91). In hrHPV-positive women 
with normal cytology, an additional cytology step after 1 year reduced the CIN3+ risk 
to only 1.6% (95% CI: 0.6-4.9) if the repeat test was normal. The CIN3+ risk in women 
with hrHPV-positive normal cytology was higher among women invited for the first 
time (29–33 years of age) (9.1%; 95% CI: 5.6–14.3) than among older women (3.0%; 
95% CI: 1.5–5.5).
Conclusion
Primary hrHPV screening with cytology triage in women aged ≥30 years is an 
effective way to stratify women on CIN3+ risk and seems a feasible alternative to 
cytological screening. Repeat cytology after 1 year for hrHPV-positive women with 
normal cytology is however necessary before returning women to routine screening.
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Introduction
Cytological screening has reduced the incidence and mortality of cervical cancer 
in countries with organised screening programmes.1 However, cytological screening 
offers a suboptimal prevention against cervical cancer as cytology has a limited 
sensitivity for high-grade cervical intraepithelial neoplasia (CIN).2;3 Many studies 
conducted by combined high-risk human papillomavirus (hrHPV) and cytology 
testing have revealed that testing for hrHPV results in a much higher sensitivity for 
high-grade CIN and cervical cancer (CIN2+) than cytology.3-9 
 Although the data collected so far are in favour of implementing hrHPV testing 
in primary screening there is still debate about the management of hrHPV-positive 
women and about the screening ages at which hrHPV testing would be most 
beneficial. In young women, the prevalence of hrHPV is high and as a 
consequence the management of hrHPV-positive women may be complicated. 
The higher number of positive primary screening tests in this age group may lead 
to adverse effects of screening if more unnecessary follow-up tests and colposcopy 
referrals are made. This is of particular importance for these women of reproductive 
age, because it has been shown that the rate of serious obstetrical complications, 
such as preterm deliveries, low birth weight and premature rupture of the 
membranes, is increased after excisional treatments for precancerous lesions.10 
 Furthermore, young women may have a disproportional high number of regressive 
CIN2 lesions. Ronco et al 9 have shown that primary hrHPV screening is particularly 
effective for women 35 years or older, whereas in younger women hrHPV screening 
would lead to over-diagnosis of regressive CIN2. On the other hand, Bulkmans et al 
5 demonstrated that in women between 30 and 60 years the total number of CIN2+ 
lesions over two screening rounds was equal in both the hrHPV plus cytology arm and 
the cytology only arm, indicating that there is no CIN2 over-diagnosis in the hrHPV plus 
cytology arm. Instead, more highgrade lesions were detected earlier in the hrHPV 
plus cytology arm than in the control arm. This indicates that in this age category 
hrHPV testing detects non-regressing, clinically relevant CIN2+ lesions earlier than 
cytology and suggests that primary hrHPV screening in women of ≥30 years is feasible. 
 To evaluate for the Dutch cervical screening programme the effectiveness of 
implementing hrHPV testing and to assess future implementation issues, we set up 
the VUSA-Screen study (Vrije Universiteit Medical Centre-Saltro laboratory population-
based cervical screening). The study was carried out within the setting of a routine 
cervical screening programme. We present the main results of this cohort study in 
which 3-year follow-up results were related to baseline hrHPV testing and cytology 
testing to find an optimal primary screening method. Special attention was given to 
the question whether hrHPV testing should be offered in combination with cytology 
or as a sole primary screening instrument. In addition, we study how hrHPV-positive 
women should be managed. Finally, we examine at what age (at 30 years or at older 
age) it would be most beneficial to start hrHPV testing.
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Patients and Methods
Patients and procedures 
The VUSA-Screen study is a cohort study within the setting of the Dutch population-
based cervical screening programme designed to evaluate the effectiveness of 
combined cervical cytology screening with hrHPV testing by the HC2 hybridisation 
assay (Qiagen, Gaithersburg, MD, USA). In the Netherlands, women are invited for 
cervical cancer screening at 5-year intervals starting in the year in which they reach 
the age of 30 and with the last invitation in the year in which they turn 60 (age range, 
29–61 years). The study was carried out in the province of Utrecht in the Netherlands 
amongwomen who were invited for the regular cervical screening programme 
between October 2003 and August 2005. The design of the study, including exclusion 
criteria, has been described previously.11 All participants gave written informed 
consent. The VUSA-Screen study was approved by the Ministry of Public Health 
(2002/02-WBO; ISBN-10: 90-5549-452-6) and registered in the trial register (NTR215, 
ISRCTN64621295). 
25 871 eligible women 
received cytology and hrHPV 
test 
Inadequate  
n = 213 
Normal smear 
n = 25 196 
BMD 
n = 337 
>BMD 
n = 125 
hrHPV- 
n = 24 175 
hrHPV- 
n = 21 112 
hrHPV- 
n = 3 063 
hrHPV+ 
n = 1 021 age matched 3:1 
170 hrHPV- 
cytology 
test at 6 
and 18 
months  
(3 CIN2 
  2 CIN3) 
167 hrHPV+ 
referred to 
colposcopy 
(36 CIN2  
   34 CIN3) 
 
10 hrHPV- 
referred to 
colposcopy 
(3 CIN2 
   3 CIN3) 
 
115 hrHPV+ 
referred to 
colposcopy 
(15 CIN2  
81 CIN3 
4 Ca) 
≥BMD hrHPV 
n=92  
referred to 
colposcopy 
≥BMD and or 
hrHPV+ n=61 
referred to 
colposcopy 
Normal 
and hrHPV- 
n=75 
routine 
follow-up 
≥BMD and or 
hrHPV+ n=81 
referred to 
colposcopy 
Normal 
and hrHPV-  
n=1 315 
routine 
follow-up 
Normal  
hrHPV 
blinded 
n=528 
18 CIN2 
22 CIN3 
1 Ca 
5 CIN2 
1 CIN3 
6 CIN2 
2 CIN3 
Early referral on request 
 
1 CIN2 
1 Ca 
Early referral on request 
 
1 CIN3 
Early referral  
on request 
 
5 CIN2 
1 CIN3 
Intake 
t=0 
Repeat  
t=12 
months 
Repeat  
t=24 
months 
Next screening 
round t=5 years 
Figure 1 Flowchart of the screening profiles of women in the VUSA-Screen study. HrHPV = high-risk human papillomavirus; 
hrHPV+ = positive hrHPV test; hrHPV- = negative hrHPV test; BMD = Borderline or mild dyskaryosis; >BMD = moderate  
dyskaryosis or worse; CIN = cervical intraepithelial neoplasia (grade 2 or 3); Ca = Cervical carcinoma. *The baseline 
hrHPV test results of these matched women were blinded.
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 From all participants, a conventional cytological smear was taken with a 
cytobrush (Rovers, Oss, the Netherlands). After preparation of the smear on a glass 
slide, the brush was placed in a vial containing 1ml UCM (Universal Collection Medium; 
Qiagen) for hrHPV testing. Cervical cytology results were reported, blinded to the 
hrHPV testing results, according to the CISOE-A classification, which is routinely used 
in the Netherlands and can be easily converted into the 2001 Bethesda system.12 
Cytological results were grouped as normal, borderline or mild dyskaryosis (BMD), 
and moderate dyskaryosis or worse (≥BMD). In the 2001 Bethesda system, BMD 
corresponds to atypical squamous cells of undetermined significance, atypical 
squamous cells, cannot exclude high-grade squamous intraepithelial lesions, or 
lowgrade squamous intraepithelial lesions. Moderate dyskaryosis or worse corre-
sponds to high-grade squamous or glandular intraepithelial lesions. 
 High-risk HPV testing was performed by HC2 high-risk HPV DNA test in an 
automated format on a rapid capture system according to manufacturer’s instructions 
(Qiagen). This test uses a cocktail probe to detect 13 high-risk HPV types: 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59 and 68. Samples with HC2 outcome of  ≥1 RLU/CO were 
considered as hrHPV positive. HC2-positive samples were tested with GP5./6.-PCR-EIA, 
13 and all specimens tested positive by GP5+/6+-PCR-EIA were typed by reverse line 
blotting.14 
 Women with BMD or worse were informed about the hrHPV test result. The hrHPV- 
positive women with BMD and all women with >BMD were directly referred for 
colposcopy (Figure 1). Women with BMD and a negative hrHPV test were offered 
cytology at 6 and 18 months and referred if cytology was abnormal (threshold BMD) 
at one of these occasions. 
 In the women with normal cytology at baseline, a subcohort was selected. In this 
subcohort, all (n = 1021) hrHPV-positive women as well as a subset of hrHPV-negative, 
cytologically normal women (n = 3063) were included. To select the hrHPV- 
negative women, each hrHPV-positive woman was matched to three randomly 
chosen hrHPV-negative women of the same age. Women were not informed about 
the hrHPV test result. Women with normal cytology and hrHPV-positive test were 
offered cytology and a blinded hrHPV test at 12 months and combined hrHPV and 
cytology testing at 24 months. Women were referred at 12 months if cytology was 
abnormal and at 24 months if cytology was abnormal and/or the hrHPV test was 
positive.
 Women in the subcohort with normal cytology and hrHPV-negative test were in-
vited for repeat testing with both tests at 24 months. These women were referred at 
24 months if cytology was abnormal and/or the hrHPV test was positive. Women with 
normal cytology who were not included in the subcohort were recalled at the next 
screening round after 5 years as part of the routine screening programme. 
 Of the women who were referred to a gynaecologist for colposcopy, colposcopy- 
directed biopsies were taken from suspicious areas of the cervix, according to 
standard procedures in the Netherlands.15 Biopsy results were reported as 
normal, CIN1, 2, or 3, or as invasive cancer, according to the international criteria.16 
Cytology and histology results were retrieved from the nationwide network and registry of 
histopathology and cytopathology (PALGA, Bunnik, the Netherlands).
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Statistical analysis
The primary outcome measure of the study was histologically confirmed CIN3+, 
detected cumulatively within 3 years after baseline. A secondary outcome was 
cumulatively detected CIN2+. In the calculations of the number of CIN3+ and CIN2+ 
lesions, also cases of cervical adenocarcinoma and cervical adenocarcinoma in situ 
were included. 
 Separate CIN3+ and CIN2+ risks were calculated for hrHPV, cytology and 
age-specific strata. The risks were adjusted for nonattendance at repeat testing. 
Non-attendance rates at 12 and 24 months may depend on previous screening test 
results and were read from flow charts (Figure 1).
 The sensitivity and specificity of the hrHPV test and cytology were adjusted for 
non-attendance at repeat testing by writing them as functions of stratum-specific 
CIN3+ or CIN2+ risks.17 Ninety-five percent confidence intervals (CIs) for the CIN3+ 
and CIN2+ risks and for the sensitivities and specificities were obtained from Bayesian 
posterior distributions. To compute posteriors, Beta (0.5,0.5) priors were imposed on 
the probabilities of moving from one box to another box in flowchart (Figure 1). 
The posterior intervals were computed via simulation. The posterior intervals may 
become narrow when one or more of the point estimates of the probabilities equal 
0 (or 1). We accounted for this by imposing a point prior at 0 (or 1) and recomputed 
the Bayesian posterior interval. The reported CIs are unions of the original and 
recomputed posterior intervals. This approach has reasonable frequentist properties 
when estimating a proportion.18 
 Analyses were done with SPSS version 15.0 (LEAD Technologies Inc., Haddonfield, 
NJ, USA), Excel (Microsoft  Corporation, Redmond, WA, USA), and Matlab version 7.9 
(The Mathworks Inc., Natick, MA, USA).
Results
Of the 25 871 women recruited for the VUSA-Screen study, 25 658 (99. 2%) had ad-
equate baseline cytology and hrHPV HC2 test. The median age of participating 
women was 44.0 years (range 29–61 years). Among the women with adequate 
cytology, 97.4% had a normal result, 1.3% had BMD and 0.5% had  >BMD. 
The proportion of women with hrHPV infection(s) was 4.1% in women with normal 
cytology, 49.6% in women with BMD and 92.0% in women with >BMD. Overall, 5.1% 
(1303 out of 25 658) of the women tested hrHPV positive by HC2. In women with BMD 
and negative hrHPV result, the overall compliance to repeat testing was 86.5%. In 
the subcohort of women with normal cytology, compliance to repeat testing was 
similar in the blinded hrHPV-positive and hrHPV-negative group (61.8% and 59.7%, 
respectively, p = 0.237). For women with normal cytology at baseline with follow-up, 
the histology follow-up at 24months showed a higher referral rates after abnormal 
cytology than after an hrHPVpositive, cytologically normal test result (57.0% vs 21.1%, 
respectively). Among women who attended at repeat testing, the average time 
to the first follow-up test was 15.0 months with a standard deviation of 4.7 months. 
The follow-up time ranged from 1.3 to 28.6 months.
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Figure 2 Age-specific prevalence of hrHPV positivity and cytological abnormalities in women of the VUSA-Screen 
study. HrHPV = high-risk human papillomavirus; cytological abnormalities  = borderline or mild  
dyskaryosis or worse (≥BMD).
 We evaluated hrHPV prevalence in seven age groups corresponding to the 
screening rounds. We found the highest hrHPV prevalence among women between 
29 and 33 years of age who were invited for the first time (10.5%; 95% CI: 9.6–11.4%). 
As the age increased, hrHPV prevalence decreased until age 49 years. The hrHPV 
prevalence in women aged 59– 61 years was 2.0% (95% CI: 1.5– 2.8%; Figure 2). Women 
aged 29 –33 years showed a significanly higher hrHPV prevalence (10.5%; 95% CI: 9.6– 
11.4%) than women aged 34–61 (4.0%; 95% CI: 3.7–4.3%) (p < 0.001). Among women 
with adequate cytology, 1.8% (95% CI: 1.62.0%) had an abnormal result (≥BMD). The 
highest proportion of abnormal cytology was found in women aged 29-33 years 
(i.e., 2.5%; 95% CI: 2.1–3.1%) and the lowest proportion was found in women aged 
59–61 years (0.6%; 95% CI: 0.3–1.0%). 
 The histological follow-up results in relation to baseline cytology and hrHPV test 
results, stratified by two age groups, are presented in Table 1. Among women with 
normal cytological results, the proportion of CIN3+ cases was 2.6% (27 out of 1021) if 
the hrHPV test was positive and 0.07% (2 out of 3063) if the hrHPV test was negative. 
For women with abnormal cytology, the proportion of CIN3+ cases was 42.2% 
(119 out of 282) if the hrHPV test was positive and 2.8% (5 out of 180) if the hrHPV test 
was negative. 
 Of 1021 women with normal cytology and a positive hrHPV test at baseline, 
92 women had abnormal cytology at 12 months follow-up of whom 76 (82.6%) tested 
hrHPV positive, 6 (6.5%) tested hrHPV negative and 10 (10.9%) women had an 
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unknown hrHPV status. Of the women with normal cytology and a positive hrHPV test 
at baseline, 528 had normal cytology at 12 months follow-up of whom 224 (42.4%) 
tested hrHPV positive, 219 (41.5%) tested hrHPV negative and 84 (15.9%) had an 
unknown hrHPV status. The attendance at 24 months was comparable for women 
with normal cytology and hrHPV-positive test at 12 months (14 women with normal 
cytology and hrHPV-negative test and 52 women with abnormal cytology and/or 
hrHPV-positive test) and women with normal cytology and hrHPV-negative test (52 
women with normal cytology and hrHPV-negative test and 6 women with abnormal 
cytology and/or hrHPV-positive test). 
 The absolute and relative sensitivity and specificity of cytology and hrHPV testing 
for detection of CIN3+ and CIN2+ are presented in Table 2. The sensitivity of hrHPV 
testing for CIN3+, adjusted for non-attendance at repeat testing, was 1.42-fold higher 
than the sensitivity of cytology (91.9% vs 64.6%) at the cost of a lower specificity (95.6% 
vs 98.7%). The sensitivity of hrHPV testing for CIN2+ was 1.63-fold higher than cytology 
(82.0% vs 50.5%); however, the specificity was 0.97 fold lower (96.0% vs 98.9%). 
 The cumulative 3-year CIN3+ and CIN2+ risks, adjusted for non-attendance at 
repeat testing, are presented in Figure 3. The CIN3+ risk was markedly lower in women 
negative for hrHPV (0.06%; 95% CI: 0.02–0.46%) than in women with negative cytology 
(0.26%, 95% CI: 0.20–0.65%). There was only a small, non-significant difference 
in CIN3+ risks between women with negative results on both tests (0.05%; 95% CI: 
0.01–0.42) and women negative for hrHPV only (0.06%; 95% CI: 0.02–0.46).Women 
with abnormal cytology (≥BMD) result had a CIN3+ risk of 26.2% (95% CI: 22.5–32.2) 
and those with an hrHPV positive test had a risk of 13.2% (95% CI: 11.4–15.9). The highest 
CIN3+ risk (i.e., 42.2%; 95% CI: 36.4–48.2) was found in hrHPV-positive women who 
had abnormal cytology. The HPV16/18 genotyping at baseline showed that hrHPV-
positive women for other types than HPV16/18 still had a CIN3+ risk of 6.6% (95% CI: 
4.8–9.0). The HPV16+ and/or 18+ women had a CIN3+ risk of 26.1% (95% CI: 21.4–31.4) 
(Figure 3).
 The majority of the hrHPV-positive women had normal cytology and those wom-
en still had a CIN3+ risk of 5.22% (95% CI: 3.72–7.91). The HPV16/18 genotyping of 
hrHPV-positive women at baseline did not result in sufficient low risks for a screenings 
programme with 5 years interval. Women with hrHPV-positive normal cytology and 
HPV16 and/or HPV18-positive test had a CIN3+ risk of 13.0% (7.93–23.6), whereas 
women who tested hrHPV positive for other high-risk types had a much lower risk 
of 2.44% (95% CI: 1.61–5.25). We also evaluated a baseline triage and follow-up 
strategy for hrHPV-positive women. Baseline cytology triage followed by repeat 
cytology testing at 1 year showed that the CIN3+ risk reduced to only 1.6% (95% CI: 
0.6–4.9) in women with normal cytology at the repeat test. In women with abnormal 
cytology at the repeat test, the CIN3+ risk was 25.0% (95% CI: 16.6 – 35.1). This CIN3+ 
risk is comparable to the CIN3+ risk of hrHPV-positive women with abnormal cytology 
at baseline.
 Analysis using CIN2+ as outcome measure found comparable results, albeit with 
higher absolute risks. The cumulative 3-year CIN2+ risk was 0.26% (95% CI: 0.14–0.69%) 
among hrHPV-negative women and 0.68% (95% CI: 0.54–1.13%) among women with 
negative cytology. The CIN2+ risk was similar for women with negative results on both 
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Table 1 Three-year cumulative histology outcome by age, baseline cytology and hrHPV results
Age Cytology hrHPV Total CIN0/1 CIN2 CIN3 AdCa SCC CIN3+ CIN2+
Invited for Normal in hrHPV+ 367 15 11 12 1 0 13 24
the first time   sub-cohort hrHPV- 1099 7 4 1 0 0 1 5
(29-33 yrs) Abnormal hrHPV+ 85 19 18 34 0 1 35 53
  hrHPV- 25 0 3 1 0 0 1 4
Others Normal in hrHPV+ 654 47 19 13 0 1 14 33
(34-61yrs) sub-cohort hrHPV- 1964 24 1 1 0 0 1 2
  Abnormal hrHPV+ 197 56 33 81 1 2 84 117
  hrHPV- 155 18 3 4 0 0 4 7
AdCa = adenocarcinoma; CIN = cervical intraepithelial neoplasia; hrHPV = high-risk human papillomavirus; hrH-
PV+= positive hrHPV test; hrHPV- = negative hrHPV test; abnormal cytology = borderline or mild dyskaryosis or worse 
(≥BMD); normal in subcohort = a cohort of women with normal cytology and hrHPV- was age matched to hrHPV-
positive women with normal cytology; SCC = squamous cell carcinoma. Women in the subcohort were invited for 
combined testing at 24 months and referred if cytology was abnormal and/or the hrHPV test was positive.
Table 2  Absolute and relative sensitivity and specificity of hrHPV testing vs cytology, adjusted for non-attendance at 
repeat testing
Screening testa Endpoint CIN3+ Endpoint CIN2+
   (95% CI) (95% CI)
Sensitivity 
     hrHPV   91.9% (61.0-96.7) 82.0% (62.9-89.6)
     Cytology 64.6% (43.3-73.1) 50.5% (38.4-58.0)
 Specificity  
     hrHPV   95.6% (95.3-95.8) 96.0% (95.7-96.3)
     Cytology 98.7% (98.5-98.8) 98.9% (98.7-99.0)
 Relative sensitivity  
     hrHPV vs cytology 1.42 (1.19-1.67) 1.63 (1.40-1.89)
 Relative specificity  
     hrHPV vs cytology 0.969 (0.966-0.971) 0.971 (0.968-0.974)
HrHPV = high-risk human papillomavirus; CI = confidence interval; CIN = cervical intraepithelial neoplasia (grade 2 
or 3 or higher). aCytology positivity was defined as a result of borderline or mild dyskaryosis or worse (≥BMD).
tests (0.24%; 95% CI: 0.12–0.64%) and women negative for hrHPV only (0.26%; 95% CI: 
0.14–0.69%). The hrHPV-positive women with normal cytology had a CIN2+ risk of 11.3% 
(95% CI: 8.90–15.2) and hrHPV-positive women with normal cytology and negative 
for HPV16/18 genotyping had a CIN2+ risk of 8.01% (95% CI: 5.53–12.6).
 When stratifying hrHPV-positive women into two age groups, there was a 
borderline non-significant difference in CIN3+ risk (adjusted for non-attendance at 
repeat testing) between women ≥34 years of age and women invited for the first time 
(aged 29–33 years) (relative risk (RR) 0.78 95% CI: 0.52–1.15). The RR for CIN2+ was 0.87 
(95% CI: 0.64–1.18). In hrHPV-positive women with normal cytology, the CIN3+ risk was 
significantly lower in women aged ≥34 years (4.0; 95% CI: 2.3-6.6) than in women 
aged 29–33 years (10.9%; 95% CI: 5.9–19.2). The corresponding RR was 3.02 (95% CI: 
1.39-7.07). The CIN2+ risk was 10.7 (95% CI: 7.3–15.3) in women with normal cytology 
and age ≥34 years, 16.6% (95% CI: 10.7–25.3) in women with normal cyto-logy and age 
29–33 years, and the corresponding RR was 0.65 (95% CI: 0.37–1.14). When stratifying 
hrHPV-positive women with abnormal cytology into two age groups, no risk difference 
between the older and younger age group was observed for CIN3+ and CIN2+ 
(RR CIN3. 1.03; 95% CI: 0.78 –1.42; RR CIN2. 0.95; 95% CI: 0.79–1.18).
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Discussion
Implementation of hrHPV testing as a primary screening instrument in cervical 
screening is still under debate. The presented study enables us to examine three 
implementation issues in more detail. First, whether hrHPV testing should be offered 
in combination with cytology or as a sole primary screening instrument. Second, how 
hrHPV-positive women should be managed. Third, the screening ages at which hrHPV 
testing would be most beneficial.
 In our study, hrHPV testing has a 27.3% higher sensitivity but a 3.1% lower 
specificity than cytology for detection of CIN3+. For CIN2+, these figures were 31.5% 
and 2.9%, respectively. These results are in line with other screening studies 6;7;19-24  which 
have demonstrated that hrHPV testing is superior to cytology in terms of sensitivity 
but not in terms of specificity. Women with a negative hrHPV test were found to 
have a very low risk of an underlying or incipient high-grade CIN lesion and their 
CIN3+ risk is not markedly lower after ascertainment that cytology is normal. 
Therefore, from a health-economic perspective, cervical screening with a primary, 
stand-alone hrHPV test seems preferable. Similar recommendations have been made 
based on the recent cost-effectiveness studies.25 
 The hrHPV testing in primary screening creates a clinical dilemma for the 
management of hrHPV-positive women. These women are at mildly but significant 
risk of CIN3+ (13.2%). However, referring all hrHPV-positive women to colposcopy may 
result in overdiagnosis and overtreatment.8 In current cytological screening 
practice, women with a BMD smear, having a CIN3+ risk of 6.4%,11 are also not 
immediately referred for colposcopy but are advised to repeat cytology testing after 
6 and 18 months.26 
 In the present study, we have used cytology as a triage tool to identify women 
at high risk for CIN3+ among the hrHPV-positive women. Women with an hrHPV- 
positive test and abnormal cytology had a CIN3+ risk of 42.2% and obviously need 
immediate colposcopy. On the other hand, hrHPV-positive women with normal 
cytology have a low, but still non-negligible CIN3+ risk of 5.2%. This risk is too high to 
delay follow-up to the next screening round (in the Netherlands 5 years) but too low to 
refer them for immediate colposcopy. Therefore, hrHPV-positive women with 
normal cytology at baseline require further triage testing and/or follow-up. In our 
study, women were retested after 1 year by means of cytology and after 2 years by 
both cytology and hrHPV. An analysis of the repeat testing results showed that the 
decision either referral to colposcopy or return to routine screening can be made 
after 1 year on the basis of one repeat cytological test. The CIN3+ risk after 1-year 
normal cytology was only 1.6%. This risk is similar to the CIN3+ risk of women with BMD 
at baseline and normal cytology at 6 and 18 months follow-up (1.2%), which is pres-
ently accepted in the Netherlands. Furthermore, the CIN3+ risk of 1.6% is also below 
the CIN3+ risk threshold proposed by Castle et al 27 (2%) to justify no further follow-up. 
The CIN3+ risk after 1-year abnormal cytology was 25% and high enough to warrant 
referral for colposcopy.
 Based on the present data, one may ask what the results are of other triage 
algorithms for hrHPV-positive women. This post hoc analysis on data of the 
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present study is beyond the scope of this paper but has been presented in a 
separate paper.28
 We observed in our cohort study that the CIN3+ and CIN2+ detection rate in 
hrHPV-positive women was similar for women invited for cervical screening for the 
fist time (age 29–33 years) and for older women (≥34 years). The same accounts for 
hrHPV-positive women with abnormal cytology. However, the CIN3+ detection rate in 
hrHPV-positive women with normal cytology was significantly higher among younger 
women (29–33) than among older women (≥34). Ronco et al 9 found in the hrHPV 
arm of women between 25 and 34 years a substantially higher proportion of CIN2 
lesions than in women ≥35 years. This coincided with an increase in detection of CIN2+ 
over two screening rounds compared with women ≥35 years. It was argued that un-
der the CIN2+ lesions detected in women younger than 35 years in the first round, a 
disproportionate number of regressive CIN2 lesions were present. We argue that such 
a potential age-related overdiagnosis does not occur in women ≥30 years of age. 
 First, in the POBASCAM study the CIN2+/CIN3+ baseline detection in women over 
30 years of age was higher in the hrHPV testing arm than in the cytology arm but over 
two screening rounds (interval 5 years), the CIN2+/CIN3+ detection rates were similar 
in both arms.5 These data indicate that the increased detection of CIN2+/3+ lesions in 
the hrHPV arm at baseline in women over 30 years of age does not lead to overdiag-
nosis of regressive CIN2+ lesions but that the lesions are merely detected earlier and 
non-regressive, clinically relevant.5
 In addition, in present study the CIN3+ and CIN2+ risk was similar in women in-
vited for the first time (29–33 years) and in women ≥34 years. Moreover, in hrHPV-
positive women with normal cytology, the CIN3+ risk was higher in women invited 
for the first time than in older women. A possible explanation is that hrHPV infections 
detected in women invited for the first time may have persisted for many years 
before being identified by screening and therefore more likely to have developed into 
high-grade lesions. These results are in line with published data from the Guanacaste 
cohort.29 In addition, we recently showed that the detection rate of CIN3+ and 
CIN2+ did not differ between women aged 29–33 years and women ≥34 years.30 
Moreover, this study indicates that hrHPV testing in women aged 29–33 years does not 
result in excessive diagnosis of regressive lesions.
Limitations and strengths of the study
A limitation of our study is that women with normal cytology were not informed 
about the hrHPV status at baseline. This concealment was necessary to maximise 
attendance at repeat testing among hrHPV-negative women with normal cytology. 
The repeat testing attendance rate in women with normal cytology was 61.8% in 
hrHPV-negative and 59.7% in hrHPV-positive women. The attendance at repeat 
testing has been shown to be particularly poor after a cytologically normal test.31 
The attendance rate of hrHPV-positive women in the present study might have been 
higher if women had been informed about their hrHPV test result. 
 We observed a higher percentage of histology reports after referral on the 
basis of abnormal cytology than after an hrHPVpositive, cytologically normal test result. 
This difference may be related to anticipated association between biopsy rate and 
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colposcopic image of the cervix. If adjusted for, the effect of hrHPV testing on CIN3+ 
will be somewhat higher than the effect reported in this study. In this regard, several 
studies have indicated that the effect of hrHPV testing will be higher when a blind 
biopsy is carried out in women with a normal colposcopic impression.32 
 Another limitation of our study may be the use of a subjective test such as cytology 
as a triage test for hrHPV-positive women. However, Leinonen et al 23 reported 
that the influence of knowing the hrHPV results in reading cytology was small. 
In this context, it is expected that in the near future molecular biomarkers can be 
used as objective triage tests of hrHPV-positive women. Suitable candidate novel 
bio-markers such as HPV mRNA,33 methylation markers34;35 or genotyping 36 might 
further enhance the efficacy of screening with hrHPV DNA.
 A strong point of our study is that this study is population based and is 
integrated in the regular screening programme of eligible women aged 29–61 years. 
The differences in sensitivity between hrHPV screening and cytological screening are 
slightly overestimated because in the practice of screening some women will not 
attend repeat testing after an hrHPV-positive test. Nevertheless, a higher attendance 
at repeat testing is to be expected once the implication of a positive hrHPV test is well 
communicated to the women and hrHPV screening becomes routine.37
Conclusions
Although cytology adds little to the reassurance from a negative hrHPV test against 
high-grade lesions, it is a very useful risk stratifier in hrHPV-positive women and results in 
a feasible screening algorithm. We showed that repeat cytology testing after 1 year 
for hrHPV-positive women with normal cytology at baseline is critical for maximising 
the benefits of primary hrHPV testing in routine cervical cancer screening.
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ABSTRACT
Background
Human papillomavirus (HPV) testing is more sensitive for the detection of high-grade 
cervical lesions than is cytology, but detection of HPV by DNA screening in two screening 
rounds 5 years apart has not been assessed. The aim of this study was to assess whether 
HPV DNA testing in the first screen decreases detection of cervical intraepithelial 
neoplasia (CIN) grade 3 or worse, CIN grade 2 or worse, and cervical cancer in the 
second screening.
Methods
In this randomised trial, women aged 29–56 years participating in the cervical screening 
programme in the Netherlands were randomly assigned to receive HPV DNA (GP5+/6+-
PCR method) and cytology co-testing or cytology testing alone, from January, 
1999, to September, 2002. Randomisation (in a 1:1 ratio) was done with computer- 
generated random numbers after the cervical specimen had been taken. At the 
second screening 5 years later, HPV DNA and cytology co-testing was done in both 
groups; researchers were masked to the patient’s assignment. The primary endpoint 
was the number of CIN grade 3 or worse detected. Analysis was done by intention to 
screen. The trial is now finished and is registered, number ISRCTN20781131.
Findings
22 420 women were randomly assigned to the intervention group and 22 518 to the 
control group; 19 999 in the intervention group and 20 106 in the control group were 
eligible for analysis at the first screen. At the second screen, 19 579 women in the 
intervention group and 19 731 in the control group were eligible, of whom 16 750 
and 16 743, respectively, attended the second screen. In the second round, CIN 
grade 3 or worse was less common in the intervention group than in the control group 
(88 of 19 579 in the intervention group vs 122 of 19 731 in the control group; relative 
risk 0.73, 95% CI 0.55–0.96; p=0•023). Cervical cancer was also less common in the 
intervention group than in the control group (four of 19 579 in the intervention group 
vs 14 of 19 731; 0.29, 0.10–0.87; p=0.031). In the baseline round, detection of CIN 
grade 3 or worse did not differ significantly between groups (171 of 19 999 vs 150 of 
20 106; 1.15, 0.92-1.43; p=0.239) but was significantly more common in women with 
normal cytology (34 of 19 286 vs 12 of 19 373; 2.85, 1.47–5.49; p=0.001). Furthermore, 
significantly more cases of CIN grade 2 or worse were detected in the intervention 
group than in the control group (267 of 19 999 vs 215 of 20 106; 1.25, 1.05-1.50; 
p=0.015). In the second screen, fewer HPV16-positive CIN grade 3 or worse were 
detected in the intervention group than in the control group (17 of 9481 vs 35 of 
9354; 0.48, 0.27–0.85; p=0.012); detection of non-HPV16-positive CIN grade 3 or worse 
did not differ between groups (25 of 9481 vs 25 of 9354; 0.99, 0.57–1.72; p=1.00). The 
cumulative detection of CIN grade 3 or worse and CIN grade 2 or worse did not differ 
significantly between study arms, neither for the whole study group (CIN grade 3 or 
worse: 259 of 19 999 vs 272 of 20 106; 0.96, 0.81–1.14, p=0.631; CIN grade 2 or worse: 
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427 of 19 999 vs 399 of 20 106; 1.08, 0.94-1.24; p=0.292), nor for subgroups of women 
invited for the first time (CIN grade 3 or worse in women aged 29–33 years: 102 of 3139 
vs 105 of 3128; 0.97, 0.74–1.27; CIN grade 2 or worse in women aged 29–33 years: 153 
of 3139 vs 151 of 3128; 1.01, 0.81–1.26; CIN grade 3 or worse in women aged 34–56 
years: 157 of 16 860 vs 167 of 16 978; 0.95, 0.76–1.18; CIN grade 2 or worse in women 
aged 34–56 years: 274 of 16 860 vs 248 of 16 978; 1.11, 0.94–1.32).
Interpretation
Implementation of HPV DNA testing in cervical screening leads to earlier detection of 
clinically relevant CIN grade 2 or worse, which when adequately treated, improves 
protection against CIN grade 3 or worse and cervical cancer. Early detection of 
high-grade cervical legions caused by HPV16 was a major component of this benefit. 
Our results lend support to the use of HPV DNA testing for all women aged 29 years 
and older. 
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Introduction
Infection with high-risk types of human papillomavirus (HPV) has a causal role in the 
development of cervical cancer.1,2 This link has stimulated the development of HPV 
DNA testing, which might be useful in primary cervical screening.3,4 Furthermore, 
prophylactic HPV16 and HPV18 vaccines have been developed and introduced in 
many countries as a primary prevention method.5,6 
 Randomised controlled screening trials of HPV DNA testing 7–11 have shown a 
decreased detection of high-grade cervical lesions at the second screening round 
compared with cytology alone. Although the screening protocols, study endpoints, 
and interval between screening rounds varied in these trials, the consistent results 
suggest that HPV DNA testing offers better protection against high-grade cervical 
lesions in second screening rounds than do cytology-based screening methods. 
Only one study10 was large enough to also show protection against cervical cancer 
in the second screening round. 
 We present the final results of the POpulation-Based SCreening study AMsterdam 
(POBASCAM) trial, a population-based, randomised controlled trial. Our main goal 
was to assess whether HPV DNA testing decreases detection of cervical intraepi-
thelial neoplasia (CIN) grade 3 or worse, of CIN grade 2 or worse, and of cervical 
cancer, in the second screening round. Additionally, to assess the most appropriate 
age at which HPV DNA testing should start, we analysed women invited for 
the first time (aged 29–33 years) and older women (34–56 years) separately. 
We also assessed how detection of high-grade lesions in two screening rounds was 
associated with particular HPV genotypes.
Methods
Study design and participants
Patients were enrolled between January, 1999, and September, 2002, as part of 
the nationwide cervical screening programme. In the Netherlands, women are 
invited for cervical cancer screening at 5 year intervals starting in the year when 
they reach age 30 years and ending in the year when they reach age 60 years. The 
design, methods, and baseline results of the trial have been described.7,12 Detection of 
neoplasia or cancer in the first 48 months was classed as detected in the first screening 
round and those detected during 48–108 months were classed as detected 
in the second screening round. The cutoff after 48 months was used because 
women in the Netherlands are invited for a new screen in the year they reach 30 years, 
35 years, 40 years, and so on. Therefore, the actual screening interval between 
invited smears is between 4 and 6 years. Women who had a history of CIN grade 2 or 
worse, had abnormal cytology in the preceding 2 years, or who had had a hysterectomy 
were excluded. Women aged 57 years or older at baseline were also excluded 
because they would not routinely receive a smear in the second round. All 
participants provided written informed consent. The trial was approved by both the 
Medical Ethics Committee of VU University Medical Centre and the Ministry of Public 
Health (The Hague, Netherlands). 
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Randomisation and masking
LR randomly assigned women to the intervention or control groups in a 1:1 ratio 
with computer-generated random numbers after the cervical specimen had been 
taken and administrative data entered into the central study database. Neither the 
molecular technicians nor the cytotechnicians had access to the central study 
database, and so were unaware of a patient’s assignment. Women in the intervention 
group were given their HPV DNA and cytology result and managed accordingly. 
For the control group, the patients and all medical personnel were masked to the 
HPV DNA test results. At the second screening round, women in both groups were 
managed according to their newly obtained HPV DNA and cytological test results. 
In both groups pathologists were aware of the cytology result but not of the HPV 
result. CIN (CIN grade 1 or worse) biopsies were reviewed by two experienced 
cervical pathologists (FJvK and LR) who were masked to the HPV and cytology results. 
Procedures 
Women were screened at baseline with either combined HPV DNA testing and 
cytology or cytology alone.12 At the second screening round 5 years later, all 
women were screened with both HPV DNA testing and cytology so that we could 
detect high-grade CIN and cancer cases in the control group that we would otherwise 
have missed with cytology alone. 
 Conventional cytological smears were taken with a Cervex-Brush (Rovers, Oss, 
Netherlands) or a cytobrush. The brush was placed in a vial containing 5 mL 
phosphate-buffered saline for HPV DNA testing. Cytology results were read according 
to the CISOE-A classification,13 which can be roughly converted to the 2001 Bethesda 
system.14 Cytological results were grouped as normal, borderline or mild dyskaryosis, 
or moderate dyskaryosis or worse. In the 2001 Bethesda system, borderline 
Normale cytology 
and high-risk HPV 
negative 
Normale cytology and  
high-risk HPV positive 
BMD 
 
Moderate dyskaryosis 
or worse 
Second screening 
round 
Cytology and high-risk HPV 
testing at 6 months 
Cytology and high-risk 
HPV testing at 6 months 
Colposcopy and 
biopsy 
Normal or BMD 
 
Moderate dyskaryosis  
or worse 
Cytology and high-risk 
HPV testing at 18 months 
Colposcopy and biopsy 
 
Normal or BMD, and 
high-risk HPV negative 
Moderate dyskaryosis or 
worse, or high-risk HPV positive 
Second screening round Colposcopy and biopsy 
Normal or BMD high-risk 
HPV negative 
Moderate dyskaryosis or worse, 
or BMD high-risk HPV positive 
Cytology and high-risk HPV 
testing at 18 months 
Colposcopy and biopsy 
 
Normal or BMD, and 
high-risk HPV negative 
Moderate dyskaryosis or worse, 
or high-risk HPV positive 
Second screening round Colposcopy and biopsy 
Figure 1 Management of women in the intervention group at the first screening round. In the second screening round 
women in both groups were managed in the same way as the intervention group were in the first screening round. 
BMD=borderline or mild dyskaryosis. HPV=human papillomavirus.
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or mild dyskaryosis corresponds to atypical squamous cells of unknown clinical 
significance, atypical squamous cells and cannot rule out high-grade squamous 
intraepithelial lesions, lowgrade squamous intraepithelial lesions, or atypical 
glandular cells. Moderate dyskaryosis or worse corresponds to both squamous and 
glandular highgrade intraepithelial lesions. 
 HPV DNA testing was done by general primer (GP5+/6+) PCR enzyme 
immunoassay,15 which detects 14 high-risk types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68). Positive specimens were typed by reverse line blotting.16 
 Figure 1 shows how patients were managed, in accordance with Dutch guide-
lines,13,17 and has been described in detail previously.7 Of the women who were 
referred for colposcopy, colposcopy-directed biopsies of suspicious parts of the 
cervix were taken for histological examination, according to standard procedures 
in the Netherlands.18 Colposcopies were not registered, therefore, data of registered 
biopsy rates were used to estimate the number of gynaecological tests. 
 Histology was examined locally and classified as normal, CIN grade 1, 2, 3, or 
invasive cancer, according to inter national criteria.19,20 Glandular intraepithelial 
neoplasia grade 1, 2, and 3 were included in their respective CIN categories. In the 
analyses presented here, the original diagnoses were used. Cytology and histol-
ogy results were retrieved from the nationwide registry of histopathology and cyto- 
pathology results and, when necessary, from individual laboratory records. The 
reviewed histological results for biopsies of CIN grade 1 or worse are shown in the 
appendix. 
 The primary outcome measure was histologically confirmed CIN grade 3 or 
worse, with a primary endpoint of the number of CIN grade 3 or worse detected. 
The secondary outcome measures were cervical cancer and CIN grade 2 or worse. 
Cervical cancer included squamous cell carcinoma, adenocarcinoma, and 
adenosquamous cell carcinoma; adenocarcinoma in situ were included in the CIN 
grade 3 group. 
Statistical analysis
The main analyses included all randomly assigned women and were done by 
intention to screen. The overall number of CIN grade 3 or worse identified in each 
group was calculated for the first screening round, the second screening round, 
and the two rounds combined. For the second round, we included only those 
women who did not have CIN grade 2 or worse at baseline and who were eligible 
for subsequent screening, because those with CIN 2 or worse were managed 
according to current treatment protocols. When enrolment was complete all 
women had the opportunity of 108 months of follow-up. Events after 108 months were 
not included. Because HPV DNA prevalence decreases with age and CIN grade 2 or 
worse can spontaneously regress in young women, we analysed women invited for 
the first time (aged 29–33 years) and older women (34–56 years) separately to assess 
the most appropriate age at which HPV DNA testing should start. 
 Reason for smear test was not recorded in the nationwide registry of 
histopathology and cytopathology results. The contribution of opportunistic screening 
in women with a negative screening test at baseline was estimated by the proportion of 
women who had an additional smear before receiving a new invitation after 5 years. 
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Differences in detection between the groups were calculated with Fisher’s exact test. 
All p values are two-sided. Analyses were done with SPSS version 12.0. 
 A study size of 44 000 was calculated to be sufficiently large to detect (with 
80% power) a significant difference in the number of lesions CIN grade 3 or worse 
between groups at the second screen after borderline or mild dyskaryosis at baseline. 
The sample size was also sufficient to show a decrease at the second round of 
CIN grade 3 or worse lesions in women in the intervention group who had normal 
cytology at baseline compared with women in the control group who had normal 
cytology at baseline. For the power calculations, we assumed that 84.5% of the 
baseline smears were cytologically normal, that 14% of the baseline smears were 
49 220 women eligible  
44 938 enrolled and randomly assigned 
4282 not enrolled 
22 420 assigned to the intervention 
group 
22 518 assigned to the control group 
   2421 excluded 
7 hysterectomy 
216 moderate dyskaryosis  
or worse in preceding 2 years 
201 missing HPV DNA test 
1997 age ≥57 years at 
baseline 
   2412 excluded 
9 hysterectomy 
217 moderate dyskaryosis or 
worse in preceding 2 years 
186 missing HPV DNA test 
2000 age ≥57 years at 
baseline 
19 999 eligible 20 106 eligible 
    420 not eligible 
267 CIN2+ in first screen 
153 hysterectomy at first 
screen 
    375 not eligible 
215 CIN2+ in first screen 
160 hysterectomy at first 
screen 
19 579 eligible 19 731 eligible 
2829 did not 
attend second 
screen 
2988 did not 
attend second 
screen 
16 750 women attended second 
screen 
16 743 women attended second 
screen 
First  
screen 
Second 
screen 
Figure 2 Trial profile. HPV=human papillomavirus. CIN2+=cervical intraepithelial neoplasia grade 2 or worse. *The major 
reason for women not to be enrolled in our study was lack of time for general practitioners to explain the objectives of 
the study.
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borderline or mild dyskaryosis, and that 4% of the normal and 15% of the borderline 
or mild dyskaryosis smears were positive for HPV DNA. The prevalences of CIN grade 
3 or worse in the second screen were assumed to be 0.4% and 0.9% for women 
with normal cytology and borderline or mild dyskaryosis at baseline, respectively. 
Furthermore, the relative risk of HPV DNA for CIN grade 3 or worse in the subsequent 
round was assumed to be 13, which is the lower bound of the 95% CI reported in a 
previous study,21 which provided a conservative estimate for the required sample size. 
The study was not powered to detect a difference in CIN grade 3 or worse at base-
line. This trial is registered as an International Standard Randomised Controlled Trial, 
ISRCTN20781131. 
  
 Intervention group Control group
       
  Total CIN0/1 CIN2 CIN3 Cervical   Total CIN0/1 CIN2 CIN3 Cervical 
          cancer     cancer
Baseline screen                     
Inadequate cytology          
   HPV DNA positive 2 0 1 0 0 0 0 0 0 0
   HPV DNA negative 31 1 0 0 0 27 2 0 0 0
Normal cytology          
   HPV DNA positive 724 48 31 29 2 766 9 6 9 1
   HPV DNA negative 18562 218 7 3 0 18607 233 4 2 0
Borderline or mild dyskaryosis          
   HPV DNA positive 185 29 24 34 3 192 30 25 29 1
   HPV DNA negative 330 28 3 3 1 335 22 2 5 0
Moderate dyskaryosis or worse          
   HPV DNA positive 146 11 26 87 5 160 20 24 93 4
   HPV DNA negative 19 6 4 3 1 19 4 4 6 0
Total 19999 341 96 159 12 20106 320 65 144 6
Subsequent round                     
Inadequate cytology          
   HPV DNA positive 0 0 0 0 0 2 0 0 0 0
   HPV DNA negative 21 0 0 0 0 27 0 0 0 0
   No HPV DNA test 21 2 0 0 0 23 0 0 0 0
Normal cytology          
   HPV DNA positive 284 18 10 9 1 272 26 14 14 0
   HPV DNA negative 8941 98 6 1 0 8811 107 3 1 0
   No HPV DNA test 7025 134 14 1 1 7108 162 7 2 1
Borderline or mild dyskaryosis          
   HPV DNA positive 67 20 9 12 0 77 16 12 15 1
   HPV DNA negative 129 7 1 2 0 118 9 2 0 1
   No HPV DNA test 164 23 14 7 0 200 22 9 11 1
Moderate dyskaryosis or worse          
   HPV DNA positive 31 3 5 20 0 41 0 6 27 3
   HPV DNA negative 8 2 3 1 0 6 0 0 4 0
   No HPV DNA test 59 10 10 26 2 58 8 9 29 4
No screening test* 2829 52 0 5 0 2988 59 0 5 3
Total  19579 369 72 84 4 19731 409 62 108 14
Both rounds                    
Total 19999 710 168 243 16 20106 729 127 252 20
Cases detected by opportunistic screening are also included. CIN3=cervical intraepithelial neoplasia grade 3. 
CIN2=cervical intraepithelial neoplasia grade 2. CIN0/1=cervical intraepithelial neoplasia grade 0 or 1. 
*Women who had no second round smear recorded.
Table 1 Cervical intraepithelial neoplasia and cervical cancers at baseline screen and subsequent screen.
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Role of the funding source 
The sponsors had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit for publication. 
Results
Figure 2 shows the trial profile. The median age at recruitment was 40.0 years 
(IQR 34.0–49.0 years) in both groups. For women without CIN grade 2 or worse, the 
median time since last cytological results was 5.0 years (4.4–5.5). Compliance to 
follow-up testing (at least one repeat smear) was higher in the control group (477 of 
527 patients [91%]) than in the intervention group (1007 of 1239 patients [81%]). The 
difference in compliance was related to baseline cytology. In the intervention group, 
456 of 515 (89%) women with borderline or mild dyskaryosis at baseline, and 551 of 724 
(76%) with normal cytology and a positive high risk HPV test complied with follow-up. 
 Attendance for the second screen was not significantly different between groups 
(16 750 of 19 579 [86%] patients in the intervention group vs 16 743 of 19 731 [85%] 
in the control group). Compliance to follow-up testing did not differ significantly 
between groups—539 (84%) of 644 patients in the intervention group and 564 (85%) 
of 667 in the control group complied. Attendance at the second screen of cytologi-
cally negative, HPV DNA positive women was much the same in the intervention and 
control groups (553 of 724 [76%] women vs 588 of 766 [77%] women). 2424 of 18 562 
(13%) women who were negative at baseline in the intervention group and 2542 of 
19 373 (13%) women who were negative at baseline in the control group had an 
additional smear before receiving a new invitation after 5 years (opportunistic 
screening). Table 1 shows the number of cervical lesions by study group, in relation 
to cytological and HPV DNA results at the first and second screens. Positive HPV 
DNA (masked in the control group) and abnormal cytology at baseline were much 
the same for the intervention and control groups.12 The number of CIN grade 0 or 1 
detected at the first and second screens was similar in the intervention and control 
groups. Most CIN grade 0 or 1 were detected after a negative first screen whereas 
most CIN grade 2 or 3, and cancer cases were detected after a positive first screen. 
 In the intervention group, 12 cancers (one adenocarcinoma and 11 squamous 
cell carcinomas) and five adenocarcinomas in situ were identified in the first screen; 
in the second screen, four cancers (one adenocarcinoma and three squamous cell 
carcinomas) and one adenocarcinoma in situ were identifi ed. In the control group, 
six cancers (two adenocarcinomas and four squamous cell carcinomas) and five 
adenocarcinomas in situ were identified at the first screen; 14 cancers (two adeno-
carcinoma and 12 squamous cell carcinomas) and four adenocarcinomas in situ 
were identified in the second screen. 
 Table 2 shows the number of high-grade cervical lesions in each group at first 
and second screens. For the first screen, detection of CIN grade 3 or worse did not 
differ significantly in the intervention group compared with the control group 
(p=0.239). Additionally, the number of cervical cancer cases did not diff er signifi cantly 
between the intervention and control groups (p=0.166). However, significantly more 
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CIN grade 2 or worse were detected at baseline in the intervention group than 
in the control group (p=0.015). In the second screen, fewer CIN grade 3 or worse 
and cervical cancers were recorded in the intervention group than in the control 
group (p=0.023 and p=0.031, respectively). However, there was no significant 
difference in detection of CIN grade 2 or worse in the intervention group compared 
with the control group in the second screen (p=0.234). When combining both rounds, 
the detection rates in the intervention and control groups were much the same 
for CIN grade 2 or worse, CIN grade 3 or worse, and for cervical cancer (table 2). 
However, over two screening rounds, a third more CIN grade 2 were recorded in the 
intervention group than in the control group (table 2). 
 In the first screen, two cancers in the intervention group were missed by HPV 
DNA testing but had abnormal cytology (in patients aged 32 years with FIGO IB1 
and aged 54 years with FIGO IA1). Three cervical cancers were missed by cytology 
testing (one patient aged 36 years and two patients aged 44 years, all three with 
FIGO IB1), but tested positive for HPV DNA. Five cervical cancers were diagnosed 
after borderline or mild dyskaryosis cytology (in patients aged 30 years with FIGO 
IB1, 32 years with FIGO IB1, 35 years with IB1, 40 years FIGO with 1B1, and 50 years 
with IA1), which could have been missed if patients were not followed up correctly. 
Only one woman who developed cervical cancer (aged 59 years with FIGO IB1) had 
a negative HPV DNA test at the second screen. She was also HPV negative in the first 
screen. 
Table 2 Occurrences of high-grade disease 
 Intervention group Control group  Intervention vs control 
 (n[%; 95% CI]) (n[%; 95% CI]) Risk difference  Relative risk  p value
   (95% CI) (95% CI)
Baseline screen*      
Cervical cancer 12 (0.06%; 0.03-0.11) 6 (0.03%; 0.01-0.07) 0.03% (–0.01 to 0.07) 2.01 (0.76 to 5.36) 0.166
CIN3 or worse 171 (0.86%; 0.73-1.00) 150 (0.75%; 0.63-0.88) 0.11% (–0.07 to 0.28) 1.15 (0.92 to 1.43) 0.239
CIN3 159 (0.80%; 0.68-0.93) 144 (0.72%; 0.61-0.85) 0.08% (–0.09 to 0.25) 1.11 (0.89 to 1.39) 0.387
CIN2 or worse 267 (1.34%; 1.18-1.51) 215 (1.07%; 0.93-1.22) 0.27% (0.05 to 0.48) 1.25 (1.05 to 1.50) 0.015
CIN2 96 (0.48%; 0.39-0.59) 65 (0.32%; 0.25-0.41) 0.16% (0.03 to 0.28) 1.48 (1.09 to 2.04) 0.014
Subsequent screen †     
Cervical cancer 4 (0.02%; 0.01-0.06) 14 (0.07%; 0.04-0.12) –0.05% (–0.09 to –0.01) 0.29 (0.10 to 0.87) 0.031
CIN3 or worse 88 (0.45%; 0.36-0.56) 122 (0.62%; 0.52-0.74) –0.17% (–0.31 to –0.03) 0.73 (0.55 to 0.96) 0.023
CIN3 84 (0.43%; 0.34-0.53) 108 (0.55%; 0.45-0.66) –0.12% (–0.26 to 0.02) 0.78 (0.59 to 1.04) 0.096
CIN2 or worse 160 (0.82%; 0.70-0.96) 184 (0.93%; 0.81-1.08) –0.12% (–0.30 to 0.07) 0.88 (0.71 to 1.08) 0.234
CIN2 72 (0.37%; 0.29-0.47) 62 (0.31%; 0.24-0.41) 0.05% (–0.06 to 0.17) 1.17 (0.83 to 1.65) 0.387
Both screens*      
Cervical cancer 16 (0.08%; 0.05-0.13) 20 (0.10%; 0.06-0.16) –0.02% (–0.08 to 0.04) 0.80 (0.42 to 1.55) 0.617
CIN3 or worse 259 (1.30%; 1.15-1.46) 272 (1.35%; 1.20-1.52) –0.06% (–0.28 to 0.17) 0.96 (0.81 to 1.14) 0.631
CIN3 243 (1.22%; 1.07-1.38) 252 (1.25%; 1.11-1.42) –0.04% (–0.25 to 0.18) 0.97 (0.81 to 1.16) 0.752
CIN2 or worse 427 (2.14%; 1.94-2.35) 399 (1.98%; 1.80-2.19) 0.15% (–0.13 to 0.43) 1.08 (0.94 to 1.24) 0.292
CIN2 168 (0.84%; 0.72-0.98) 127 (0.63%; 0.53-0.75) 0.21% (0.04 to 0.38) 1.33 (1.06 to 1.68) 0.017
*n=19 999 in the intervention group, n=20 106 in the control group. †n=19 579 in the intervention group, n=19 731 in the 
control group. CIN3=cervical intraepithelial neoplasia grade 3. CIN2=cervical intraepithelial neoplasia grade 2.
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 For women positive for high-risk HPV, with normal cytology at first screen, the 
number of high-grade lesions differed between the intervention and control group 
in both first and second screens (table 3). These women also have a substantial risk 
of CIN grade 3 or worse in the second screen in the intervention and control groups. 
At first screen, CIN grade 3 or worse was not significantly different between the 
intervention and control groups for women with moderate dyskaryosis or worse (96 
of 165 women vs 103 of 179; RR 1.01, 95% CI 0.84–1.21; p=0.9) and for women with 
borderline or mild dyskaryosis (41 of 515 women vs 35 of 527; 1.20, 0.78–1.85; p=0.5). 
However, more CIN grade 3 or worse lesions were detected in women with normal 
cytology in the intervention group than in the control group (34 of 19 286 patients vs 
12 of 19 373; 2.85, 1.47–5.49; p=0.001). At the second screen, excluding women who 
had CIN grade 2 or worse, or who had hysterectomy at baseline, numbers of CIN 
grade 3 or worse were not significantly different between study groups in women with 
Table 3 Cervical cancers and high grade intraepithelial neoplasia by test results in the first and second screen rounds. 
 First screen Second screen
 Total Cervical CIN3 CIN2  Cervical  CIN3 CIN2
  cancer    cancer 
Intervention group         
Inadequate cytology         
   HPV positive 2 0 0 1  0 0 0
   HPV negative 31 0 0 0  0 0 1
Normal cytology         
   HPV positive 724 2 29 31  0 36 20
   HPV negative 18562 0 3 7  2 36 40
Borderline or mild dyskaryosis         
   HPV positive 185 3 34 24  1 9 8
   HPV negative 330 1 3 3  0 1 2
Moderate dyskaryosis or worse         
   HPV positive 146 5 87 26  1 2 1
   HPV negative 19 1 3 4  0 0 0
Total  19999 12 159 96  4 84 72
Control group         
Inadequate cytology         
   HPV positive 0 0 0 0  0 0 0
   HPV negative 27 0 0 0  0 0 0
Normal cytology         
   HPV positive 766 1 9 6  8 57 18
   HPV negative 18607 0 2 4  4 32 36
Borderline or mild dyskaryosis         
   HPV positive 192 1 29 25  0 13 5
   HPV negative 335 0 5 2  0 2 2
Moderate dyskaryosis or worse         
   HPV positive 160 4 93 24  2 3 1
   HPV negative 19 0 6 4  0 1 0
Total  20106 6 144 65  14 108 62
CIN3=cervical intraepithelial neoplasia grade 3. CIN2=cervical intraepithelial neoplasia grade 2.
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baseline moderate dyskaryosis or worse (three of 39 vs six of 48; 0.61, 0.16–2.30; p=0.7) 
and in women with baseline borderline or mild dyskaryosis (11 of 443 vs 15 of 461; 0.75, 
0.35–1.62; p=0.6). However, CIN grade 3 or worse differed between groups in women 
with normal cytology at the first screen (74 of 19 066 vs 101 of 19 196; 0.74, 0.55–0.99; 
p=0.049).  
 The cumulative number of CIN grade 3 or worse lesions detected over two 
screening rounds was much the same for both study groups in women with moderate 
dyskaryosis or worse at baseline (99 of 165 vs 109 of 179; 0.99, 0.83–1.17), women 
with borderline or mild dyskaryosis at baseline (52 of 515 vs 50 of 527; 1.06, 0.74–1.54), 
and women with normal cytology at baseline (108 of 19 286 vs 113 of 19 373; 0.96, 
0.74–1.25). Furthermore, the cumulative number of CIN lesions of grade 3 or worse 
over two screening rounds was significantly lower for women who tested negative 
for HPV DNA at baseline in the intervention group than for those who had normal 
cytology at baseline in the control group (50 of 18 942 vs 113 of 19 373; 0.45, 0.32–0.63). 
Figure 3 Histological results for women aged 29–33 years (A) and 34–56 years (B), by study group and screening round.
CIN2=cervical intraepithelial neoplasia grade 2. CIN3=cervical intraepithelial neoplasia grade 3. I=intervention. 
C=control.
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Use of CIN grade 2 or worse as an outcome measure gave much the same result (107 
of 18 942 vs 177 of 19 373; 0.62, 0.49–0.79). Use of reviewed histological results did not 
give different results (appendix). 
 373 of 3139 (12%) women aged 29–33 years in the intervention group and 379 of 
3128 (12%) women aged 29–33 years in the control group had HPV DNA at baseline 
(p=0.786). By contrast, HPV at baseline was detected in 684 of 16 860 (4%) women in 
the intervention group aged 34–56 years and in 739 of 16 978 (4%) of women in the 
control group aged 34–56 years (p=0.176). 152 of 3139 (5%) women in the intervention 
group aged 29–33 years at baseline had biopsy samples taken, compared with 129 
of 3128 (4%) women in the control group aged 29–33 years. In women aged 34–56 
years, baseline screen biopsy samples were taken from 456 of 16 860 (3%) patients 
in the intervention group and 407 of 16 978 (2%) in the control group. 712 of 3136 
Table 4 HPV types at baseline and subsequent screens and number of HPV-positive CIN grade 3 or worse and CIN grade 
2 or worse detected. 
 Total number of women CIN3+ CIN2+
Intervention group   
First screen   
   HPV16 333 (32%) 101 (63%) 135 (56%)
      Inadequate 1 (0%) 0  1 (0%)
      Normal 202 (19%) 23 (14%) 36 (15%)
      BMD 55 (5%) 22 (14%) 30 (12%)
      >BMD 75 (7%) 56 (35%) 68 (28%)
  Other HPV type(s) 724 (68%) 59 (37%) 107 (44%)
      Inadequate 1 (0%) 0 0
      Normal 522 (49%) 8 (5%) 26 (11%)
      BMD 130 (12%) 15 (9%) 31 (13%)
      >BMD 71 (7%) 36 (23%) 50 (21%)
Second screen   
  HPV16 100 (26%) 17 (40%) 23 (35%)
      Normal 70 (18%) 6 (14%) 10 (15%)
      BMD 19 (5%) 4 (10%) 5 (8%)
      >BMD 11 (3%) 7 (17%) 8 (12%)
  Other HPV type 282 (74%) 25 (60%) 43 (65%)
      Normal 214 (56%) 4 (10%) 10 (15%)
      BMD 48 (13%) 8 (19%) 16 (24%)
      >BMD 20 (5%) 13 (31%) 17 (26%)
Control group   
Second round   
  HPV16 99 (25%) 35 (58%) 42 (46%)
      Normal 53 (14%) 7 (12%) 10 (11%) 
      BMD 24 (6%) 8 (13%) 11(12%)
      >BMD 22 (6%) 20 (33%) 21 (23%) 
  Other HPV type 293 (75%) 25 (42%) 50 (54%)
      Inadequate 2 (1%) 0 0
      Normal 219 (56%) 7 (12%) 18 (20%)
      BMD 53 (14%) 8 (13%) 17 (18%)
      >BMD 19 (5%) 10 (17%) 15 (16%)
Data are n (%). CIN3+=cervical intraepithelial neoplasia grade 3 or worse. CIN2+=cervical intraepithelial neoplasia 
grade 2 or worse. BMD=borderline or mild dyskaryosis. 
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(23%) women aged 29–33 years in the intervention group had repeat screening test 
or histology, or both, after the baseline round compared with 554 of 3128 (18%) in the 
control group. In women aged 34–56 years, follow-up was 3100 of 16 860 (18%) in the 
intervention group and 2887 of 16 978 (17%) in the control group. If women with a 
negative first screen were not counted in the numerator, follow-up among women 
aged 29–33 years was 355 of 3139 (11%) in the intervention group and 172 of 3128 (5%) 
in the control group, for women aged 34–56 years follow-up was 843 of 16 860 (5%) in 
the intervention group and 497 of 16 978 (3%) in the control group. For the two screening 
rounds combined, the two study groups did not differ significantly for CIN grade 3 or 
worse and CIN grade 2 or worse for both women aged 29–33 and those aged 34–56 
(figure 3). The ratio of CIN grade 3 or worse detection between the intervention and 
control groups was 0.97 (102 of 3139 vs 105 of 3128; 95% CI 0.74–1.27) for women aged 
29–33 years and 0.95 (157 of 16 860 vs 167 of 16 978; 0.76–1.18) for women aged 34–56 
years. Ratios for CIN grade 2 or worse were 1.01 (153 of 3139 vs 151 of 3128; 0.81–1.26) 
and 1.11 (274 of 16 860 vs 248 of 16 978; 0.94–1.32) for women aged 29–33 years and 
34–56 years, respectively. 
 Finally, we compared the number of CIN grade 3 or worse and CIN grade 2 or 
worse at first and second screens for HPV16-positive and HPV16-negative women 
(table 4). We only included women with a valid HPV DNA test result. Individual HPV 
types other than HPV16 were not analysed separately because of their low prevalence 
in cervical lesions. For the first screen in the intervention group 101 (59%) of 171 of the 
CIN grade 3 worse and 135 (51%) of 267 of the CIN grade 2 or worse lesions were 
HPV16 positive. In women with normal cytology, 23 (68%) of 34 of CIN lesions of grade 
3 or worse were HPV16 positive and in women with abnormal cytology, 78 (57%) of 
137 of CIN grade 3 or worse lesions were HPV16 positive. In the second screen, fewer 
HPV16-positive CIN grade 3 or worse were detected in the intervention group than in 
the control group (17 of 9481 vs 35 of 9354; RR 0.48, 95% CI 0.27–0.85; p=0.012) whereas 
detection of non-HPV16-positive CIN grade 3 or worse did not differ (25 of 9481 vs 25 
of 9354; 0.99, 0.57–1.72; p=1.00). The proportion of HPV16 in HPV-positive CIN grade 3 
or worse and grade 2 or worse lesions was also lower in the intervention group than 
in the control group but the positivity ratio was not significantly different for either CIN 
grade 3 or worse (17 of 42 vs 35 of 60, 0.69; 0.45–1.06; p=0.08) or for CIN grade 2 or 
worse (23 of 66 vs 42 of 92; 0.76, 0.51–1.14; p=0.17). 
Final results of the POBASCAM trial
71
CHAPTER 4
C
H
A
PT
ER
 4
Panel: Research in context
Systematic review
This trial was designed in 1997, when no data about performance of HPV testing 
in population-based screening existed. The design was based on several findings.  
First, HPV prevalence data obtained by general primer PCR in women with  
normal cervix, cervical intraepithelial neoplasia (CIN) grade 1–3 and cervical  
cancer26 led to the hypothesis that HPV testing by general primer PCR could be 
used for cervical cancer screening.27 After improvement of our first generation 
general primer PCR by elongation of the primers and addition of an easy readout,15 
to allow high-throughput HPV detection, we applied this GP5+/6+ general primer 
PCR in case-control studies, showing that high-risk HPV was present in nearly all 
cervical carcinomas.28 Analysis of normal cervical scrapings of women who later 
developed cervical cancer showed that the same HPV type as that in the  
carcinoma could be found in the preceding normal smear.29 
A subsequent prospective study on a gynaecological outpatient population  
showed that the presence of a persistent HPV infection in women with an  
abnormal smear was associated with progressive CIN disease.30,31 For the 
design of the POBASCAM trial the Dutch health council, an independent advisory 
body of the government, required that the study be done in the setting of the  
nationwide screening programme, which has a screening interval of 5 years, which 
is why the results are only now available. 
Interpretation
The final results accord with those of similar randomised controlled trials that used 
shorter screening intervals, such as Swedscreen,8 ARTISTIC,9 and NTCC,10 as well 
as those of our interim analysis,7 showing that HPV testing significantly reduces 
detection of CIN grade 3 or worse in the second screening round relative to  
conventional cytology. Additionally, as was the case in the NTCC trial, the final 
POBASCAM data also show that HPV screening protects against cervical cancer  
better than does cytology alone. By contrast with other studies, CIN was  
diagnosed by pathologists in daily routine practice rather than by a reviewed 
diagnosis, to study the performance of HPV screening in a routine population-
based setting. Review of CIN diagnoses did not affect the results of the study.  
As such, the study can be classed as an implementation study.  
Furthermore, the long screening interval as used in POBASCAM allows assessment 
of whether a cervical lesion is persistent or regressive. Our study also lends support  
to the notion that HPV screening does not have to be postponed until patients 
reach age 35 years but can be implemented at age 30 years because the  
cumulative detection of CIN grade 3 or worse and CIN grade 2 or worse across two 
screening rounds does not differ between women aged 29–33 years and women 
34 years or older.
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Discussion
Our results showed that fewer CIN lesions of grade 3 or worse and cervical cancer 
were detected during second screens in women who were screened for HPV DNA 
in combination with cytology at first screen than those who had cytology alone. 
Furthermore, the value of HPV DNA testing is lent support by the finding that women 
who tested negative for HPV DNA in the first screen had significantly fewer 
CINs of grade 3 or worse detected over two screening rounds than did women 
with normal cytology at baseline. These findings accord with previously reported 
data.4,7–11 However, our study has longer follow-up than other studies did because 
the screening interval in the Netherlands is longer than that in other countries 
(5 years vs 3 years). This difference is important because it enables us to assess whether 
a cervical lesion is persistent or regressive. Our study also suggests that HPV screening 
does not have to be postponed until age 36 years or older but can be started at age 
30 years because the cumulative two screen detection of CIN of grade 3 or worse 
and grade 2 or worse did not differ between women aged 29–33 years and women 
older than 33 years. Moreover, we showed that early detection of high-grade cervical 
lesions caused by HPV16 was a major component of the benefit of adding high-risk 
HPV testing to cytology. 
 The interim analysis of 17 155 women from this trial did not show a significant 
difference between the intervention and control groups in the number of cervical 
cancers detected at the second screening round.7 Our final analysis of the whole 
population was large enough to identify a significant difference in the number of 
cervical cancers in the intervention group versus the control group at the second 
screen. Such an effect on cervical cancer in the second screening round because 
of HPV DNA testing has only been shown in one previous trial.10 The investigators 
reported no cervical cancer in the second screen in 47 369 women screened by HPV 
DNA testing, whereas nine cervical cancers were recorded in 47 001 women in the 
control group. Reduced mortality from cervical cancer because of primary HPV DNA 
testing was also shown in a trial in India.22 34 deaths from cervical cancer occurred in 
the HPV DNA testing group (34 126 women) compared with 64 in the control group 
(31 488 women). 
 The decreased relative risks of CIN grade 3 or worse and cervical cancer in the 
second screening round occurred after an increase in relative detection of CIN 
grade 2 or worse in the baseline screen in the intervention group compared with the 
control group. By contrast with our interim findings,7 we failed to show a significant 
difference in the detection of CIN grade 3 or worse in the first screen in the whole 
study population. However, our study was powered to detect a significant difference 
in the number of CIN grade 3 or worse at the second round rather than at the first 
screen. Also, in some other randomised trials no significant difference in detection 
of CIN grade 3 or worse at the first screen occurred after HPV DNA testing, despite 
decreased detection of CIN grade 3 or worse in the second screening round.8,9 When 
we stratified our analysis on the basis of baseline cytology, we did not note a significant 
difference in the occurrence of CIN grade 3 or worse in women with borderline or 
mild dyskaryosis or moderate dyskaryosis or worse but report a significant difference 
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in the number of CIN grade 3 or worse in women with normal cytology. The latter 
finding matches our expectations because no additional testing was recommended 
for women in the control group with baseline normal cytology. The extra CIN grade 
3 or worse cases detected by HPV DNA testing compared with cytology are the 
main benefit of using HPV DNA testing for primary screening. The failure to detect 
a relative difference in the occurrence of CIN grade 3 or worse could be related 
to the decision to change the cytological classification criteria in 1996, whereas 
the study was powered by cytological results collected earlier. Notably, the use of 
more stringent criteria for borderline or mild dyskaryosis and moderate dyskaryosis 
or worse resulted in a decrease of borderline or mild dyskaryosis in the Netherlands, 
from 11% in 1999 to 3% in 2004.13 This explains the low occurrence of CIN grade 3 
or worse in women with borderline or mild dyskaryosis compared with other studies. 
The cumulative number of women with CIN grade 3 or worse and grade 2 or worse over 
both screening rounds did not differ substantially between study groups, which lends 
support to the idea that HPV DNA testing leads to earlier detection of clinically 
relevant high-grade lesions that, with the exception of a small number of CIN grade 2 
lesions, do not regress. 
 An important issue is the age at which HPV DNA testing should be offered in 
primary screening. HPV DNA prevalence is age dependent,23,24 therefore HPV DNA 
testing in young women might have a different risk-benefit ratio to HPV DNA test-
ing in older women. Ronco and colleagues10 reported that HPV DNA testing in 
women aged 25–34 years could lead to substantial overdiagnosis of regressive CIN 
grade 2 or worse lesions, particularly when HPV DNA positive women in this age 
group are directly referred for colposcopy without further triage testing. Our results 
suggest that with the triage algorithm used in this trial HPV DNA testing in women 
aged 29–33 years does not result in excessive diagnosis of lesions destined to regress 
and lends support to the implementation of HPV DNA testing in programmed cervical 
screening starting at age 30 years. 
 The protective effect against CIN grade 3 or worse in the second screen in the 
intervention group was largely attributable to HPV16. HPV16 is the main genotype 
present in cervical cancer, hence, the early detection of HPV16-associated CIN grade 
3 lesions is expected to eventually have an effect on long-term outcomes such as 
cancer morbidity and mortality. However, our study was not large enough to provide 
detailed information about the effect of other, non-HPV16 types, in the first and second 
screening round. This investigation needs a pooled analysis of many screening studies, 
which is being done (pooling Swedscreen, NTCC, and data from this study).8,10 
 Variation in histological classification of cervical lesions between individual 
centres might be a limitation of our study. However, we believe that the use of 
the original diagnosis closely matches treatment guidance and mimics future 
implementation of HPV DNA testing in population-based screening programmes. 
Moreover, use of histological classification obtained after review by two experienced 
cervical pathologists, although leading to more CIN grade 2 or worse and CIN grade 
3 or worse diagnoses, did not change our conclusions. 
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 A strength of our study is the large size of the trial and the longitudinal design. 
We included all cytology and histological follow-up data derived from the nation 
wide registry within 9 years after the first screen. The trial was done within the regular 
Dutch nationwide screening programme. Together with the HC2 assay, the GP5+/6+ 
PCR method is clinically validated and performs much the same as HC2 in sensitivity, 
specificity, and intra-laboratory and inter-laboratory agreement.25 Therefore, our 
results can be considered representative for organised cervical screening. 
 Our results are from a population-based screening programme in which CIN 
diagnosis was made in routine pathology laboratories. Therefore, our study can be 
viewed as an implementation study, representative for organised screening and as 
such provides the strongest evidence to date in favour of implementation of HPV 
testing in nationwide cervical screening programmes (panel). On the basis of these 
data the Health Council of the Netherlands, an independent advisory body of 
the Dutch Government, has issued advice to the minister of health to convert the 
current cytology-based cervical screening programme to an HPV testing-based 
programme starting at 30 years. Additionally, offer of HPV testing using self- 
collected cervico-vaginal samples to women who do not respond to an invitation 
for cervical screening results in a response of about 30%,32 showing that a proportion 
of women prefer self-sampling to a smear taken by a physician. Studies should 
investigate the acceptance of this alternative for HPV testing in regular attendees to 
the screening programme. Ultimately, this option will likely increase attendance 
to cervical screening programmes. 
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ABSTRACT
Introduction
High-risk human papillomavirus (hrHPV) testing has a higher sensitivity but lower 
specificity than cytology for detection of high-grade intraepithelial neoplasia (CIN). 
To avoid over-referral to colposcopy and overtreatment, hrHPV-positive women re-
quire triage testing and/or follow-up. 
Methods
A total of 25,658 women (30–60 years) enrolled in a population-based cohort study 
had an adequate baseline Pap smear and hrHPV test. The end-point was cumulative 
two-year risk of CIN grade 3 or worse (CIN3+). In a post-hoc analysis, fourteen triage/ 
follow-up strategies for hrHPV-positive women (n = 1,303) were evaluated for colposcopy 
referral rate, positive (PPV) and negative predictive value (NPV). Five strategies 
involved triage testing without a repeat test and nine strategies involved triage testing 
followed by one repeat testing. The tests were cytology, hrHPV, HPV16/18 genotyping 
and HPV16/18/31/33/45 genotyping. 
Results
Results were adjusted for women in the cohort study who did not attend repeat testing. 
Of the strategies without repeat testing, combined cytology and HPV16/18/31/33/45 
genotyping gave the highest NPV of 98.9% (95%CI 97.6–99.5%). The corresponding 
colposcopy referral rate was 58.1% (95%CI 55.4–60.8%). Eight of the nine strategies 
with retesting had an estimated NPV of at least 98%. Of those, cytology triage 
followed by cytology at 12 months had a markedly lower colposcopy referral rate of 
33.4% (95%CI 30.2–36.7%) than the other strategies. The NPV of the latter strategy was 
99.3% (95%CI 98.1–99.8%). 
Conclusion
Triage hrHPV-positive women with cytology, followed by repeat cytology testing yielded 
a high NPV and modest colposcopy referral rate and appear to be the most 
feasible management strategy.
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Introduction
Strong evidence is now available that testing for high-risk human papillomavirus 
(hrHPV) infection is more sensitive than cytology in detecting high-grade cervical 
intraepithelial neoplasia (CIN).1–7 However, hrHPV testing also detects more transient 
hrHPV infections than cytology,1,8 which may lead to over-referral for colposcopy 
and thus overtreatment.5 Management of hrHPV-positive women is, therefore, of 
major concern. In particular, in countries with an efficient cytology-based screening 
program and a moderate colposcopy referral rate such as the Netherlands and the 
United Kingdom, the increased burden on healthcare resources upon introduction 
of a less-specific screening test may be substantial. To control the number of 
colposcopy referrals, hrHPV-positive women should not be offered colposcopy 
immediately but should be further stratified by means of triage testing and repeat testing. 
Several triage suggestions have been made in the literature including cytology, hrHPV 
geno-typing and hrHPV-type specific persistence analysis and p16 staining,1, 9, 10 but no 
uniform algorithm has emerged until now.
 To evaluate the effectiveness of hrHPV testing in primary cervical screening, we set 
up the Vrije Universiteit Medical Centre- Saltro laboratory population-based cervical 
screening (VUSA-Screen study) within the routine cervical screening program in the 
Netherlands. Women participating in this cohort received combined hrHPV testing 
and cytology instead of cytology. We used the data from the cohort study for post-hoc 
analyses to determine feasible triage and followup testing schemes for hrHPV-positive 
women. We compared 14 triage/followup testing strategies using cytology, hrHPV 
testing and/or HPV genotyping. The end points were negative (NPV) and positive 
predictive values (PPV) for CIN grade 3 or worse (CIN3+) and colposcopy referral 
rates. The estimates of the end points were adjusted for women in the cohort study 
who did not attend repeat testing.
Material and Methods
Study design VUSA-screen
VUSA-screen is a population-based cohort study designed to evaluate the effectiveness 
of combined cervical cytology screening with hrHPV testing by HC2 hybridization 
assay (Qiagen, Gaithersburg, MD). The study was carried out in the Utrecht province 
of the Netherlands in the setting of the regular Dutch screening program that invites 
women aged 30–60 years to be screened every 5 years. The design of the study has 
been described elsewhere.11 In brief, women invited for regular cervical screening 
were recruited between October 2003 and August 2005. Women with a history of 
cervical intraepithelial neoplasia grade 2 or worse (CIN2+) or abnormal cytology 
in the preceding 2 years were excluded from analysis. Participating women gave 
written informed consent. The VUSA-screen study was approved by the Ministry of 
Public Health (2002/02-WBO; ISBN-10: 90-5549-452-6) and registered in the trial register 
(NTR215, ISRCTN64621295).
 Cervical scrapings were taken by a cytobrush (Rovers, Oss, the Netherlands), 
and after making a conventional cytological smear, the brush was placed in a 
container with 1 ml universal collection medium (Qiagen, Gaithersburg) for hrHPV 
HC2 testing (cocollection for HPV testing and conventional cytology). Cytology 
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results were reported, blinded to the hrHPV testing results, according to the CISOE-A 
classification, which is used in the Dutch screening program and can be easily 
converted into the 2001 Bethesda system.12 Cytological results were grouped as normal, 
borderline or mild dyskaryosis (BMD) and >BMD (moderate dyskaryosis or worse). 
In the 2001 Bethesda system, BMD corresponds to atypical squamous cells of 
undetermined significance; atypical squamous cells, cannot rule out high-grade 
squamous intraepithelial lesions or low-grade squamous intraepithelial lesions and 
>BMD corresponds to high-grade squamous intraepithelial lesions.
 Women with BMD or worse and positive in hrHPV test were directly referred for 
colposcopy. In women with normal cytology at baseline, a substudy was carried out. 
In this substudy, all hrHPV-positive women (n = 1,021) were included as well as a sub-
set of n = 3,063 hrHPV-negative, cytologically normal women. Women with normal 
cytology were not informed about the hrHPV test result. HrHPV-positive women with 
normal cytology were offered cytology and a blinded hrHPV test at 12 months and 
combined hrHPV testing and cytology at 24 months. Women were referred at 12 
months if cytology was abnormal and at 24 months in case of a positive hrHPV test 
and/or abnormal cytology (Fig. 1).
 Of the women who were referred to a gynecologist for colposcopy, colposcopy- 
directed biopsies were taken for histological examination of suspicious areas on the 
cervix, according to standard procedures in the Netherlands.13 Biopsy results were 
reported as normal, cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3 or as 
invasive cancer, according to international criteria.14,15 Glandular intraepithelial 
neoplasia grades 1, 2 and 3 were included in CIN. Cytology and histology results were 
retrieved from the nationwide network and registry of histopathology and cytopathology 
(PALGA; Bunnik, the Netherlands). We included all lesions diagnosed after the referral 
smear and within 3 years after baseline.
hrHPV DNA testing
hrHPV testing was performed by the HC2 hrHPV DNA test (13 hrHPV types) in an 
automated format on a rapid capture system (RCS; Qiagen, Gaithersburg, MD) as 
described before. Samples were considered positive if they attained or exceeded 
threshold of 1.0 RLU/CO (corresponding with 1 pg/mL HPV16 DNA).
 HC2 positive samples were tested with GP5+/6+-PCR-EIA,16 and all specimens 
tested positive by GP5+/6+-PCR-EIA were typed by reverse line blotting according to 
established protocols.17
Statistical Analysis
The primary endpoint of the study was cumulatively detected CIN grade 3 or worse 
(CIN3+). A secondary outcome was cumulatively detected CIN2+.
 In our post-hoc analysis, 14 triage per followup strategies for hrHPV-positive 
women with no or a single repeat test were evaluated with respect to NPV, PPV, 
sensitivity, specificity and the colposcopy referral rate. For the repeat test, the 12-month 
screening test in the cohort study was used. The 24-month screening test was used if 
the 12-month test was missing. To gain insight into the impact of replacing cytological 
screening by hrHPV screening on the colposcopy referral rate in the entire screening 
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population, we also calculated an overall colposcopy referral rate by multiplying the 
colposcopy referral rate in hrHPV-positive women by the hrHPV prevalence. 
 HrHPV-positive women with normal cytology and without a valid repeat 
combination test result (repeat cytology and hrHPV test result) were considered as 
lost to followup. We accounted for this loss-to-followup by replacing raw counts by 
expected counts. The expectations were calculated under the assumption that 
women with normal cytology at baseline without a valid repeat test result had the 
same disease risk as women with a valid repeat test result. Furthermore, we classified 
a woman as having CIN0/1 if she was referred for colposcopy at baseline and had 
no detected CIN2+ or if she had a valid repeat test result and no detected CIN2+. 
25	  658	  women	  aged	  30-­‐60	  years.	  
Adequate	  baseline	  cytology	  and	  hrHPV	  test	  
Normal	  	  
(98.2%)	  	  
n	  =	  25	  196	  
BMD	  
(1.3%)	  
n	  =	  337	  
>BMD	  
(0.5%)	  
n	  =	  125	  
hrHPV+	  women	  
n	  =	  1303	  
Normal	  &	  hrHPV+	  
(4.1%)	  
n	  =	  1021	  
BMD	  &	  hrHPV+	  
(49.6%)	  
n	  =	  167	  
>BMD	  &	  hrHPV+	  
(92.0%)	  
n	  =	  115	  
Repeat	  	  
smear&hrHPVtest	  
at	  1	  and	  2	  years	  
Referral	  for	  
colposcopy	  if	  at	  1	  
year	  cyto	  ≥BMD	  
or	  hrHPV+	  
21	  CIN2	  
24	  CIN3	  
diagnosed	  
Referral	  for	  
colposcopy	  
Referral	  for	  
colposcopy	  
36	  CIN2	  
34	  CIN3	  
diagnosed	  
15	  CIN2	  
18	  CIN3	  
4	  Ca	  
diagnosed	  
Figure 1 Flowchart of the screening profiles of hrHPV-positive women in the VUSA-Screen study.
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The latter implies that women with a double negative test at 24 months, which are 
returned to routine screening, are classified as CIN0/1.
 For each new strategy, we estimated the expected number of colposcopy 
referrals and the expected number of CIN3+ and CIN2+ detected by the strategy. 
Furthermore, on the basis of the screening strategy used in the cohort study, we 
estimated the expected number of CIN3+ and CIN2+ in the whole cohort. We 
calculated the PPV and NPV for CIN3+ of a new strategy as:
 
 
PPV = Expected number of CIN3 + in women referred for colposcopy Expected number of women referred for colposcopy
NPV1= 1- Expected number of CIN3 + in women not referred for colposcopy   Expected number of women not referred for colposcopy
The sensitivity and specificity for CIN3+ were calculated as
Sensitivity = Expected number of CIN3 + in women referred for colposcopy Expected number of CIN3 + in cohort
Specificity = Expected number of CIN0=1=2 in women not referred for colposcopy Expected number of CIN0=1=2 in cohort  
 Ninety-five percent confidence intervals were calculated for the outcome 
measures using the Wilson Score method,18 where the sample size was set equal to 
the number of cases observed in the cohort study. To evaluate the strategies, we 
considered a NPV for CIN3+ of at least 98% (corresponding with a 2-year CIN3+ risk of 
at maximum 2%) to be a minimal requirement.19
 We considered the following five strategies for hrHPV-positive women with 
triage at baseline but without a repeat test: (i) cytology (threshold BMD), (ii) 
HPV16/18 genotyping, (iii) HPV16/18/31/33/45 genotyping, (iv) combined cytology 
and HPV16/18 genotyping and (v) combined cytology and HPV16/18/31/33/45 
genotyping (Table 1). We considered nine strategies with baseline triage followed by 
one round of repeat testing. In the first five of these strategies, baseline triage testing 
consisted of cytology only: (vi) cytology triage at baseline and cytological testing at 12 
months; (vii) cytology triage at baseline and hrHPV testing at 12 months; (viii) cytology 
triage at baseline and HPV type persistence at 12 months; (ix) cytology triage at baseline 
and combined cytology and hrHPV testing at 12 months and (x) cytology triage 
at baseline and combined cytology and HPV16/18 genotyping at 12 months. 
In the last four strategies, baseline triage testing consisted of cytology combined with 
hrHPV16/18 genotyping. For the repeat tests, strategies (xi–xiv) were similar to 
strategies (vi–ix) (Table 2).
 Analyses were done with SPSS version 15.0 (LEAD Technologies Inc., 
Haddonfield, NJ), Excel (Microsoft Corporation, Redmond, WA) and MATLAB version 
7.9 (The MathWorks Inc., Natick, MA).
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Results
VUSA-screen characteristics
Of the 25,871 women participating in the VUSA-screen study, 25,658 (99.2%) had an ad-
equate baseline Pap smear and hrHPV test. The median age of participating women 
was 44.0 years (range 29–61 years). Among the women with an adequate Pap smear, 
98.2% had normal cytology, 1.3% had BMD and 0.5% had >BMD (Fig. 1). The proportion 
of women with a positive hrHPV HC2test was 4.1% among those with normal cytology, 
49.6% in those with BMD and 92.0% in women with >BMD. Overall, 5.1% (1,303/25,658) 
of the women tested hrHPV positive.
 The 1,021 hrHPV-positive women with normal baseline cytology received a rec-
ommendation to return at 12 and 24 months for a smear and a hrHPV test. A total of 
535 of these women had at least one round of followup with a hrHPV test and a smear 
for evaluation of cytology. Among women who attended at repeat testing, the av-
erage time to the first followup test was 15.0 months with a standard deviation of 4.7 
months. The followup time ranged from 1.3 to 28.6 months.
Evaluation of triage strategies for hrHPV-positive women
Detailed results of the five strategies without a repeat test are presented in Table 1. 
The highest NPV of 98.9% (95%CI: 97.6–99.5%) was obtained with the strategy of com-
bined cytology and HPV16/18/31/33/45 genotyping. None of other four strategies 
met the NPV threshold for CIN3+ of 98% and, therefore, these strategies were not 
acceptable. However, the strategy with combined cytology and HPV16/18/31/33/45 
genotyping resulted in a high colposcopy referral rate of 58.1% (95%CI: 55.4–60.8%) 
among hrHPV-positive women. This would translate into a referral rate of 2.95% (95%CI: 
2.75–3.17%) in the total screening population, which is almost threefold higher than 
obtained with baseline cytology triage only (colposcopy referral rate of 1.09%; 95%CI: 
0.96–1.22%).
 Table 2 shows detailed results of the nine strategies with baseline triage testing fol-
lowed by one round of repeat testing. Eight strategies had a NPV for CIN3+ above the 
threshold of 98%. The PPVs of these strategies were acceptable, ranging from 17.7 to 
37.5%. Strategies with hrHPV testing at followup showed high colposcopy referral rates 
(ranging from 65.7 to 73.0%).
 The lowest colposcopy referral rate in hrHPV-positive women was obtained with 
cytology triage at baseline followed by repeat cytology testing at 12 months (33.4%). 
In the total screening population, this would result in a colposcopy referral rate of 
1.70% (95%CI:1.54–1.85%), a 1.55-fold increase compared with baseline cytology 
triage only.
 The NPV and PPV of the 14 strategies are graphically displayed in Figure 2. Nine 
strategies had an estimated NPV greater than 98%, eight strategies with and one 
without repeat testing. Strategies with hrHPV testing in followup (strategies vii, ix, xii and xiv) 
showed not only the highest NPV but also the lowest PPV. The strategy with cytology triage 
followed by cytology testing showed both a high PPV and high NPV (Fig. 2, upper right 
corner).
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Figure 2 NPV and PPV for CIN3+ of the 14 triage/follow-up strategies for hrHPV-positive women, adjusted for non-attendance at repeat testing  
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 Figure 2 NPV and PPV for CIN3+ of the 14 triage/follow-up strategies for hrHPV-positive women, adjusted for 
non-attendance at repeat testing. PPV = positive predictive value; NPV = negative predictive value ; o triage 
strategy without a repeat test ; n triage strategy followed by on round of repeat testing; Bars represent 95% confidence 
intervals; cyto = strategy (i); HPV16/18 = strategy (ii); HPV16/18/31/33/45 = strategy (iii); cyto&HPV16/18 = strategy (iv); 
cyto&HPV16/18/31/33/45 = strategy (v); cyto + cyto = strategy (vi); cyto + hrHPV = strategy (vii); cyto + HPV type pers = 
strategy (viii); cyto + cyto&hrHPV = strategy (ix); cyto + cyto&HPV16/18 = strategy (x); cyto&hrHPV16/18 + cyto = strategy 
(xi); cyto&hrHPV16/18 + hrHPV = strategy (xii); cyto&hrHPV16/18 + HPV type pers = strategy (xiii) ; cyto&hrHPV16/18 + 
cyto&hrHPV = strategy (xiv).
Discussion
Implementation of hrHPV testing as a primary screening test in cervical screening 
may soon be reality. However, at the moment there is still debate about how to 
manage hrHPV test-positive women, because hrHPV testing is less specific than 
cytology.7  Referring all hrHPV-positive women to colposcopy will result in over-
diagnosis, over-treatment and high costs. Therefore, triage and/or followup 
strategies for hrHPV-positive women are needed. The VUSA-Screen cohort study 
enabled us to examine this issue in more detail.
 Five triage strategies without repeat test were investigated, with cytology, 
hrHPV, HPV16/18 genotyping and HPV16/18/31/33/45 genotyping as triage tests. 
A triage strategy was considered feasible if the NPV was equal to or exceeded a 
predefined threshold of 98%.19 Of the five triage strategies, one strategy (cytology 
combined with HPV16/18/31/33/45) met the NPV criterion of 98%. This strategy would 
be attractive for implementation, because no follow-up is needed. However, a 
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major disadvantage is the high overall colposcopy referral rate in the total population 
(2.95%). In addition to the increase in the costs that would result from this strategy, it also 
poses a large burden on the colposcopy capacity of gynecologists. By adding one 
repeat test at 12 months, it is possible to reduce this referral rate markedly. The most 
attractive strategy was cytology triage at baseline followed by repeat cytology 
testing at 12 months, with an overall colposcopy referral rate in the total population of 
1.70 and a NPV of 99.3 (95%CI: 98.1–99.8%).
 Loss-to-followup may be a problem when implementing a screening strategy 
with a repeat test. In this study, the loss-to-followup of women with normal 
cytology at baseline was about 40%. Other studies have also shown that attendance 
at repeat testing is poor, particularly after a cytologically normal test.7, 20 Therefore, 
adequate communication is necessary to improve attendance at repeat testing. 
In the POBASCAM trial in the Amsterdam area in the Netherlands, follow-up at 
repeat testing was 77%.7 Depending on the magnitude of envisaged loss to follow-up, 
a direct triage strategy without a repeat visit could be an alternative option if the 
almost threefold increase in colposcopy rate compared with baseline cytology only 
triage testing could be accommodated. Such an increase in colposcopy rate is 
expected to lead to capacity problems in the Netherlands where the annual 
number of colposcopy referrals is low due to a well-functioning cytological screening 
program (about 12,000 per year). Therefore, for the Netherlands, it is preferable to 
implement the strategy with cytology triage at baseline and a repeat cytology test 
at 12 months. This can be implemented against much less extra colposcopies. 
Moreover, this increase in colposcopy rate is accompanied by an almost similar 
increase in the number of detected CIN3+. Furthermore, after a few 
rounds of hrHPV screening a decline in colposcopy referrals is expected 
because the extra detection of high-grade lesions (with subsequent treatment) will 
lead to a reduced rate of abnormalities in subsequent screening rounds.4, 7, 20
 A point of consideration in our current study is the low followup at repeat testing. 
HrHPV-positive women with normal cytology and a representative age-matched 
subcohort of hrHPV-negative women with normal cytology were invited for repeat 
testing after 1 and/or 2 years and were referred for colposcopy if they presented 
with abnormal cytology and/or positive hrHPV test. In our study, women with 
normal cytology were not informed about the hrHPV status at baseline. The concealment 
was necessary to maximize attendance at repeat testing among hrHPV- 
negative women with normal cytology. It is likely that the attendance rate in our study 
would have been higher if women had been informed about their hrHPV test result. 
In addition to the women, cytotechnicians were not informed about the hrHPV test 
result. In a single hrHPV testing strategy with cytology triage for hrHPV-positive women, 
the hrHPV test result may be known to the cytotechnician. Awareness of the negative 
or positive hrHPV test result may affect the criteria for defining abnormalities because 
the interpretation of cytology is subjective. In a recent Finnish randomized trial,21 
cytotechnicians in the hrHPV screening arm were informed about the hrHPV screening 
test result. However, the hrHPV test information in that study only had a small effect on 
cytology assessment, and, therefore, on the CIN3+ detection rate and the number of 
colposcopies.
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 Furthermore, implementation of HPV vaccination may have an effect on the 
cost effectiveness of screening programs. In particular, it is expected that vaccination 
reduces the PPV of cytological screening since fewer women will develop high-grade 
cervical lesions.22, 23 In particular, the reading performance for cytological slides is likely 
to deteriorate when the occurrence of an abnormal smear becomes less common.24 
However, HPV vaccination will have a stronger effect on PPV of a primary cytological 
screening test than on the PPV of triage or repeat cytology in hrHPV-positive women. 
The reason is that the prevalence of hrHPV will also decrease after vaccination, and 
this partly compensates the decrease in PPV if cytological evaluation is limited to 
hrHPV-positive women. Therefore, we think that the proposed strategy with cytologi-
cal triage at baseline and repeat cytology at 1 year will also be an interesting triage 
strategy for vaccinated women.
 A strong point of our study is the longitudinal design and the older age range of 
study participants (30–60 year), which is the age for which hrHPV testing is most widely 
advocated.4, 7, 25, 26 In our study, we took into account all the cytology and histological 
follow-up data derived from the national wide network of registry within 3-years after 
baseline. The study was population-based and part of a routine organised screening 
activity in a low-risk population, indicating that the results could be implemented in 
routine practice.
 Other studies have suggested to follow-up hrHPV-positive women with normal cy-
tology by one repeat hrHPV test10 or by a combined cytology and hrHPV test.27 Our 
study indicates that implementation of these strategies lead to a substantial increase 
in colposcopy referral rate, eventually referring two third of all hrHPV-positive women. 
However, it should be kept in mind that in the Netherlands, the cytological screening 
program is very efficient, which is demonstrated by a cytology abnormality rate of 
1.8% (Fig. 1)28 with a similarly low colposcopy referral rate. However, in countries with 
already higher cytological abnormality, and related colposcopy rates, such triage 
strategies would, depending on the screening interval, have a much lower impact on 
the current number of colposcopies in those countries.21, 29
 Finally, in addition to CIN3+ risk considerations, implementation of a triage and 
follow-up strategy for hrHPV-positive women asks for acceptability by physicians and 
women. To prevent anxiety among women who are directed back to routine screening, 
it is essential that the last screening test is negative. A repeat visit for cytology only at 1 
year, meets this requirement, but, e.g., implementation of HPV16/18 genotyping after 
1 year seems less straightforward as women who will be hrHPV-positive but HPV16/18 
negative at a repeat visit, may feel uncomfortable about their mixed test result even 
if their CIN3+ risk is low enough to return to the next screening round. This may be al-
leviated with a triage test that directly detects HPV16/18 at baseline, rather than using 
a consensus test first. Finally, the logistics of a triage and follow-up strategy in national 
programme should preferably be simple.
 In conclusion, our post-hoc analysis of triage strategies for hrHPV-positive women, 
based on the VUSA-screen cohort strongly points to the use of cytological testing 
both at baseline and at 12 months in countries with low rates of cytological 
abnormalities and long screening intervals (5 years). This is a feasible triage strategy 
because it has a high NPV for CIN3+, modest colposcopy referral rate and is easy to 
communicate to physicians and women. However, in countries with higher rates of 
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cytological abnormalities, shorter screening intervals and higher colposcopy rates, 
other triage strategies involving for instance combined cytology and 
HPV16/18/31/33/45 genotyping at baseline without repeat testing might be 
considered for implementation.
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ABSTRACT
Background
We evaluated the performance of primary high-risk human papillomavirus (hrHPV) 
testing by hybrid capture 2 (HC2) with different thresholds for positivity, in comparison 
with conventional cytology.
Methods
We used data of 25 871 women (aged 30–60 years) from the intervention group of the 
VUSA-Screen study (VU University Medical Center and Saltro laboratory population-
based cervical screening study), who were screened by cytology and hrHPV. Primary 
outcome measure was the number of cervical intraepithelial neoplasia grade 3 or 
higher (CIN3+), detected within 3 years. We compared baseline cytology testing with 
three possible hrHPV screening strategies at different relative light unit/cutoff (RLU/
CO) thresholds.
Results
Compared with baseline cytology testing, hrHPV DNA testing as a sole primary screening 
instrument did not yield a superior sensitivity, as well as lower colposcopy referral rate 
and lower false positivity rate at any RLU/CO threshold. The hrHPV screening at 1 RLU/
CO threshold with cytology triage at baseline and at 12 months revealed the highest 
sensitivity for CIN3+ (relative sensitivity of 1.32), although still displaying a 
lower colposcopy referral rate than cytology testing (relative colposcopy rate of 
0.94). Higher thresholds (>1RLU/CO) yielded lower colposcopy rates, but resulted in 
substantial loss in sensitivity.
Conclusion
The hrHPV testing at the commonly used threshold of 1 RLU/CO with cytology triage at 
baseline and at 12 months showed a much higher sensitivity with a lower colposcopy 
referral rate compared with cytology testing.
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Introduction
New promising methods of cervical cancer prevention have been introduced since 
the recognition that infection with high-risk human papillomavirus (hrHPV) is the 
necessary cause of cervical cancer.1-3 The recently introduced prophylactic HPV 
vaccine may have a major impact on preventing this global disease. The 
prophylactic vaccines have shown to be highly effective in preventing premalignant 
lesions.4-7 However, it is generally agreed upon that cervical cancer screening will 
need to continue even for vaccinated women.8-10 
 Although cytological screening has reduced the incidence and mortality 
of cervical cancer,11 it has a limited sensitivity. The much more sensitive hrHPV test 
has been suggested as an alternative primary screening instrument,12-17 given that 
a clinically validated hrHPV assay is used.18 At present, the FDA approved hybrid 
capture 2 (HC2) assay is most commonly used. However, hrHPV testing using such 
a test has also shown a 4–6% lower specificity than conventional cytology,12;19 
because many detected infections are transient and regress without developing 
high-grade lesions. 
 In population-based screening, specificity is of utmost importance, as it basically 
determines the costs of the programme and the amount of unwanted adverse 
effects (anxiety, repetitive and confirmatory tests, as well as unnecessary colposcopy 
referrals and treatments) in the generally healthy population. Cytological triage of 
hrHPV DNA-positive women has been found to improve the specificity of the screening 
test.12;20;21 Another, easier and potentially cost saving option is to adapt the threshold, 
that is, increase the relative light unit/cutoff (RLU/CO) threshold, of the HC2 test. This 
would particularly be useful if it obviates the need for repeat testing. Several studies 
have examined baseline hrHPV testing strategies with triage of hrHPV-positive women 
at higher thresholds than the one conventionally used (i.e., RLU/CO of ≥1).16;22-25 
This did not result in a strategy that ensured higher sensitivity as well as higher specificity 
in terms of lower colposcopy referral rates compared with cytological screening. 
 The aim of this study was to investigate the effect of hrHPV HC2 testing with higher 
thresholds on the sensitivity and specificity in terms of colposcopy referral rate and 
false positivity rate, considering a number of different hrHPV screening strategies. We 
searched for strategies that improved the specificity of hrHPV screening by increasing 
the RLU/CO threshold, while maintaining a higher sensitivity than baseline cytologi-
cal testing. We used data from the intervention group of the VUSA-Screen study (VU 
University Medical Center and Saltro laboratory population-based cervical screening 
study), a study performed within the routine cervical programme of the Netherlands. 
Women participating in this cohort received combined hrHPV testing and cytology. 
The primary end points were cervical intraepithelial neoplasia grade 3 or higher 
(CIN3+), detected within 3 years.
HC2 testing at different thresholds
CHAPTER 6
98
C
H
A
PTER 6
Materials and methods
Study design VUSA-screen
The VUSA-Screen is a population-based study designed to evaluate the effectiveness 
of combined cervical cytology screening with hrHPV testing by HC2 hybridisation 
assay (Qiagen, Gaithersburg, MD, USA). The study was carried out in the Utrecht 
province of the Netherlands in the setting of the regular screening programme that 
invites women, aged between 30 and 60 years of age, to be screened every 5 years. 
The design of the study has also been described elsewhere.26 Between October 2003 
and August 2005, women invited for the regular cervical screening programme were 
asked to participate in the VUSA-Screen study. Women were excluded from the analy-
sis if they had a history of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) or 
abnormal cytology in the preceding 2 years. Women who agreed to receive cytology 
and hrHPV testing gave written informed consent. 
 Conventional cytological smears were taken with a cytobrush (Rovers, Oss, 
the Netherlands). After preparation of a conventional smear on a glass slide, 
the brush was placed in a vial containing 1ml UCM (Universal Collection Medium, 
Digine Corp., Gaithersburg, MD, USA) for hrHPV testing. Cervical cytology results were 
reported, blinded to the hrHPV testing results, according to the CISOE-A classification, 
which is routinely used in the Netherlands and can be converted into the 2001 Bethesda 
system.27 Cytological results were grouped as normal, BMD (borderline or mild 
dyskaryosis) and >BMD (moderate dyskaryosis or worse). In the 2001 Bethesda system, 
BMD corresponds to atypical squamous cells of undetermined significance; atypical 
squamous cells cannot rule out high-grade squamous intraepithelial lesions; or 
low-grade squamous intraepithelial lesions and >BMD corresponds to high-grade 
squamous intraepithelial lesions.
 Women with BMD or worse were informed about the hrHPV test result. The hrHPV- 
positive women with BMD and all women with >BMD were directly referred for 
colposcopy (Figure 1). Women with BMD at baseline and a negative hrHPV test were 
offered cytology testing at 6 and 18 months and referred if cytology was abnormal 
(threshold BMD) at one of these occasions. 
 In the women with normal cytology at baseline, a sub-study was carried out. In this 
sub-study, all (n = 1021) hrHPV-positive women as well as a subset of hrHPV-negative 
cytologically normal women (n = 3063) were included. To select the hrHPV-negative 
women, each hrHPV-positive woman was matched to three randomly chosen 
hrHPV-negative women of the same age. Women with normal cytology were not 
informed about the hrHPV test result. The hrHPV-positive women with normal cytology 
were offered cytology and a blinded hrHPV test at 12 months, and combined hrHPV 
testing and cytology at 24 months. A woman was referred at 12 months if cytology 
was abnormal and at 24 months if the hrHPV test was positive and/or cytology was 
abnormal. The hrHPV-negative, cytologically normal women in the sub-study were in-
vited for combined testing at 24 months, and referred if cytology was abnormal and/
or the hrHPV test was positive. If a woman with normal cytology and a negative hrHPV 
test was not invited for repeat testing after 24 months, cytological and/or histological 
follow-up results was not included.
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cytology and 
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n= 3063 at 24m 
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hrHPV+ 
 
 Referral 
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Figure 1 Flowchart of the study design. BMD, borderline or mild dyskaryosis; colpo, colposcopy; cyto, cytology; hrHPV, 
high-risk human papillomavirus; m, months.
 The VUSA-Screen study was approved by the Ministry of Public Health 
(2002/02-WBO; ISBN-10: 90-5549-452-6) and registered in the trial register (NTR215, 
ISRCTN64621295).
Colposcopy
Of the women who were referred to a gynaecologist for colposcopy, colposcopy- 
directed biopsies were taken from suspicious areas of the cervix, according to 
standard procedures in the Netherlands.28 Biopsy results were reported as normal, 
cervical intraepithelial neoplasia grade 1, 2, 3, or as invasive cancer, according to 
the international criteria.29;30 Cytology and histology results were retrieved from the 
nationwide network and registry of histopathology and cytopathology (PALGA; 
Bunnik, the Netherlands).
hrHPV testing
The hrHPV testing was performed by the HC2 high-risk HPV DNA test in an automated 
format on a rapid capture system according to the manufacturer’s instructions 
(Qiagen). This test uses a cocktail probe to detect 13 high-risk HPV types: 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Positive controls containing 1pgml-1 of 
cloned HPV-16 DNA and negative controls (provided by the manufacturer) were in-
cluded in each assay (Qiagen). The results of the HC2 assay were expressed as RLU/
CO ratio, representing the ratio between the emission from a sample to the average 
emission of three positive controls. Initially, the threshold of 1 RLU/CO, as proposed by the 
manufacturer, was used to classify a specimen as positive or negative.
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Statistical analysis
The primary outcome measure of the study was histologically confirmed CIN3+, 
detected cumulatively within 3 years after baseline. A secondary outcome was 
cumulatively detected CIN2+. In the calculations of the number of CIN3+ and CIN2+ 
lesions, cases of cervical adenocarcinoma and cervical adenocarcinoma in situ 
were also included. 
 The absolute specificity of hrHPV testing with RLU/CO thresholds between 
1 and 100 and the absolute specificity of cytology were computed as follows. 
Specificities were adjusted for nonattendance at repeat testing by applying Bayes’s 
rule, which means that the specificities were computed from the positive and negative 
predictive values for CIN3+ (and CIN2+), as well as the baseline prevalences of HC2 
and cytology test outcome strata.31;32 For this purpose, the baseline test outcomes were 
grouped into seven strata: (1) >BMD and hrHPV+, (2) >BDM and hrHPV-, (3) BMD and 
hrHPV+, (4) BMD and hrHPV-, (5) normal and hrHPV+, (6) normal and hrHPV-, and age 
≤35 years, and (7) normal and hrHPV-, and age >35 years. We defined two separate 
age strata for hrHPV-negative women with normal cytology at baseline because 
hrHPV-negative normal women were age-matched to hrHPV-positive normal women, 
and women ≤35 years were therefore overrepresented in follow-up. The positive 
and negative predictive values were computed only on the basis of women with at 
least one repeat test. For hrHPV-positive, cytologically normal women, the 12-month 
screening tests were used as repeat tests. The 24-month screening tests were used if 
the 12-month tests were missing. For BMD hrHPV-negative women, the 6-month results 
were used as repeat test results and the 18-month results were used if the 6-month 
results were missing. The specificities presented were therefore adjusted for women 
without repeat testing, but were not adjusted for differences in intensity of follow-up 
testing among women with at least one repeat test. 
 Furthermore, we compared baseline cytology (threshold BMD) with three 
possible hrHPV screening strategies at RLU/CO thresholds between 1 and 100. The 
 Table 1 Number of test positives and negatives, CIN3+ and CIN2+ detected, stratified for cytology and HC2 thresholds.
  Histology 
 End point CIN3+ End point CIN2+
   Test positive Test negative Detected Missed Detected Missed 
Test   n (% of total n=25 658) n	 n	 n	 n	 n
Baseline 462 (1.80) 1021 124 27 181 57
 cytology
(threshold BMD)
HC2 cutoff
   1 1303 (5.08) 180 146 5 227 11
   2 1147 (4.47) 336 144 7 224 14
   5 1006 (3.92) 477 141 10 216 22
   7 954 (3.72) 529 137 14 212 26
     10 877 (3.42) 606 131 20 203 35
    30 654 (2.55) 829 118 33 184 54
     50 572 (2.23) 911 104 47 162 76
   100 433 (1.69) 1050 89 62 133 105
BMD=borderline or mild dyskaryosis; CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2=hybrid  
capture 2.
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following hrHPV screeningstrategies were used: (1) baseline hrHPV testing only; (2) 
cytology triage of hrHPV-positive women at baseline and one repeat cytological test 
for cytologically normal women; and (3) cytology triage of hrHPV-positive women 
at baseline and one repeat combined cytology and hrHPV HC2 test (with RLU/CO 
values as used at baseline) for cytologically normal women. For each comparison, 
we computed the relative sensitivity for CIN3+ (and CIN2+), relative false positivity rate 
and relative colposcopy referral rate. Analogous to the calculation of the specificity, 
the relative rates were calculated by combining positive and negative predictive val-
ues (here for CIN3+, CIN2+ and colposcopy referral) and baseline test outcomes. Be-
cause double-negative women cancel out when calculating relative rates,33 we only 
needed to define five baseline strata: (1) >BMD and hrHPV+, (2) >BDM and hrHPV-, (3) 
BMD and hrHPV+, (4) BMD and hrHPV- and (5) normal and hrHPV+.
 The 95% confidence intervals (CIs) were calculated for absolute specificity 
using the Wilson Score method (Brown et al, 2001), in which the sample size was set 
equal to the number of cases observed in the cohort study. 
 Analyses were done with SPSS version 15.0 (LEAD Technologies Inc, 
Haddonfield, NJ, USA), and Excel (Microsoft Corporation, Redmond, WA, USA).
Results
Study subjects
Of the 25 871 women from the intervention group of VUSA-Screen study, 25 658 (99.2%) 
had an adequate baseline Pap smear. Among women with adequate Pap smears, 
25 196 had normal cytology of whom 1021 (4.1%) tested hrHPV-positive, 337 women 
had a BMD result of whom 167 (49.6%) tested hrHPV-positive and 125 women had a 
>BMD result of whom 115 (92.0%) tested hrHPV-positive. The median age of participat-
ing women was 44.0 years (range, 29–61 years). The hrHPV results of positive RLU/CO 
(i.e., RLU/ CO ≥1) showed a mean of 224.5 (range, 1.0–2565.7).
 The number of test positives and negatives, CIN3+ and CIN2+ detected, 
stratified for cytology and HC2 thresholds are presented in Table 1.
Table 2 Comparison of specificity between baseline hrHPV test with different RLU/CO thresholds and baseline cytology 
testing for CIN3+ and CIN2+, adjusted for non-attendance at repeat testing.
  End point CIN3+ End point CIN2+
Test Specificity (%) 95% CI Specificity (%) 95% CI
Baseline cytology 98.7 98.5–98.8 98.9 98.8–99.0
(threshold BMD)
 Baseline HC2 positivity threshold, RLU/CO
   1 95.5 95.3–95.8 95.9 95.7–96.2
   2 96.2 95.9–96.4 96.5 96.3–96.8
   5 96.7 96.5–96.9 97.1 96.8–97.3
   7 96.9 96.7–97.1 97.2 97.0–97.4
     10 97.2 96.9–97.4 97.5 97.3–97.7
     30 98.0 97.8–98.1 98.3 98.1–98.4
     50 98.2 98.0–98.4 98.5 98.3–98.6
   100 98.7 98.5–98.8 98.9 98.7–99.0
BMD=borderline or mild dyskaryosis; CI=confidence interval; CIN=cervical intraepithelial neoplasia (grade 2 or 3 or 
higher); HC2=hybrid capture 2; hrHPV=high-risk human papillomavirus; RLU/CO=relative light unit/cutoff.
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Table 3 Relative colposcopy referral rates, relative sensitivity, relative false positivity rate of HC2 RLU/CO thresholds at 
baseline alone vs baseline cytology testing, adjusted for non-attendance at repeat testing.
    End point CIN3+ End point CIN2+
 Relative colposcopy  Relative Relative false Relative Relative false
Test referral rate  sensitivity positivity rate sensitivity positivity rate
Baseline cytology Reference Reference Reference Reference Reference
(threshold BMD) 
Baseline HC2 positivity threshold, RLU/CO
   1    2.82 1.36 3.35 1.50 3.67
   2 2.48 1.34 2.89 1.48 3.12
   5 2.18 1.31 2.49 1.42 2.65
   7 2.06 1.28 2.34 1.40 2.48
    10 1.90 1.22 2.14 1.34 2.25
    30 1.42 1.08 1.53 1.20 1.55
    50 1.24 0.95 1.34 1.05 1.35
   100 0.94 0.80 0.99 0.82 1.01
BMD=borderline or mild dyskaryosis; CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2=hybrid capture 
2; RLU/CO=relative light unit/cutoff.
 Table 2 presents the specificity for detected CIN3+ and CIN2+ lesions for 
baseline cytology testing (threshold BMD) and for a strategy of primary HC2 testing 
without follow-up testing at different RLU/CO thresholds. Compared with baseline 
cytology testing, hrHPV testing at the standard threshold of 1 RLU/CO had a lower 
specificity for CIN3+ (95.5 vs 98.7%) and CIN2+ (95.9 vs 98.9%). The specificity for CIN3+ 
and CIN2+ increased with increasing RLU/CO thresholds. Only at a RLU/CO threshold 
of 100, hrHPV testing reached the same specificity for CIN2+ (i.e., 98.9%) and CIN3+ 
(i.e., 98.7%) as cytology. 
 The relative colposcopy referral rate, relative sensitivity and relative false 
positivity rate of primary HC2 testing at different RLU/CO thresholds vs baseline cytology 
testing are presented in Table 3. Compared with cytology, hrHPV testing at a thresh-
old of 1 RLU/CO would result in a 2.8-fold higher number of colposcopy referral rates. 
With increasing HC2 threshold, the relative colposopy referral rates decreased, result-
ing in a relative rate of 1.9 at 10 RLU/CO and 0.94 at 100 RLU/CO.
 At the standard test positivity threshold for HC2 (i.e., 1 RLU/CO), the relative sen-
sitivity of hrHPV was superior to that of cytology, both for CIN3+ (relative sensitivity of 
1.36) and CIN2+ relative sensitivity of 1.50). With increasing HC2 threshold values, the 
relative sensitivity for CIN3+ decreased, resulting in a relative sensitivity of 1.22 at 10 
RLU/CO and 0.80 at 100 RLU/CO. Results were comparable using CIN2+ as outcome 
measure.
 There was no HC2 threshold that resulted in an improved false positivity rate and 
concomitant colposcopy referral rate, without compromising its sensitivity. In fact, 
the HC2 threshold (i.e., 100 RLU/CO) at which a lower colposcopy referral rate was 
reached compared with cytology, also revealed lower sensitivities for CIN3+ and 
CIN2+ (Table 3). As no strategy of sole hrHPV testing at baseline improved on baseline 
cytology testing, some form of triage or follow-up testing is required.
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 Table 4 shows the impact of raising the HC2 threshold in the context of two 
triage and follow-up strategies for HC2-positive women compared with baseline 
cytology testing. For the strategy with cytology triage at baseline and at 12 months, 
HC2 screening at RLU/CO thresholds between 1  and 30 resulted in higher sensitivities 
for both CIN2+ and CIN3+, compared with baseline cytology testing. This strategy 
showed lower colposcopy referral rates and false positivity rates at all analysed RLU/
CO thresholds (1–100).
 For the strategy with cytology triage at baseline and combined cytology and HC2 
testing (with the same threshold as used at baseline) at 12 months, only at threshold 
30, a lower false positivity and colposcopy rate in combination with higher sensitivities 
for CIN3+ and CIN2+ than baseline cytology testing was found. However, at RLU/CO 
30, the gain in sensitivity compared with cytology was only marginal. 
 The relative sensitivity vs relative false positivity rate of the three investigated 
screening strategies, compared with baseline cytology testing, is graphically shown 
in Figure 2. Baseline cytology testing is presented in the origin (relative sensitivity = 1, 
relative specificity = 1). Quadrant II represents combinations of sensitivity and false 
positivity rates that are superior to baseline cytology testing. The strategy with base-
Table 4 Relative colposcopy referral rates, relative sensitivity, relative false positivity rate of HC2 positivity threshold with 
baseline triage and repeat testing strategy vs baseline cytology testing, adjusted for non-attendance at repeat testing.
  End point CIN3+ End point CIN2+
    Relative  Relative  Relative
    colposcopy Relative false positivity Relative false positivity
Test    referral rate sensitivity rate sensitivity rate
Baseline cytology   Reference Reference Reference Reference Reference
(threshold BMD)               
Baseline HC2 Baseline  Repeat test         
positivity threshold,  triage test at 12 months
RLU/CO
 1 Cytology Cytology 0.94 1.32 0.80 1.36 0.67
 2 Cytology Cytology 0.89 1.29 0.74 1.34 0.60
 5 Cytology Cytology 0.84 1.25 0.69 1.31 0.60
 7 Cytology Cytology 0.82 1.22 0.68 1.29 0.52
 10 Cytology Cytology 0.79 1.17 0.65 1.23 0.50
 30 Cytology Cytology 0.65 1.02 0.52 1.09 0.38
 50 Cytology Cytology 0.57 0.90 0.45 0.96 0.33
 100 Cytology Cytology 0.46 0.75 0.36 0.74 0.28
              
 1 Cytology Cytology and HC2a 1.88 1.36 2.07 1.50 2.12
 2 Cytology Cytology and HC2a 1.68 1.34 1.81 1.47 1.82
 5 Cytology Cytology and HC2a 1.45 1.30 1.51 1.40 1.48
 7 Cytology Cytology and HC2a 1.37 1.27 1.41 1.37 1.37
 10 Cytology Cytology and HC2a 1.30 1.21 1.33 1.29 1.30
 30 Cytology Cytology and HC2a 0.96 1.05 0.92 1.14 0.84
 50 Cytology Cytology and HC2a 0.81 0.93 0.76 1.01 0.68
 100 Cytology Cytology and HC2a 0.59 0.76 0.52 0.78 0.46
BMD=borderline or mild dyskaryosis; CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2=hybrid capture 
2; RLU/CO=relative light unit/cutoff. aHC2 RLU/CO threshold as at baseline.
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line HC2 testing alone was inferior to baseline cytology testing for all RLU/CO thres-
holds. The strategy with cytology triage of HC2-positive women and cytology testing 
at 12 months showed the best combination of relative sensitivity and false positivity 
rates for RLU/CO between 1 and 30. The RLU/CO data points for this strategy form 
a steep curve. This indicates that at increasing RLU/CO thresholds, the reduction 
in false positivity rate in this strategy is relatively small, whereas the decrease in 
sensitivity is substantial. Thus, low RLU/CO values are required to maintain high 
sensitivity.
 
is of particular importance for women of reproductive age, because
it has been shown that the rate of serious obstetrical complications,
such as preterm deliveries, low birth weight and premature rupture
of the membranes, is increased after excisional treatments for
precancerous lesions (Kyrgiou et al, 2006). Therefore, there is a
need to identify strategies that minimise the need for colposcopy
referrals with hrHPV testing, while maintaining its advantage in
terms of sensitivity. A number of studies have evaluated the
optimisation of cervical screening by studying the different hrHPV
HC2 cutoff levels for test positivity (Kuhn et al, 2000; Schiffman
et al, 2000; Clavel et al, 2001; Kulmala et al, 2004; Ronco et al,
2006a, b; Kotaniemi-Talonen et al, 2008; Sargent et al, 2010).
Kotaniemi-Talonen et al concluded that when used as a sole
screening test, the hrHPV test cutoff level can be increased to 10
RLU/CO. The specificity of hrHPV screening, however, remained
lower than that with conventional cytology testing even at the
threshold of 10 RLU/CO. This is in line with our findings for the
strategy of baseline HC2 testing only. It should be noted that the
hrHPV test may compare to be more favourable with cytology in
other countries. In the Netherlands and Finland, the specificity of
cytology is quite high. This is also the case for other European
screening programmes (Cuzick et al, 2006), but worldwide the
specificity of cytology is highly variable (Nanda et al, 2000). Ronco
et al (2006a, b) proposed only a slight increase of the threshold up
to 2.00 RLU/CO when HC2 is used for population-based screening.
The same threshold has been proposed by Sargent et al (2010). A
minimal increase in threshold reflects a preference for a sensitive
screening strategy. We found that, in an hrHPV DNA screening
strategy with cytology triage and cytology testing at one follow-up
visit, an increased sensitivity as well as decreased colposcopy
referral rate is possible with RLU/CO thresholds up to 30. Given
our observation that hrHPV testing cannot be used as a sole
screening instrument and that triage and repeated testing is
necessary anyhow, we also prefer a low threshold of 1 to maintain
the highest sensitivity.
There are some limitations in our study. In this study, women
received cytology and hrHPV testing, and based on both results,
women were referred for colposcopy. Therefore, we were not able to
compare different RLU/CO thresholds outcomes with current
cytology screening programme but only with baseline cytology
testing. Furthermore, we adjusted for non-attendance at repeat
testing, but the results were not adjusted for differences in intensity
of follow-up testing. In addition, actual colposcopies were not
reported. Another limitation of our study may be the use of a
subjective test, such as cytology, as a triage test for hrHPV-positive
women. Awareness of the negative or positive hrHPV test result may
affect the criteria for defining cellular abnormalities. However, in this
study, the cytotechnicians were not informed about the hrHPV test
result. Nevertheless, even in case cytotechnicians were aware of the
hrHPV test results, as in a Finnish trial (Leinonen et al, 2009), the
hrHPV test information only had a small effect on cytology
assessment, and therefore on the CIN3þ detection rate and the
number of colposcopies. In this context, it may be expected that in
the near future molecular biomarkers may be used as objective triage
tests of hrHPV-positive women. Suitable candidate novel biomarkers
such as HPV mRNA (Molden et al, 2005), p16 ink4a (Carozzi et al,
2008), methylation markers (Overmeer et al, 2008, 2009) or
genotyping might further enhance the efficacy of screening with
hrHPV DNA (Cuschieri et al, 2004). Presently, we are investigating
the possible value of such alternative triage tests in hrHPV-positive
women and preliminary results show that better results can be
obtained than with cytology (Heideman et al, 2010).
Our finding that hrHPV testing alone at the predefined assay
threshold of 1 RLU/CO had a somewhat lower specificity than
cytology for CIN2þ and CIN3þ is consistent with results from
other randomised and nonrandomised studies using HC2 testing
(Kotaniemi-Talonen et al, 2005; Arbyn et al, 2006; Cuzick et al,
2006, 2008; Ronco et al, 2006a, b; Mayrand et al, 2007; Kitchener
et al, 2009; Leinonen et al, 2009) or another clinically validated
hrHPV test (Bulk et al, 2007; Naucler et al, 2007). However,
compared with these studies, our observed specificity of the
hrHPV test was relatively high (i.e., 95.9% (95% CI 95.7–96.2) for
CIN2þ and 95.5% (95% CI 95.3–95.8) for CIN3þ ). At least in
part, this difference in specificity estimates may be explained by
differences in the design of hrHPV screening studies and study
populations. Our study included hrHPV testing combined with
cytology. In addition, it was conducted within the setting of an
organised cervical screening programme with high invitational
coverage and low incidence of cervical cancer.
A strong point of this study is the longitudinal design and the
older age range of study participants (30–60 years), which is the
age for which hrHPV testing is most widely advocated (Wright Jr
et al, 2004; Naucler et al, 2007; Ronco et al, 2009). The study was
population-based and part of a routine organised screening
activity in a low-risk population, indicating that the results could
be implemented in routine practice.
To conclude, no RLU/CO threshold was found for which HC2
testing at baseline resulted in a similar or lower colposcopy referral
rate than baseline cytology, while maintaining a higher sensitivity.
Superior combinations of sensitivity and colposcopy rate are
possible for HC2 testing with cytology triage at baseline and
repeated cytology testing after 1 year. As increasing the RLU/CO
threshold only marginally decreases colposcopy referral rate while
substantially reducing sensitivity, we suggest maintaining the
currently used RLU/CO threshold of 1. This results in more than
30% higher sensitivities for CIN3þ than cytology testing at a 20%
lower false positivity rate and 6% lower colposcopy referral rate.
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Figure 2 Relative sensitivity vs relative false positivity rate for three
strategies for hybrid capture 2 (HC2)-positive women at different relative
light unit/cutoff (RLU/CO) thresholds compared with baseline cytology
(cyto) testing, for detection of cervical intraepithelial neoplasia grade 3 or
higher (CIN3þ ). Relative sensitivity for detection of CIN3þ is plotted on
the y-axis, against the relative false positivity rate on the x-axis. The used
HC2 RLU/CO thresholds are indicated at the respective positions above
each plot. I: quadrant with relative sensitivity and relative false positivity rate
greater than cytology; II: panel with relative sensitivity greater than and
relative false positivity rate lower than cytology; III: panel with relative
sensitivity lower than and relative false positivity rate lower than cytology;
IV: panel with relative sensitivity and relative false positivity rate lower than
cytology. BMD, borderline or mild dyskaryosis.
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is of particular importance for women of reproductive age, because
it has been shown that the rate of serious obstetrical complications,
such as preterm deliveries, low birth weight and premature rupture
of the membranes, is increased after excisional treatments for
precancerous lesions (Kyrgiou et al, 2006). Therefore, there is a
need to identify strategies that minimise the need for colposcopy
referrals with hrHPV testing, while maintaining its advantage in
terms of sensitivity. A number of studies have evaluated the
optimisation of cervical screening by studying the different hrHPV
HC2 cutoff levels for test positivity (Kuhn et al, 2000; Schiffman
et al, 2000; Clavel et al, 2001; Kulmala et al, 2004; Ronco et al,
2006a, b; Kotaniemi-Talonen et al, 2008; Sargent et al, 2010).
Kotaniemi-Talonen et al concluded that when used as a sole
screening test, the hrHPV test cutoff level can be increased to 10
RLU/CO. The specificity of hrHPV screening, however, remained
lower than that with conventional cytology testing even at the
threshold of 10 RLU/CO. This is in line with our findings for the
strategy of baseline HC2 testing only. It should be noted that the
hrHPV test may compare to be more favourable with cytology in
other countries. In the Netherlands and Finland, the specificity of
cytology is quite high. This is also the case for other European
screening programmes (Cuzick et al, 2006), but worldwide the
specificity of cytology is highly variable (Nanda et al, 2000). Ronco
et al (2006a, b) proposed only a slight increase of the threshold up
to 2.00 RLU/CO when HC2 is used for population-based screening.
The same threshold has been proposed by Sargent et al (2010). A
minimal increase in threshold reflects a preference for a sensitive
screening strategy. We found that, in an hrHPV DNA screening
strategy with cytology triage and cytology testing at one follow-up
visit, an increased sensitivity as well as decreased colposcopy
referral rate is possible with RLU/CO thresholds up to 30. Given
our observation that hrHPV testing cannot be used as a sole
screening instrument and that triage and repeated testing is
necessary anyhow, we also prefer a low threshold of 1 to maintain
the highest sensitivity.
There are some limitations in our study. In this study, women
received cytology and hrHPV testing, and based on both results,
women were referred for colposcopy. Therefore, we were not able to
compare different RLU/CO thresholds outcomes with current
cytology screening programme but only with baseline cytology
testing. Furthermore, we adjusted for non-attendance at repeat
testing, but the results were not adjusted for differences in intensity
of follow-up testing. In addition, actual colposcopies were not
reported. Another limitation of our study may be the use of a
subjective test, such as cytology, as a triage test for hrHPV-positive
women. Awareness of the negative or positive hrHPV test result may
affect the criteria for defining cellular abnormalities. However, in this
study, the cytotechnicians were not informed about the hrHPV test
result. Nevertheless, even in case cytotechnicians were aware of the
hrHPV test results, as in a Finnish trial (Leinonen et al, 2009), the
hrHPV test information only had a small effect on cytology
assessment, and therefore on the CIN3þ detection rate and the
number of colposcopies. In this context, it may be expected that in
the near future molecular biomarkers may be used as objective triage
tests of hrHPV-positive women. Suitable candidate novel biomarkers
such as HPV mRNA (Molden et al, 2005), p16 ink4a (Carozzi et al,
2008), methylation markers (Overmeer et al, 2008, 2009) or
genotyping might further enhance the efficacy of screening with
hrHPV DNA (Cuschieri et al, 2004). Presently, we are investigating
the possible value of such alternative triage tests in hrHPV-positive
women and preliminary results show that better results can be
obtained than with cytology (Heideman et al, 2010).
Our finding that hrHPV testing alone at the predefined assay
threshold of 1 RLU/CO had a somewhat lower specificity than
cytology for CIN2þ and CIN3þ is consistent with results from
other randomised and nonrandomised studies using HC2 testing
(Kotaniemi-Talonen et al, 2005; Arbyn et al, 2006; Cuzick et al,
2006, 2008; Ronco et al, 2006a, b; Mayrand et al, 2007; Kitchener
et al, 2009; Leinonen et al, 2009) or another clinically validated
hrHPV test (Bulk et al, 2007; Naucler et al, 2007). However,
compared with these studies, our observed specificity of the
hrHPV test was relatively high (i.e., 95.9% (95% CI 95.7–96.2) for
CIN2þ and 95.5% (95% CI 95.3–95.8) for CIN3þ ). At least in
part, this difference in specificity estimates may be explained by
differences in the design of hrHPV screening studies and study
populations. Our study included hrHPV testing combined with
cytology. In addition, it was conducted within the setting of an
organised cervical screening programme with high invitational
coverage and low incidence of cervical cancer.
A strong point of this study is the longitudinal design and the
older age range of study participants (30–60 years), which is the
age for which hrHPV testing is most widely advocated (Wright Jr
et al, 2004; Naucler et al, 2007; Ronco et al, 2009). The study was
population-based and part of a routine organised screening
activity in a low-risk population, indicating that the results could
be implemented in routine practice.
To conclude, no RLU/CO threshold was found for which HC2
testing at baseline resulted in a similar or lower colposcopy referral
rate than baseline cytology, while maintaining a higher sensitivity.
Superior combinations of sensitivity and colposcopy rate are
possible for HC2 testing with cytology triage at baseline and
repeated cytology testing after 1 year. As increasing the RLU/CO
threshold only marginally decreases colposcopy referral rate while
substantially reducing sensitivity, we suggest maintaining the
currently used RLU/CO threshold of 1. This results in more than
30% higher sensitivities for CIN3þ than cytology testing at a 20%
lower false positivity rate and 6% lower colposcopy referral rate.
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Figure 2 Relative sensitivity vs relative false positivity rate for three
strategies for hybrid capture 2 (HC2)-positive women at different relative
light unit/cutoff (RLU/CO) thresholds compared with baseline cytology
(cyto) testing, for detection of cervical intraepithelial neoplasia grade 3 or
higher (CIN3þ ). Relative sensitivity for detection of CIN3þ is plotted on
the y-axis, against the relative false positivity rate on the x-axis. The used
HC2 RLU/CO thresholds are indicated at the respective positions above
each plot. I: quadrant with relative sensitivity and relative false positivity rate
greater than cytology; II: panel with relative sensitivity greater than and
relative false positivity rate lower than cytology; III: panel with relative
sensitivity lower than and relative false positivity rate lower than cytology;
IV: panel with relative sensitivity and relative false positivity rate lower than
cytology. BMD, borderline or mild dyskaryosis.
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Figure 2 Relative sensitivity  relative false positivity rate for three strategies for hybrid capture 2 (HC2)-positiv  en 
at different relative light unit/cutoff (RLU/CO) thresholds compared with baseline cytology (cyto) testing, for detection of 
cervical intraepithelial neoplasia grade 3 or higher (CIN3+). Relative sensitivity for detection of CIN3+ is plotted on 
the y-axis, against the relative false positivity rate on the x-axis. The used HC2 RLU/CO thresholds are indicated at the 
respective positions above each plot. I: quadrant with relative sensitivity and relative false positivity rate greater than 
cytology; II: panel with relative sensitivity greater than and relative false positivity rate lower than cytology; III: panel with 
relative sensitivity lower than and relative false positivity rate lower than cytology; IV: panel with relative sensitivity and 
relative false positivity rate lowerthan cytology. BMD = borderlin  or mild dyskaryosis.
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Discussion
In this study, we evaluated three possible cervical screening strategies that are based 
on hrHPV testing with different HC2 thresholds and compared them with baseline 
cytology testing (threshold BMD). We aimed to improve the specificity of hrHPV 
screening by increasing the RLU/CO threshold, while maintaining a higher sensitiv-
ity than baseline cytological testing. The results are based on data from the VUSA-
Screen study, a population-based cohort study carried out in the Utrecht province of 
the Netherlands. We found that compared with baseline cytology testing, there was 
no HC2 RLU/CO threshold for which a screening strategy of hrHPV testing as a sole 
primary screening instrument resulted in both superior sensitivity as well as similar 
(or lower) colposcopy rate and equal (or higher) specificity. As baseline hrHPV testing 
cannot improve baseline cytology testing, even at increased RLU/CO thresholds, we 
conclude that some form of triage and follow-up is required in hrHPV screening. 
 Given that follow-up testing is required in hrHPV-positive women, we searched 
for a strategy that did not increase colposcopy referral rate compared with 
cytological testing. A screening strategy that was clearly superior to baseline 
cytological testing was primary hrHPV screening, with RLU/CO thresholds between 
1 and 30 and cytology triage at baseline and repeated cytology testing at 12 months. 
This strategy was not only more sensitive than baseline cytology testing but also 
resulted in lower false positivity rates and in fewer colposcopy referrals. Using HC2 RLU/
CO thresholds between 1 and 5 results in higher sensitivity (relative sensitivity between 
1.32 and 1.25, respectively) and a reduced colposcopy referral rate (between 6 and 
16%, respectively) compared with baseline cytology testing. The current threshold of 1 
RLU/CO makes optimal use of the superior sensitivity of the hrHPV test for CIN3+/CIN2+, 
without actually increasing the colposcopy referral rate compared with baseline 
cytology. The colposcopy referral rate of this strategy is therefore substantially lower 
than a screening scenario with baseline hrHPV testing only. In addition, a screening 
strategy with a high sensitivity may allow for extension of the screening interval, which 
in turn reduces colposcopy referral rates.34 
 An important issue in the debate about implementation of hrHPV testing has been 
the increased adverse effects in terms of unnecessary referrals for colposcopy among 
women with a positive hrHPV test. The issue of overdiagnosis and overtreatment 
is of particular importance for women of reproductive age, because it has been 
shown that the rate of serious obstetrical complications, such as preterm deliveries, 
low birth weight and premature rupture of the membranes, is increased after 
excisional treatments for precancerous lesions.35 Therefore, there is a need to identify 
strategies that minimise the need for colposcopy referrals with hrHPV testing, while 
maintaining its advantage in terms of sensitivity. A number of studies have evaluated 
the optimisation of cervical screening by studying the different hrHPV HC2 cutoff levels 
for test positivity.36;20;22;24;25;37-39 Kotaniemi-Talonen et al 24 concluded that when used 
as a sole screening test, the hrHPV test cutoff level can be increased to 10 RLU/
CO. The specificity of hrHPV screening, however, remained lower than that with 
conventional cytology testing even at the threshold of 10 RLU/CO. This is in line with our 
findings for the strategy of baseline HC2 testing only. It should be noted that the hrHPV 
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test may compare to be more favourable with cytology in other countries. In the 
Netherlands and Finland, the specificity of cytology is quite high. This is also the case for 
other European screening programmes,12 but worldwide the specificity of cytology 
is highly variable.40 Ronco et al 20;39 proposed only a slight increase of the threshold 
up to 2.00 RLU/CO when HC2 is used for population-based screening. The same 
threshold has been proposed by Sargent et al.25 A minimal increase in threshold 
reflects a preference for a sensitive screening strategy. We found that, in an hrHPV 
DNA screening strategy with cytology triage and cytology testing at one follow-up 
visit, an increased sensitivity as well as decreased colposcopy referral rate is possible 
with RLU/CO thresholds up to 30. Given our observation that hrHPV testing cannot be 
used as a sole screening instrument and that triage and repeated testing is necessary 
anyhow, we also prefer a low threshold of 1 to maintain the highest sensitivity. 
 There are some limitations in our study. In this study, women received cytology 
and hrHPV testing, and based on both results, women were referred for colposcopy. 
Therefore, we were not able to compare different RLU/CO thresholds outcomes 
with current cytology screening programme but only with baseline cytology testing. 
Furthermore, we adjusted for non-attendance at repeat testing, but the results were 
not adjusted for differences in intensity of follow-up testing. In addition, actual colpos-
copies were not reported. Another limitation of our study may be the use of a subjective 
test, such as cytology, as a triage test for hrHPV-positive women. Awareness of the 
negative or positive hrHPV test result may affect the criteria for defining cellular 
abnormalities. However, in this study, the cytotechnicians were not informed about 
the hrHPV test result. Nevertheless, even in case cytotechnicians were aware of the 
hrHPV test results, as in a  Finnish trial,41  the hrHPV test information only had a small 
effect on cytology assessment, and therefore on the CIN3+ detection rate and the 
number of colposcopies. In this context, it may be expected that in the near future 
molecular biomarkers may be used as objective triage tests of hrHPV-positive women. 
Suitable candidate novel biomarkers such as HPV mRNA,42 p16 ink4a,43 methy-
lation markers,44;45 or genotyping might further enhance the efficacy of screening with 
hrHPV DNA.46  Presently, we are investigating the possible value of such alternative 
triage tests in hrHPV-positive women and preliminary results show that better results 
can be obtained than with cytology.47
 Our finding that hrHPV testing alone at the predefined assay threshold of 
1 RLU/CO had a somewhat lower specificity than cytology for CIN2+ and CIN3+ is 
consistent with results from other randomised and nonrandomised studies using 
HC2 testing,12;14;19;20;39;41;48;49 or another clinically validated hrHPV test.15;50 However, 
compared with these studies, our observed specificity of the hrHPV test was relatively high 
(i.e., 95.9% (95% CI 95.7–96.2) for CIN2+ and 95.5% (95% CI 95.3–95.8) for CIN3+). 
At least in part, this difference in specificity estimates may be explained by differences 
in the design of hrHPV screening studies and study populations. Our study included 
hrHPV testing combined with cytology. In addition, it was conducted within the setting 
of an organised cervical screening programme with high invitational coverage and 
low incidence of cervical cancer. 
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 A strong point of this study is the longitudinal design and the older age range 
of study participants (30–60 years), which is the age for which hrHPV testing is most 
widely advocated.15;51;52 The study was population-based and part of a routine or-
ganised screening activity in a low-risk population, indicating that the results could be 
implemented in routine practice. 
 To conclude, no RLU/CO threshold was found for which HC2 testing at 
baseline resulted in a similar or lower colposcopy referral rate than baseline cytology, 
while maintaining a higher sensitivity. 
 Superior combinations of sensitivity and colposcopy rate are possible for HC2 testing 
with cytology triage at baseline and repeated cytology testing after 1 year. As 
increasing the RLU/CO threshold only marginally decreases colposcopy referral rate 
while substantially reducing sensitivity, we suggest maintaining the currently used RLU/
CO threshold of 1. This results in more than 30% higher sensitivities for CIN3+ than cytology 
testing at a 20% lower false positivity rate and 6% lower colposcopy referral rate.
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General Discussion
The role of hrHPV testing in cervical cancer screening
In many developed countries, cytology-based cervical cancer screening programmes 
have decreased the incidence and mortality of cervical cancer.1-5 However, in recent 
years, this decreasing effect on the incidence of cervical cancer has levelled off.4;6 
This can be explained by the varying screening uptake among women, a relatively 
high number of false-negative cytology tests (lack of sensitivity)7;8 and suboptimal 
follow-up of screen-positive women. In addition, although the incidence of squamous 
cell carcinoma has decreased, the incidence of cervical adenocarcinoma does not 
display a decreasing trend.9 These findings confirm that adenocarcinoma and its 
precursor lesions are difficult to detect by cervical cytology. In addition, the incidence 
of adenocarcinoma seems to be increasing in young women.9
 Since hrHPV testing has a higher sensitivity and offers better protection against 
high-grade cervical lesions and cervical cancer than cytology, implementation of 
hrHPV testing as primary cervical cancer screening test is presently considered in 
many countries.
 Here, we will discuss whether cervical screening can be improved by 1. 
hrHPV testing to triage women with borderline or mild dyskaryosis and 2. imple-
menting hrHPV testing as a primary screening test. Furthermore, we addressed the 
following questions: at what age should hrHPV testing be started? What is the appropriate 
triage algorithm for hrHPV-positive women to minimize the loss of specificity with 
hrHPV screening compared to cytology screening? In addition, we will discuss how 
cervical screening can be improved by hrHPV testing on self-collected cervico- 
vaginal specimens. Finally, effects of HPV vaccination on screening and future as-
pects of hrHPV-based screening are discussed.
 
HrHPV testing to triage women with borderline or mild dyskaryosis 
Currently, cervical cancer screening programmes are based on cytology. About 2.5% 
of the women participating in the Dutch population-base screening programme 
have a bordeline or mild dyskaryosis (BMD) test result.10 Of these women, only 10%-
20% harbor CIN2+ lesions.11;12 These women are therefore not directly referred for 
colposcopy but are advised to repeat cytology at 6 and 18 months and are only 
referred for colposcopy if any of the repeat cytology tests is abnormal (threshold 
≥ BMD). The majority of referred women, however, will have meaningless lesions that 
will regress spontaneously.12 To reduce the number of referrals and colposcopies, the 
New Dutch guidelines13 allowed laboratories to choose to include hrHPV testing at 
the repeat visit at 6 months (Figure 1). This guideline change was a first step in the 
transition towards hrHPV testing. The complexity of this follow-up testing strategy is 
considerable since women with a repeat smear of BMD and who test positive for 
hrHPV are referred to a gynecologist, while those with a negative hrHPV test still get 
a repeat smear at 18 months after the first test (Figure 1). Moreover, only women with 
a normal repeat smear and negative hrHPV test are referred back to the screening 
programme, whereas their hrHPV-positive counterparts are offered repeat cytology 
at 18 months. Women with a repeat smear of >BMD are, independent of the hrHPV 
test result, directly referred to the gynecologist. 
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 We studied whether a less complex referral strategy is possible where women with 
BMD are triaged  at baseline with hrHPV testing (Chapter 2).14 In this algorithm women 
with BMD and a positive hrHPV test are directly referred for colposcopy while the 
women with BMD and a negative hrHPV test are advised to repeat cytology at 6 and 
18 months. 
 Our study showed that hrHPV triaging of women with BMD resulted in a high CIN3 
and CIN2+ detection rate (10.7% and 22.3%, respectively). This finding is consistent 
with meta-analyses that have shown that hrHPV triaging has a higher sensitivity than 
repeat cytology for detection of CIN2+.12;15 Furthermore, in our study women with BMD 
and a negative hrHPV test had a low three-year risk to develop high-grade lesions 
(CIN3 of 1.2% and CIN2+ of 2.9%)14 and therefore could be directly referred to the 
routine screening. The next regular screening round (interval 5 year) could serve as a 
safety net, at least for women aged ≤ 55 years who will still be invited for screening.
BMD BMD 
     Cytology only 
t=0 
t=6 
t=18 
Cytology and hrHPV 
Normal ≥BMD 
Cytology 
>BMD BMD Normal 
Referral to 
colposcopy 
Referral to 
colposcopy 
hrHPV- hrHPV+ hrHPV- hrHPV+ 
Cytology 
Next 
screening 
round 
30% 70% 
Figure 1 Flowchart for the follow-up of women with BMD cytology in the Netherlands [adapted from 13].
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 Disadvantage of triage by hrHPV testing at baseline is that approximately 20% of 
the women will have cleared their hrHPV infection in the first 6 months of follow-up. 
As a consequence, hrHPV triaging at baseline might result in 51.5% higher colposcopy 
referral rates than repeat cytology (colposcopy referral rates of 57.6% versus 38.0%, 
respectively). However, our study showed that hrHPV triaging did not lead to an 
increase in the referral rate per detected CIN3. The medical costs per detected CIN3 
were even slightly lower for hrHPV triaging than for repeat cytology testing.
 Advantages of baseline triaging instead of repeat cytology are ease of 
implementation, low loss of follow-up, fast diagnosis and low distress for participating 
women.
__________________________________________________________________________________
Recommendations
• HrHPV triaging of women with BMD has shown to be at least as effective for 
detection of CIN3 as repeat cytology. Women with BMD should be directly 
triaged by hrHPV testing instead of by repeat cytology testing to achieve a fast 
diagnosis and therefore reduce unnecessary distress for women. 
• Women with BMD and hrHPV-positive test should be referred for colposcopy, 
since these women have a high risk to develop CIN3 and CIN2+ (20.4% and 41.9%, 
respectively).
• Women with BMD and hrHPV-negative test result have an acceptable low 3 year 
CIN3+ risk of 1.3% and CIN2+ risk of 2.9% and therefore could be referred to routine 
screening.
__________________________________________________________________________________
Primary hrHPV based screening
We evaluated hrHPV testing in two prospective population-based screening 
studies: the POBASCAM trial that followed 40,105 women aged 29-56 for two screen-
ing rounds (9 year interval) and the VUSA-screen study that followed 48,088 women 
aged 29-61 for 3 years.  
 Both studies showed that hrHPV testing has a higher cross-sectional sensitivity, but 
lower specificity than cytology for detecting CIN2+ (Chapter 3 and 4).16;17 These results 
are in line with other screening studies.12;18-22 These trials showed that the cross-section-
al sensitivity of hrHPV testing for CIN2+ was 49% and for CIN3+ was 30% higher than 
that of cytology, while the specificity of hrHPV testing was 2.5-4% lower.23 
 The POBASCAM trial furthermore showed that hrHPV testing in combination 
with cytology resulted in higher detection of CIN2+ lesions compared to cytology 
testing alone at the first round. This resulted in an improved protection against CIN3+ 
at the second screening round compared with cytology alone (relative risk 0.73, 95% 
CI 0.55-0.96) (Chapter 4).16 These findings are in agreement with other randomised con-
trolled trails, 22;24;25 and our interim analysis.26 Additionally, as was the case in the NTCC 
trial,27 our study showed that hrHPV testing provides better protection against cervical 
cancer in the second screening round than cervical cytology (relative risk 0.29, 95% 
CI 0.10-0.87). Collectively, all trials showed that hrHPV testing significantly reduces 
detection of CIN3+ lesions in the second screening round relative to cytology. 
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 These results suggest that an extension of the screening interval may be 
considered when hrHPV testing is implemented.22;26 This is also consistent with the 
results of the VUSA-Screen study and other studies,28-31 showing a very low detection 
of CIN3+ and CIN2+ lesions after a negative hrHPV test (Chapter 3).17 A model study 
based on data from the POBASCAM study 32 indicate that an extension of screening 
interval to 7.5 years is possible without increasing the cancer risk as presently observed 
with 5-yearly cytology. 
 Questions have risen whether the increased sensitivity of hrHPV testing results 
in over-diagnosis of lesions that otherwise would have regressed spontaneously. 
The long screening interval used in the POBASCAM trail (5 years) may provide some 
information on whether a cervical lesion is persistent or regressive. The POBASCAM 
trial showed that over-diagnosis in the women studied (30-60 year) does not seem a 
clinically relevant problem since the cumulative number of women with CIN3+ over 
both screening rounds did not differ between intervention (hrHPV & cytology) and the 
control (cytology only) group (259 of 19,999 vs 272 of 20,106; 0.96, 95%CI 0.81-1.14). 
This result supports the idea that hrHPV testing leads to earlier detection of clinically 
relevant lesions.
 Another important question is whether hrHPV testing should be offered in 
combination with cytology or as a single, primary screening instrument. Because 
hrHPV testing has a very high sensitivity, others and we showed that combined test-
ing with cytology was not better than hrHPV screening alone in detecting CIN3+ 
and CIN2+ lesions (pooled detection ratios of 1.04 (95%CI 0.92-1.17 for CIN3+ and 
1.06 (95%CI 0.97-1.16 for CIN2+, respectively).16;17;23;27 For this reason, cervical screen-
ing with a primary stand-alone hrHPV test seems preferable. This recommendation is 
confirmed by cost-effectiveness studies.32-34
 About 20% of all cervical cancers are adenocarcinomas.35 A problem of the 
present cytology-based programmes is that in contrast to squamous cell carcinomas 
the incidence of adenocarcinomas is not decreasing.36-38 Reasons for this finding are 
1) the poor cytological definition of the precursor lesions of adenocarcinomas except 
for adenocarcinoma in situ resulting in poor recognition by the cyto-pathologists and 
2) the localization of these lesions higher in the endocervical canal. Exfoliation of 
representative abnormal cells is therefore limited and abnormal cylinder cells are 
more difficult to detect by the cytopathologist. Studies demonstrated that hrHPV 
testing has a higher sensitivity for precursor lesions of adenocarcinoma of the cervix 
than cytology testing.39;40 The NTCC trial 27 reported a higher occurrence of adeno-
carcinomas after cytology screening compared to hrHPV screening, confirming the 
notion that cytology is particularly less effective in preventing adenocarcinomas. 
However, in the POBASCAM trail no significant differences in detection of adeno- 
carcinomas between intervention (hrHPV & cytology) and control arm (cytology) 
was detected, probably because the number of cervical adenocarcinomas in this 
study was small. Therefore, the results from prospective trials need to be pooled to 
determine whether hrHPV testing prevents adenocarcinomas better than 
cytology. Presently, these pooled trial data are analysed in the PreHdict consortium 
(www.ecca.info/campaigns/prehdict.html).
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 Another issue is how much each of the HPV genotypes contributes to the 
detection of CIN3+ and CIN2+. The POBASCAM study showed that hrHPV testing 
mainly resulted in early detection of HPV16 associated CIN2+ lesions in the first screen-
ing round followed by a reduction of HPV16 CIN3+ lesions in the second round. This 
finding is in agreement with the finding that HPV16 is the most common genotype in 
cervical cancer.41 The contribution of other non-HPV16 genotypes could not be as-
sessed because of the limited numbers of women in the study. 
__________________________________________________________________________________
Recommendations
• HrHPV testing in cervical screening provides better protection against CIN3+ and 
cervical cancer in the second screening round than cytology by earlier detection 
of clinically relevant CIN2+ lesions in the first round. 
• HrHPV testing alone should become the primary screening method.  
• Women with a negative hrHPV test have an extremely low risk to develop 
high-grade cervical lesions. Longer screening intervals (up to 7.5 years) may 
therefore be used. 
__________________________________________________________________________________
Age to begin screening
An important issue is the age at which hrHPV testing should be offered in primary 
screening. Women under the age of 30 years have a high prevalence of hrHPV 
infections and the majority of these infections are generally cleared in a relatively short 
time.42;43 Screening young women under 30 years by hrHPV testing results in detection 
of  mostly transient hrHPV infections. As women become olders the prevalence of 
hrHPV decreases and stabilizes at the age of 35 years. Older women are more likely 
to have a persistent infection and they are therefore more likely to benefit from inter-
vention. In addition, incidence and mortality rates for cervical cancer among women 
younger than 30 are low.44;45 In the Netherlands, 4.5% of all carcinomas are found 
under the age of 30 year.9 The benefit of screening all women between 25-30 years 
does not outweigh the negative screening effects (high referral rates for colposcopy, 
which in turn might result in unnecessary treatment and the risk of preterm births and 
substantial anxiety). Therefore, it has been decided in the Netherlands that hrHPV 
testing should not be used to screen women younger than 30 years.46
 Ronco and colleagues 27 reported that hrHPV testing in women aged 25-34 years 
could lead to substantial over-diagnosis of regressive CIN2+ lesions. As a result, they 
suggested that hrHPV screening should not start in women younger than 35 years. In 
the POBASCAM trial, our separate analyses of women attending screening for the first 
time (age 29-33 years) and older women (age 34-56 years) revealed that the CIN3+ 
detection rates over two rounds were similar for the intervention and control group 
within both age subgroups. Also for CIN2+, the detection rates were similar for the in-
tervention and control group (see Figure 3. Chapter 4). These data therefore indicate 
that hrHPV testing in women aged 29-33 does not result in excessive diagnosis of cer-
vical lesions and argues for implementation of hrHPV testing in programmed cervical 
screening at a starting age of 30 years. 
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 In addition, we observed in the VUSA-Screen study that the CIN3+ and CIN2+ 
detection rate in hrHPV-positive women was similar for women invited for cervical 
screening for the fist time (age 29–33 years) and for older women (>34 years).47 Thus 
also the data from the VUSA-Screen study support the notion that screening should 
start at the age of 30.
__________________________________________________________________________________
Recommendations
• Screening by primary hrHPV testing should start at the age of 30 years. 
__________________________________________________________________________________
Management of hrHPV-positive women
An adverse effect of using an hrHPV test for cervical screening is that transient 
infections are detected. In population-based screening, specificity of the screening 
test is of utmost importance, as it basically determines the costs of the programme 
and the occurrence of adverse effects (repeat screening test(s), colposcopy refer-
rals, treatment of regressive lesions, anxiety) in the generally healthy population. At 
first, it is therefore important to use a clinically validated hrHPV test in primary cervical 
screening.48 Secondly, management of hrHPV-positive women deserves attention. 
 In the Netherlands, about 5% of the women between 30 and 60 years of age are 
hrHPV-positive,10;49 and approximately 13% of them have an underlying CIN3+ and 
about 22% a CIN2+ lesion.47 Therefore, not all hrHPV-positive women should be directly 
referred because this would result in a substantial increase in colposcopies and may 
result in overtreatment. The latter is particularly problematic because unnecessary 
excisional treatment of cervical lesions may result in preterm delivery in subsequent 
pregnancies.50;51
 An option to improve the specificity of an hrHPV-based screening algorithm is to 
narrow the definition for a positive hrHPV screening test, for example by increasing the 
threshold of the hybrid capture 2 HPV DNA test (> 1 RLU).52-54 Kotaniemi-Talonen et al.52 
and Ronco et al.53 concluded that the cutoff can be increased to, respectively 10 
RLU/CO and 2 RLU/CO. However, in our VUSA-Screen study (Chapter 6),54 we found 
that there was no HC2 threshold for which single hrHPV screening resulted in both 
superior sensitivity and specificity compared to cytology screening. Therefore, we 
conclude that changing the threshold of the HC2 test is not sufficient and that some 
form of triage and/or follow-up testing is required for hrHPV-positive women. 
 Several triage suggestions for hrHPV-positive women have been made in the 
literature. Because cytology has a relatively high specificity,12 it seems suitable to triage 
hrHPV-positive women. Also genotyping for HPV16 and HPV18 has been considered 
as triage option as those types are associated with strongly increased CIN2+ risk.55;56
 We compared 14 triage/follow-up testing strategies using cytology, hrHPV testing 
and/or HPV genotyping (Chapter 5).49 A triage strategy was considered feasible if the 
2-year CIN3+ risk was equal to or lower than 2% (corresponding with a NPV of at least 
98%), which is presently considered acceptable according to the Dutch screening 
guidelines. The most attractive strategy was cytology testing at baseline and at 12 
months because it has a low 2-year CIN3+ risk (below 1%), a high PPV of 37.5% and 
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results in only a modest colposcopy referral rate in the total population (1.70%, 95% 
CI 1.54-1.85). In addition, this strategy is easy to communicate to physicians and 
women. Another attractive but more costly strategy is combined cytology and 
HPV16/18 genotyping at baseline followed by repeat cytology at 12 months. This 
strategy has a low CIN3+ risk (0.3%) and a lower PPV of 25.6% but results in a relatively 
high colposcopy referral rate in the total population (2.53%, 95CI 2.34-2.73). Both 
strategies entail short-term recalls of hrHPV-positive (for the second strategy hrHPV- 
positive but HPV16/18 negative), cytology negative women and demand a high level 
of compliance to follow-up. One baseline strategy without repeat testing, i.e. 
combined cytology with HPV16/18/31/33/45 genotyping may be considered as an 
alternative because it resulted in a CIN3+ risk of test negative women of <1% and 
does not depend on follow-up compliance. However, such a strategy has a low 
PPV of 20.7% and will lead to a high overall colposcopy referral rate in the total 
population (2.95% (95%CI: 2.75-3.17). 
 It should be kept in mind that in the Netherlands, cytology has a high quality. 
The cytology test shows a relatively high sensitivity and specificity and the 
cytological abnormality rates are low. As a result, the most attractive strategy to triage 
hrHPV-positive women is cytology testing at baseline and at 12 months. However, in 
countries where the quality of cytology is worse, cytology and HPV16 and HPV18 
genotyping might be an alternative triage tool. 
 Loss to follow-up is a major risk factor of a screening strategy with a repeat 
test. Several studies have shown that attendance at repeat testing may be poor, 
particularly after a cytologically normal test result.24;26;57 Appropriate communication 
strategies are therefore necessary to establish high attendance at repeat testing. In 
addition, the logistics of a triage and follow-up strategy should preferably be simple. 
 Although cytology is an appropriate triage tool for hrHPV-positive women, triage 
can be improved since the test is subjective and has a rather low reproducibility. 
Several new molecular biomarkers identified by molecular carcinogenesis research are 
developed to use as triage test. One of them is p16/ki67 dual-stain cytology. This test 
may be used as surrogate marker of cell cycle deregulation mediated by transform-
ing hrHPV infections. Promising results have been shown and the test (CINTEC®) seems 
to perform better than cytology.58;59 However, application of the CINTEC® test still 
requires cyto-pathological experience and prospective studies are needed to 
validate the published data. Another marker may be the HPV-Proofer E6/E7 mRNA 
test (Norchip®), detecting an active infection with cell- transforming potential for five 
hrHPV types.60;61 Indeed a positive E6/E7 mRNA test is associated with CIN3+/CIN2+ but 
the risk of women with a negative E6/E7 mRNA test is too high to dismiss these women 
from further follow-up. In addition, promoter methylation analyses of tumor suppressor 
genes have been proposed as triage tool for hrHPV-positive women. CADM1 and 
MAL methylation markers showed to be promising candidates 62-64 but prospective 
studies are needed. These studies are presently ongoing. These molecular biomarkers 
may pave the way to a complete molecular-based cervical screening program, 
potentially also suitable to medium/low resource countries.
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__________________________________________________________________________________
Recommendations
• HrHPV-positive women need to be triaged to prevent over-diagnosis, over- 
treatment and high costs. 
• In countries with a high quality of cytology, cytology testing at baseline followed 
by repeat cytology testing at 12 months is an attractive triage tool.
• In countries where the quality of cytology is less good, triage by combined 
cytology and HPV16/18 genotyping at baseline followed by repeat cytology at 
12 months might be considered for implementation.
__________________________________________________________________________________
Improve screening participation by hrHPV testing on self-collected material 
In the Netherlands about 35% of the invited women do not respond to a screening 
invitation.65 More than half of the cervical cancer cases detected in the Netherland 
did not have a previous cervical smears.8;66 Therefore, attempts should be made to 
increase the number of women participating in the programme. Offering women 
a user-friendly self-sampling device for collecting cervico-vaginal material for hrHPV 
testing has shown to increase participation rate.67-69 
 Self-sampling devices enable women to take their own (cervico-)vaginal sample 
at a suitable time and place. About 30% of the non-participating women responded 
actively by returning a self-sampling device,68;70;71 which is considerably higher than 
the rates of 10-17% obtained when women were sent one or two reminders for 
regular screening. Furthermore, the yield of high-grade lesions was higher in self- 
sampling responders (non-responders to an invitation of the regular screening 
program who positively reacted to offering hrHPV testing on self-collected material) 
compared to screening participants.68;70;71 The hrHPV test performed comparable 
in terms of sensitivity for CIN2+ on self-sample material and on smears taken by the 
general practitioner.72-75
 In addition, self-sampling may improve participation in countries with cultural 
and religious programme barriers by increasing acceptance and access to cervical 
cancer screening. Furthermore, self-sampling can improve screening in countries 
with lack of medical staff and screening facilities. Indeed, self-sampling has shown to 
facilitate access to cervical screening in developing regions 76;77 and may well lead to 
increased screening participation. 
 However, cytology cannot be performed on self-collected material, most likely 
due to the fact that self-sampled material mostly contain admixed vaginal cells and 
relatively few intact cervical cells (so called cervical indicator cells) indicative for 
a high-grade precursor lesion of the cervix. For triage testing the women who test 
hrHPV-positive on self-collected (cervico-)vaginal material have therefore to be 
referred to the general practitioner for a cervical cytology smear. This extra visit to the 
physician results in discomfort for the women and loss to follow-up , and is unfeasible 
in under-resourced settings lacking medical services. Application of triage testing 
directly on the self-sampled specimens by a non-morphological biomarker test would 
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be an ideal alternative to select hrHPV-positive women in need of colposcopy. 
Studies nowadays evaluate new molecular triage markers that are directly applicable 
on self-sampling tests, such as methylation markers.64;78 In this way a complete molecular 
objective non-morphological cervical screening can be offered. This will make 
cervical screening also available to medium and low resource countries. 
__________________________________________________________________________________
Recommendations
• Offering self-sampling for hrHPV testing is a promising, effective alternative to 
sampling by clinicians and improves screening compliance rates. 
__________________________________________________________________________________
HPV vaccination
The HPV vaccination programme started in the Netherlands in 2009 for girls of 12 years 
old with a catch-up for 13-16-year old girls.79 The prophylactic HPV vaccines have 
shown to be highly efficacious to prevent high-grade cervical lesions at a population 
level.80-88 It is assumed that HPV16/18 VLP L1 vaccines will prevent about 70%-80% of 
the squamous cell carcinomas and 90% of the adenocarcinomas.41;89 Since the HPV 
vaccines only have a prophylactic effect when women are hrHPV-negative, they 
are given to young, hrHPV naïve girls. However, HPV vaccination coverage for the 
first dose in the Dutch population targeted by the catch-up campaign was about 
55%, lower than the aimed 70%.90;91 There was a lower uptake among women in 
conservative religious and ethnic communities and among women with lower 
socioeconomic status.91 Therefore, better communication strategies are needed to 
increase the vaccination attendance rate. 
 It is, however, of note that the potential benefit of HPV vaccination might be 
larger than the coverage would indicate because of indirect (herd immunity) 
protection to non-vaccinated women. 
 Vaccination does not eliminate the need for cervical cancer screening.  The 
vaccinated women remain at risk of developing cervical cancer associated with 
non-HPV16/18 genotypes.81-83;92;93 Even if hrHPV cross-protection is taken into account, 
about 20% of the cervical carcinomas will not be prevented by vaccination. 
 HPV vaccination is expected to have an impact on the effectiveness of cytology 
and hrHPV screening. Vaccination probably decreases hrHPV positivity, cytological 
abnormalities and reduces the number of high-grade cervical lesions. In countries 
with effective screening programmes and high coverage rates (i.e., Denmark Finland, 
Iceland, the Netherlands, and the UK), the impact of vaccination on the reduction of 
cervical cancer cases is expected to be relatively small. The impact of vaccination 
would be further attenuated if vaccination leads to a false sense of security resulting 
in lower adherence to the screening programme. Therefore, it is very important to 
educate and motivate women to attend cervical screening programme, even if they 
are vaccinated. The effect of vaccination is expected to be higher on the incidence 
of adenocarcinomas because HPV16 and 18 are associated with more than 90% of 
the adenocarcinomas. HPV vaccination may negatively influence current cytology 
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based screening since the decrease of cytological abnormalities and high-grade 
lesions may deteriorate the quality of smear reading.94 This is an additional reason 
to implement hrHPV testing as primary screening test since this test is objective. 
Cytology could be used as triage test for hrHPV-positive women, because in this group the 
occurrence of abnormal smear is increased. 
__________________________________________________________________________________
Recommendations
• Besides HPV vaccination screening for cervical abnormalities will remain important 
to prevent cervical cancer because 1. the current vaccines protect against 
about 70%-80% of the cervical cancer cases and  2. the participation rate of 
vaccination will never reach 100% leaving a considerable number of women at 
risk of getting infected by hrHPV.
__________________________________________________________________________________
Future perspectives 
We showed that hrHPV testing is superior to cytology as a primary screening test in 
cervical cancer screening programmes for women 30 years and older. Additionally, 
we presented feasible triage algorithms for hrHPV-positive women. Taken together, 
time has come for implementing hrHPV testing in nationwide cervical screening 
programmes.
 Offering self-sampling to women who do not attend regular screening resulted 
in a response rate of about 30%.67;68;70;71 Moreover, the number of CIN3+ and CIN2+ 
lesions detected by hrHPV testing in non-responders was significantly higher than 
in women responding to the regular screening programme. These results support 
implementation of self-sampling in the cervical screening programme, at least for 
non-attendees.68;70
 In the future, self-sampling may be offered as primary screening test to all women 
eligible for cervical screening. Ideally, women would be given the choice for either 
self-sampling or physician-collection. These options need to be further analysed in 
implementation studies followed by cost-effectiveness analyses. 
 Topics of further research include ways to improve triage testing of hrHPV-positive 
women. Although cytology has shown to be an effective triage method in an hrHPV 
screening setting, this approach is labor intensive, subjective and unfeasible in under-
resourced settings lacking medical services. Objective and reproducible biomarkers 
may improve triage of hrHPV-positive women. Studies have shown that methylation 
markers (methylation of the promoter regions of tumor suppressor genes involved 
in cervical carcinogenesis) are promising triage tools to distinguish women with 
clinically meaningful cervical disease amongst those who are hrHPV-positive without an 
underlying cervical high-grade lesion. Further research about the potential of 
different biomarkers in triaging hrHPV-positive women is needed.
 Appropriate communication and education of both women and physicians 
about hrHPV and cervical cancer is very important to increase vaccination coverage 
and to motivate women to participate in the screening programme. In this way cervical 
cancer morbidity and mortality can be reduced.  
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Summary
Worldwide, cervical cancer is the third most common female malignancy with the highest 
incident rates reported in low resource countries. In countries with cervical cancer 
screening, the incidence and mortality rates of cervical cancer have decreased. 
Cytology-based screening enables cancer prevention by early detection of 
pre-malignant lesions, which can be treated effectively.
 The recognition that a persistent infection with hrHPV is the necessary cause of 
cervical cancer has resulted in the development of new methods of cervical cancer 
prevention. These comprise secondary prevention by hrHPV testing for early detection 
of cervical cancer and primary prevention through HPV vaccination. This thesis 
presents recent work exploring the possibilities of hrHPV testing in triage of women 
with borderline or mildly dysplastic smears (BMD, Pap2/3a1) and the potential clinical 
impact of using the hrHPV test in primary screening.
 
Chapter 1 provided a general introduction of cervical cancer epidemiology, human 
papillomavirus infections, cervical carcinogenesis and cervical cancer prevention.
In Chapter 2, we studied whether it is feasible to use the hrHPV test as baseline 
triage test for women with BMD. In many European countries, including the Netherlands, 
women with BMD in screening are recalled for repeat testing and they are only 
referred for colposcopy if the cytological abnormality persists. Because the majority 
(>80%) of these women do not have a high-grade lesion, a significant burden is 
imposed on women and the health care system. Therefore, we compared repeat 
cytology testing at 6 and 18 months to direct referral of women with BMD and a 
positive hrHPV test. In this study, almost all CIN3 and CIN2+ lesions were found in 
hrHPV-positive women, whereas women with a negative hrHPV test had 
an acceptably low CIN3 and CIN2+ risk. Compared to repeat cytology testing, 
baseline triaging by hrHPV testing can be implemented against low costs, and 
leads to a faster diagnosis and less distress for women. We therefore support 
the strategy of referring hrHPV-positive women with BMD immediately for 
colposcopy and to refer those who are hrHPV-negative to routine screening.
In Chapter 3, we presented the main results of the population based VUSA-Screen 
study (VU University Medical Center SAltro laboratory population-based cervical 
Screening) in which 3-year follow-up results were related to baseline hrHPV testing 
and cytology testing to find an optimal primary screening method. In line with other 
studies, this study demonstrated that hrHPV testing is superior to cytology in terms of 
sensitivity but not in terms of specificity. Women with a double (cytology and hrHPV) 
negative test did not have a markedly lower CIN3+ and CIN2+ risk than women with a 
single negative hrHPV test. Therefore, from a health-economic perspective, cervical 
screening with a primary, stand-alone hrHPV test seems preferable. HrHPV-positive 
women have a non-negligible risk for CIN3+ (13.2%) and CIN2+ (21.9%). To prevent 
unnecessary colposcopy referrals, hrHPV-positive women should not be offered 
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colposcopy immediately but should be further stratified by means of triage/repeat 
testing. Since cytology in the Netherlands has a high specificity for threshold CIN3+, 
we used cytology for this purpose. Women with an hrHPV-positive test and abnormal 
cytology had a high CIN3+ (42.2%) and CIN2+ (60.3%) risk and need immediate 
colposcopy. HrHPV-positive women with normal cytology have a low, but still non-
negligible CIN3+ (5.2%) and CIN2+ (11.3%) risk. We showed that repeat cytology testing 
after 1 year for hrHPV-positive women with normal cytology at baseline is however 
necessary before returning women to routine screening. In present study the CIN3+ 
and CIN2+ risk was similar in women invited for the first time (29-33 years) and in women 
≥34 years. Moreover, the CIN3+ risk in women with hrHPV-positive normal cytology 
was higher among women invited for the first time (29-33 years) than among older 
women.
In  Chapter 4, we presented the final data from the POBASCAM (POpulation BAsed 
SCreening study AMsterdam) trial. In this randomised trial, women were randomly 
assigned to receive hrHPV and cytology co-testing (intervention group) or cytology 
testing alone (control group). At the second round 5 years later, hrHPV and cytology 
co-testing was done in both groups. At baseline, hrHPV testing detected more 
clinically relevant, CIN2+ lesions compared with screening using cytology 
only. This improved detection of cervical lesions at baseline led to 
reduced detection of CIN3+ and cervical cancers in the second round. The higher 
protectionof CIN3+ lesions in the second round by hrHPV testing appeared to be 
largely attributable to HPV16. HrHPV testing in women aged 29-33 did not result in 
excessive detection of regressive cervical lesions. Collectively, these results support 
hrHPV testing in cervical screening starting at age 30.
In  Chapter 5, we showed the results of triage strategies for hrHPV-positive women. 
HrHPV testing as a primary screening test requires efficient management of hrHPV-
positive women. Most hrHPV infections will clear spontaneously and only a minority 
of hrHPV-positive women will have or develop clinically meaningful lesions. Thus, an 
effective triage strategy that determines which hrHPV-positive women should be 
referred for colposcopy is crucial to prevent unnecessary colposcopies and treatment. 
Our analysis of triage strategies for hrHPV-positive women based on the data from the
VUSA-Screen study points to use cytological testing at baseline, followed by repeat 
cytology testing at 12 months. This is a feasible triage strategy because hrHPV-positive 
women with 2 times negative cytology have an acceptably low CIN3+ and CIN2+ 
risk (0.7% and 2.9%, respectively), and it is accompanied with a modest colposcopy 
referral rate (33.4%). Moreover, this strategy is easy to communicate to participating 
women and physicians.
In Chapter 6 we studied the effect of increasing the threshold level of hrHPV testing 
by HC2 on the sensitivity and specificity for CIN3+ and on the colposcopy referral rate. 
We found that increasing the HC2 threshold could result in similar or lower colposcopy 
referral rates than cytology screening but only at the cost of a lower sensitivity. 
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However, superior performance in terms of both sensitivity and colposcopy rate was 
possible if HC2 testing, at the standard threshold, was combined with cytology triage 
at baseline and repeat cytology testing after 1 year as earlier defined in Chapter 5.
Finally, in Chapter 7 we provided a general discussion of the results presented in 
this thesis, and discusses possible future developments, prospects and clinical 
consequences of hrHPV testing. We conclude that hrHPV testing is superior to cytology 
as a primary screening test in cervical cancer screening programmes for women 
30 years and older. Additionally, we presented feasible triage algorithms for hrHPV- 
positive women. In the future, new objective biomarkers may improve triage of 
hrHPV-positive women.
C
H
A
PT
ER
 8
Summary
CHAPTER 8
131
C
H
A
PTER 8
Samenvatting
CHAPTER 8
132
Samenvatting
Baarmoederhalskanker is na borst- en darmkanker de meest voorkomende 
vorm van kanker onder vrouwen wereldwijd, met de hoogste incidentie in 
ontwikkelingslanden. In landen met een bevolkingsonderzoek voor het opsporen 
van baarmoederhalskanker zijn de incidentie- en sterftecijfers van deze 
vorm van kanker afgenomen. Het huidige screeningsprogramma maakt 
gebruik van cytologisch onderzoek van de baarmoederhals met als doel om de 
voorstadia van baarmoederhalskanker op te sporen en tijdig te behandelen. 
 De ontdekking dat een infectie met het Humaan Papillomavirus (HPV) 
een voorwaarde is voor het ontstaan van baarmoederhalskanker heeft 
geleid tot de ontwikkeling van nieuwe methoden voor de preventie van 
baarmoederhalskanker. Deze omvatten zowel nieuwe methoden van vroege 
opsporing van baarmoederhalskanker als van primaire preventie via vaccinatie 
tegen HPV. In dit proefschrift wordt recent werk gepresenteerd waarin de 
mogelijkheden en effecten worden onderzocht van het gebruik van HPV testen 
bij primaire screening en bij triage van licht afwijkende uitstrijkjes (BMD, Pap2/3a1).
Hoofdstuk 1 bevat een algemene introductie over baarmoederhalskanker, HPV 
infecties, de ontstaanswijze van baarmoederhalskanker en de verschillende 
methoden die gebruikt kunnen worden om baarmoederhalskanker te voorkomen. 
In hoofdstuk 2 hebben we onderzocht of het gebruikelijke follow-up advies voor 
vrouwen met een BMD uitstrijk kan worden vervangen door een risicoselectie te 
maken op basis van de hoog risico (hr)HPV test. In veel Europese landen, waaronder 
Nederland, worden vrouwen met een BMD uitstrijk in het screeningsprogramma 
opgeroepen voor herhaal uitstrijkjes. Alleen vrouwen met persistent afwijkende 
uitstrijkjes worden verwezen naar de gynaecoloog voor colposcopie. Omdat de 
meerderheid (>80%) van deze vrouwen geen hoogwaardige laesie (CIN2+) heeft is dit 
een behoorlijke belasting voor de vrouwen en voor de gezondheidszorg. Daarom 
hebben we het standaard follow-up advies voor BMD uitstrijkjes (herhaal uitstrijk na 
6 en 18 maanden) zoals toegepast in een controle groep vergeleken met baseline 
hrHPV triage in een interventie groep. In de interventie groep werden vrouwen met 
een BMD uitstrijk en hrHPV-positieve test direct doorgestuurd voor colposcopie en 
vrouwen met een hrHPV-negatieve test kregen het standaard follow-up advies. In 
dit onderzoek werden bijna alle CIN3 en CIN2+ laesies gevonden in hrHPV-positieve 
vrouwen, terwijl vrouwen met een negatieve hrHPV-test een laag CIN3 en CIN2+ 
risico hadden. Vergeleken met herhaal uitstrijkjes kan baseline triage met hrHPV tests 
ingevoerd worden tegen lage kosten en resulteert het in een snellere diagnose en 
minder belasting voor de betreffende vrouwen. Daarom is het testen van vrouwen 
met een BMD uitstrijk op de aanwezigheid van hrHPV aan te bevelen. Wij adviseren 
vrouwen met een BMD en hrHPV-positieve test direct door te sturen voor colposcopie en 
vrouwen met een hrHPV-negatieve test terug te sturen naar het bevolkingsonderzoek. 
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In hoofdstuk 3 hebben we de belangrijkste resultaten van de VUSA-Screen studie 
(VU University Medical Center SAltro laboratory population-based cervical 
Screening) gepresenteerd. De drie-jaar follow-up resultaten werden gekoppeld 
aan de baseline hrHPV en cytologie uitslag voor het vinden van een optimale 
primaire screeningsmethode. Overeenkomstig met andere studies, toonde deze 
studie aan dat de hrHPV test een hogere sensitiviteit heeft dan cytologie maar een 
lagere specificiteit. Omdat het risico na alleen een negatieve hrHPV test 
nagenoeg gelijk was aan het risico na een gecombineerd (hrHPV en cytologie) 
negatief test resultaat, heeft testen met uitsluitend hrHPV de voorkeur. Vrouwen 
met een positieve hrHPV test hebben een verhoogd risico op CIN3+ (13.2%) 
en CIN2+ (21.9%). Om onnodige colposcopie doorverwijzingen te beperken 
moeten niet alle hrHPV-positieve vrouwen direct doorgestuurd worden maar moet 
er een risico stratificatie plaats vinden. Aangezien cytologie in Nederland een 
hoge specificiteit voor CIN3+ heeft is het een goed hulpmiddel voor risico stratifi-
catie van hrHPV-positieve vrouwen. De vrouwen met hrHPV-positieve test en afwi-
jkende cytologie dienen verwezen te worden voor colposcopie vanwege het sterk 
verhoogde risico op CIN3+ en CIN2+. Vrouwen met hrHPV-positieve test en nor-
male cytologie hebben een welliswaar kleiner, maar niet te verwaarlozen risico op 
CIN3+ (5.2%) en CIN2+ (11.3%) en dienen daarom terug-geroepen te worden voor 
herhaal cytologie na 1 jaar. In deze studie was het CIN3+ en CIN2+ risico vergeli-
jkbaar voor vrouwen die voor het eerst uitgenodigd werden voor het bevolking-
sonderzoek (29-33 jaar) en voor oudere vrouwen (≥34 jaar). Het CIN3+ risico was 
zelfs hoger voor vrouwen met hrHPV-positieve test en normale cytologie die voor 
het eerst uitgenodigd werden (29-33 jaar) dan voor oudere vrouwen (≥34 jaar). 
De vijf-jaars follow-up resultaten over twee screeningsronden van de totale 
POBASCAM trial (POpulation BAsed SCreening study AMsterdam) zijn in 
hoofdstuk 4 gepresenteerd. In deze gerandomiseerde trial kregen vrouwen 
ofwel een combinatietest van hrHPV en cytologie (interventie groep), ofwel alleen 
de cytologische test (controle groep). In de eerste screeningsronde detecteerde 
de groep met de hrHPV test meer klinisch relevante CIN2+ laesies in 
vergelijking met screening met behulp van cytologie alleen. In de tweede ronde 
vijf jaar later werden in beide groepen een combinatie van hrHPV en cytologie 
uitgevoerd. De verbeterde detectie van CIN2+ laesies door hrHPV testen 
in de eerste ronde resulteerde in een verminderde detectie van CIN3+ en 
baarmoederhalskanker in de tweede ronde. Dit klinisch voordeel is grotendeels 
te danken aan een vroege detectie van hooggradige cervicale laesies die 
worden veroorzaakt door HPV16. Het screenen van vrouwen die voor het eerst 
worden uitgenodigd voor bevolkingsonderzoek (29-33 jaar) met behulp van de 
hrHPV test resulteerde niet in detectie van regressieve cervicale laesies. Deze 
veronderstelling is gebaseerd op de observatie dat over twee screeningsronden 
de CIN3+ en CIN2+ detectie niet verschilde tussen vrouwen 29-33 jaar en vrouwen 
34 jaar en ouder. Kortom, deze resultaten ondersteunen de implementatie van de 
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hrHPV test in het reguliere bevolkingsonderzoek voor vrouwen vanaf de leeftijd 
van 30 jaar.
Primair screenen met hrHPV in het bevolkingsonderzoek vereist een efficiënte 
follow-up van hrHPV-positieve vrouwen. Omdat de meeste hrHPV infecties spontaan 
verdwijnen en slechts een minderheid van de hrHPV-positieve vrouwen een klinisch 
relevante afwijking ontwikkelen. Een effectieve triage strategie die bepaalt welke 
hrHPV-positieve vrouwen moeten worden doorverwezen is van cruciaal belang om 
onnodige colposcopie onderzoek en behandeling te voorkomen. In hoofdstuk 5 
analyseren we triage strategieën voor hrHPV-positieve vrouwen op basis van de 
gegevens van de VUSA-Screen studie. Uit deze studie komt de volgende triage 
strategie naar voren: cytologische onderzoek bij aanvang gevolgd door herhaalde 
cytologie na 12 maanden. Dit is een haalbare triage strategie omdat hrHPV- 
positieve vrouwen met 2 maal een negatieve cytologie test een aanvaardbaar 
laag CIN3+ en CIN2+ risico hebben en het resulteert in een beperkte hoeveelheid 
colposcopie doorverwijzingen. Bovendien is deze strategie is eenvoudig uit te 
leggen aan de deelnemende vrouwen en artsen.
In hoofdstuk 6 evalueerden we het effect van primair hrHPV screening 
gebruik makend van HC2 met verschillende afkapwaarden voor een positieve 
test in vergelijking met cytologie. We onderzochten het effect op sensitiviteit en 
specificiteit voor CIN3+ en op het aantal colposcopie doorverwijzingen. Het 
verhogen van de HC2 afkapwaarde resulteerde in een vergelijkbare of lager 
aantal colposcopie doorverwijzingen dan cytologie maar dit ging ten kosten van 
de sensitiviteit. Superieure prestaties in termen van zowel de sensitiviteit als het 
aantal colposcopie doorverwijzingen werden verkregen met de HC2 toegepast 
met de standaard afkapwaarde gecombineerd met cytologie triage op 
baseline en herhaal cytologie testen na 1 jaar zoals eerder omschreven in hoofdstuk 5.
Tenslotte beschrijft hoofdstuk 7 een algemene discussie van de resultaten van dit 
proefschrift, en bespreekt mogelijke toekomstige ontwikkelingen, vooruitzichten en 
klinische gevolgen van hrHPV testen. Dit proefschrift toont nader bewijs dat het testen 
op hrHPV superieur is aan cytologie als primaire screeningstest naar baarmoeder- 
halskanker voor vrouwen 30 jaar en ouder. Daarnaast hebben we haalbare triage 
strategieën gepresenteerd voor hrHPV-positieve vrouwen. In de toekomst kan de 
triage van hrHPV-positieve vrouwen mogelijk verbeterd worden door nieuwe 
objectieve biomarkers.
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studeerde zij de opeenvolgende jaren aan de Erasmus 
Universiteit te Rotterdam. Tijdens haar studie geneeskunde 
behaalde zij een Master of Neuroscience, eveneens aan 
de Erasmus Universiteit. In het kader van deze Master 
opleiding heeft ze onderzoek verricht naar oculomotor 
reflexen onder begeleiding van prof.dr. MA Frens in het 
Erasmus MC. 
Na het behalen van haar artsexamen heeft zij een jaar onderzoek verricht naar 
HPV-infecties en baarmoederhalskanker in het Leids Cytologisch en Pathologisch 
Laboratorium, te Leiden in samenwerking met dr. M.E. Boon en prof.dr. Th.J.M. 
Helmerhorst. In oktober 2006 begon zij aan haar promotie-onderzoek op de 
afdeling pathologie van het VU Medisch Centrum te Amsterdam, wat resulteerde in 
dit proefschrift. In januari 2010 is zij gestart met haar opleiding tot gynaecoloog in het 
Kennemer Gasthuis te Haarlem (opleider dr. J.P. Lips). Sinds november 2012 vervolgt 
zij haar opleiding in Amsterdam aan het VU Medisch Centrum (opleider prof.dr. J.I.P. 
de Vries). 
Dorien is getrouwd met Stefan Pool en woont in Leiden. Zij hebben sinds september 
2011 samen een dochter Sofie. 

